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QUILL ON SCALPEL This section provides a medium through which Canadian surgeons can declare themselves, 
briefly and informally, on the day-to-day affairs of surgery.
Diabetes and the Surgeon
D. Michael Grace, MD, FACS, FRCSC
Member, Editorial Board, Canadian Journal o f  Surgery. Associate Professor o f Surgery, 
University o f Western Ontario, University Hospital, London, Ont.
v ~>
I n this issue (pages 421 to 426), Warnock and colleagues describe 
a technique of pancreatic islet isola­
tion, purification and implantation 
which can produce normoglycemia 
in dogs for prolonged periods. This 
work is important because it has­
tens that day when successful islet 
transplantation may be used to 
fight the devastating long-term ef­
fects of insulin-dependent diabetes 
mellitus.
Diabetes mellitus of both types is 
a common problem in both medical 
and surgical patients. Efforts to 
control blood sugar levels may com­
plicate routine surgical procedures, 
and infection or emergency opera­
tion makes management of the dia­
betic even more difficult. Abdominal 
pain may be difficult to assess in a 
patient with ketoacidosis. Surgeons 
may also be called to treat compli­
cations of diabetes, such as foot 
infection or ulceration resulting 
from diabetic vascular disease or 
neuropathy. In spite of aggressive 
conservative treatment, diabetes 
and its associated complications are 
the most common cause of non- 
traumatic limb amputation. Diabetic 
renal disease is now a common 
cause of chronic renal failure. In 
such patients, it is a challenge to 
establish an arteriovenous fistula or 
graft for hemodialysis because the 
rate of atherosclerosis is accelerated 
and the arterial wall is of poor
quality. Renal transplantation car­
ried out by surgeons for end-stage 
renal failure in diabetes can present 
a moral and technical dilemma. The 
results are improving, but chronic 
immunosuppression can further 
complicate the management of a 
“brittle” diabetic. Diabetes is also 
the most common cause of blind­
ness in Canada and ophthalmolo­
gists must often treat retinal disease 
and cataracts in diabetics. Non­
insulin-dependent diabetes mellitus 
occurs later in life but may produce 
similar complications. The role of 
gastroplasty in the treatment of 
morbid obesity remains controver­
sial, but there is no doubt that 
substantial weight loss in obese
v *1
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GRACE
diabetics corrects the condition and 
may reduce the frequency and se­
verity of subsequent problems.
The prevention of complications 
in insulin-dependent diabetics re­
mains insoluble in spite of world­
wide research efforts. Genetic coun­
selling may prevent some cases, and 
better understanding of the immu­
nologic causes of diabetes may help 
to prevent the disease or result in 
the early treatment of others. Rec­
ognition of the autoimmune nature 
of diabetes mellitus in rats led to 
the demonstration that cyclosporine 
could prevent the disease.1 Trials of 
cyclosporine in insulin-dependent 
diabetics have demonstrated that 
the condition may be prevented or 
severity reduced if cyclosporine is 
started early.2 However, the number 
of children who can be treated is 
small and treatment is expensive. 
Moreover, it remains to be proven 
whether the complications are in­
deed prevented. Cyclosporine car­
ries its own set of complications, 
including renal damage, which may 
be nearly as serious as the ne­
phropathy one is trying to prevent. 
Tight control of blood sugar levels 
by regular insulin injection or use 
of insulin pumps has resulted in an 
increased number of hypoglycemic 
reactions but has not decreased the 
retinopathy, nephropathy, neuropa­
thy or peripheral vascular disease. 
A national trial is attempting to 
answer this question with certain­
ty.3
To surgeons, transplantation of 
the whole pancreas has usually 
made more sense than it has to 
endocrinologists. Our emphasis has 
been on improved techniques, graft 
survival and freedom from insulin 
requirement when we should be 
striving for normal metabolism and 
freedom from diabetic complica­
tions. We were also encouraged by 
the success of other transplants. 
Renal transplantation proved more 
effective in humans than in animals,
it improved the quality of life and 
saved money. Liver and heart trans­
plants were dramatic, effective and 
lifesaving. The technical problems 
of pancreatic transplantation are no 
more challenging than those of 
renal transplantation, although 
management of the pancreatic duct 
has been controversial. When the 
pancreatic duct was drained to the 
peritoneal cavity, pancreatic ascites 
resulted and gave way to enteric 
anastomosis or occlusion of the 
duct with polymers. Now drainage 
of the duct to bladder has achieved 
better results and has allowed clos­
er monitoring of rejection by mea­
surement of urinary amylase levels. 
Surgeons familiar with the potential 
for pancreatitis or pancreatic cysts, 
abscesses or fistulas after pancreat­
ic surgery have respect for this 
organ and the potential complica­
tions of transplantation. The results 
in transplantation of the pancreas 
have improved so that, currently, an 
average of 50% of grafts are func­
tioning after 1 year and most pa­
tients survive.4 Between 1966 and 
March 1988, 1394 pancreatic trans­
plants were reported to the Pancre­
as Transplant Registry at the Uni­
versity of Minnesota.4 Results have 
improved steadily due to better im­
munosuppression and surgical tech­
niques.
The questions that have not been 
answered include the appropriate 
indications for transplantation of 
the pancreas, the timing of the 
procedure and its effect on the 
complications of diabetes. Trans­
plantation of the pancreas early in 
the course of diabetes in rats can 
prevent nephropathy.5 Therefore, 
pancreatic transplantation carried 
out early in the course of human 
diabetes makes sense; however, not 
all diabetics have complications, 
and the long-term risks of im­
munosuppression and rejection are 
substantial. It, therefore, makes 
more sense to transplant the pan­
creas in diabetics with renal failure 
who receive a renal transplant and 
are already on immunosuppression. 
Simultaneous renal and pancreatic 
transplantations appear not to harm 
the kidney and may result in better 
pancreatic survival.4 Unfortunately, 
transplantation may not reverse dia­
betic complications.67 It is not sur­
prising that severe retinopathy, 
neuropathy or nephropathy do not 
improve with normoglycemia. Al­
though pancreatic transplantation 
should continue to be evaluated as 
part of research protocols, it is 
difficult to recommend its wide­
spread use until immunosuppres­
sion is free of side effects and it is 
clear that the complications of dia­
betes can be prevented or delayed.
Because many of the technical 
complications of pancreatic trans­
plantation are due to unnecessary 
exocrine tissue, transplantation of 
pancreatic islets has always been 
more attractive. The dilemma is 
that isolation techniques are espe­
cially difficult in larger animals, 
that prolonged function of trans­
planted islets is poor and that islets 
seem more susceptible to rejection 
than whole pancreas. The best 
route of injection has not been 
established with certainty, although 
portal injection via the umbilical 
vein is easiest in humans. Vascular 
complications in animals can be 
prevented by islet transplantation,8 
but islets appear not to function as 
well or as long as whole pancreas, 
even when rejection is not a factor.5 
New techniques for decreasing pan­
creatic islet immunogenicity include 
prolonged culture at 24°C,9 use of 
multiple donors10 and treatment of 
islets with ultraviolet irradiation.11 
Fetal islets from multiple donors 
have been used in China with limit­
ed success,12 but there are ethical 
barriers to the use of such tech­
niques in North America. Trans­
plantation of islets encapsulated in 
a membrane that prevents rejection
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but allows diffusion of insulin is an 
exciting technique developed in 
Canada.13 This method has proven 
effective in rodents, but fibrosis 
around the capsules may limit its 
long-term effectiveness in larger an­
imals.
Isolation and purification of suffi­
cient numbers of islets from one 
donor to maintain blood sugar lev­
els in a recipient increases the 
chances of successful transplanta­
tion in humans. This would be even 
more likely if improved isolation 
techniques could be combined with 
methods to decrease islet immuno- 
genicity. Unfortunately, destruction 
of transplanted islets by autoim­
mune reaction rather than rejection 
is still a risk. Studies on the preven­
tion of diabetes by immunosuppres­
sion and on the relation between 
control of diabetes and its complica­
tions must continue. Canadian cen­
tres should perform and closely 
evaluate transplants of whole pan­
creas and follow with interest the 
results achieved around the world 
and reported regularly by the Pan­
creas Transplant Registry at the 
University of Minnesota. However, 
islet transplantation may be the best 
hope for treating insulin-dependent 
diabetes mellitus, so Canadian sur­
geons must continue to follow and 
contribute to this work.
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Dilution and infusion rates:
Dose Diluent Time
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SURGEONS’ UPDATE
Researchers Seek Improved 
Treatment for Patients 
Requiring Hip Replacement
A group of researchers at the Uni­
versity of Waterloo, Waterloo, Ont., 
is searching for ways to improve 
the results of surface replacement 
of the hip, a procedure they believe 
has advantages over the traditional 
technique of hip replacement.
The group consists of Greg 
McNeice, a civil engineer with ex­
pertise in stress analysis and a 
bioengineering background, John 
Medley, a mechanical engineer with 
a background in biotribology, 
Wayne Brodland, a specialist in the 
area of biomechanics, Martine La- 
Berge, a mechanical engineer 
whose expertise includes clinical ex­
perimentation with biomaterials, 
particularly in surface replacement 
for synovial joints, and several stu­
dents.
Hip replacement, says one of the 
researchers, has not always provid­
ed a permanent solution since 
“even under the best of circum­
stances the implant-bone interface 
may break down after a number of 
years” , but surface replacement has 
also presented difficulties. Says 
McNeice, “We’ve heard of instances 
where the cap slipped off the end of 
the bone as early as one year after it 
was implanted.”
The researchers believe that 
some of the problems with the 
surface replacement procedure are
Contributions to this column are welcome. 
Please send your material to: Miss Laurel 
Williamson, Canadian Journal of Surgery, 
PO Box 8650, Ottawa, Ont. K1C 0C8
caused by the material used. The 
metal cap that is placed over the 
shaved femoral head does not have 
the same properties as the bone it 
replaces, so when the bone is 
capped “it may become stress- 
shielded and when this happens, the 
bone no longer carries normal 
stress and...it disappears and you 
get progressive failure”. The effect 
of stresses on the femoral head is 
one of the problems that will be 
studied. Softer, more compliant ma­
terial will be tested for use as the 
cap or as a layer to be placed 
between the cap and the bone. The 
researchers also hope to develop 
improved methods for cementing 
the cap to the shaved bone.a
New Director of Training 
and Evaluation at Royal 
College
The Royal College of Physicians 
and Surgeons of Canada has ap­
pointed Jean-Pierre DesGroseilliers, 
FRCPC, as its Director of Training 
and Evaluation, succeeding Robert
FIG. 1 — J-P. DesGroseilliers.
F. Maudsley, FRCSC. Dr. DesGross- 
eilliers comes to the Royal College 
from the University of Ottawa, 
where he was Assistant Dean, Fac­
ulty of Health Sciences, but has 
in the past participated on several 
College committees and survey 
teams. ■
CJS Coeditor Named 1988 
Sims Travelling Professor
Dr. Lloyd D. MacLean, who was 
appointed the 1988 Sir Arthur Sims 
Commonwealth Travelling Profes­
sor by the Royal College of Sur­
geons of England, begins his travels 
this month. During the next 3 
months Dr. MacLean will be visiting 
various centres in New Zealand, 
Australia, Malaysia and Hong 
Kong; then in April he will be off 
again — this time to the British 
Isles. The Sims Professor’s role is 
both academic — assisting in the 
advancement of medical science by 
lecturing, teaching or engaging in 
research — and ambassadorial.■
Ontario’s Health Ministry 
Awards Annual Research 
Grants
The Ontario Ministry of Health re­
cently awarded $5 million to fund 
87 new and ongoing health care 
research projects.
A group at the University of 
Toronto hopes to improve the out­
come of corneal transplant surgery; 
20% of corneal transplants fail, the 
majority during the first year. The 
researchers will study data on 600
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patients, collected by the Corneal 
Transplant Registry from 18 Ontar­
io surgeons who perform corneal 
transplants. Factors that can affect 
success or failure of a transplant, 
such as the interval between the 
donor’s death and removal of the 
eye, the interval before surgery and 
method of storage of the eye be­
tween removal and surgery, will be 
analysed. The study is expected to 
be completed by early 1991.
A Hamilton research group will 
study geographic variation in can­
cer rates across the province of 
Ontario. They are asking the ques­
tion — Is there more variation in 
cancer incidence from one region to 
another than one would expect by
BOOK REVIEWS
ANDROLOGY. John P. Pryor and 
Larry I. Lipshultz. 340 pp. Illust. 
Butterworth & Co. (Publishers) Ltd., 
London, 1987. $65.95 (US). ISBN 
0-407-02361-5.
Andrology represents a current review 
of 12 selected topics related to male 
reproductive disorders. The subject-ori­
ented format is of value not only to the 
urologist-in-training but also to the 
practising general urologist, because 
this area of urology is taking up in­
creasingly more clinical time.
The topics are well selected to pro­
vide a state-of-the-art review of uncom­
mon and specialized subjects, including 
intersex, hypospadias and epispadias, 
and the increasingly topical subjects of 
impotence, infertility and vasectomy. 
The material is directed primarily to the 
clinician, giving a more basic discussion 
of disorders of intersex, ejaculatory 
disturbances, and hormone function 
and regulation of the prostate. The 
chapter on impotence is weak in the 
area of diagnostic investigation; howev­
er, the discussion on the treatment of 
impotence is extensive and current. All
chance? If a substantial variation is 
found, the researchers will deter­
mine if it is possible to link these 
variations to environmental factors 
such as water quality, air pollution, 
terrestrial radiation, urbanization, 
industrialization or occupation. The 
study will be based on data collect­
ed by the Ontario Cancer Treatment 
and Research Foundation registry 
from 1976 to 1985.■
Multiorgan Transplant Unit 
Opens in Vancouver
A multiorgan transplant unit, ad­
ministered jointly by Vancouver
General Hospital and the British 
Columbia Transplant Society, was 
opened recently by British Colum­
bia Health Minister Peter Dueck. 
Patients requiring transplant sur­
gery will no longer be required to 
travel to other provinces or coun­
tries. Care will be provided both 
before and after surgery in the 
eight-bed unit equipped with state- 
of-the-art diagnostic and monitor­
ing technology. A budget of 
$3 680 000 will cover operating 
costs for the first year and an 
additional $350 000 will be used to 
purchase new equipment.*
Laurel Williamson
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chapters are well referenced and the 
text is extensively indexed.
This book is an excellent current 
review of the subject of andrology, it 
provides outstanding reference material 
for further study and is presented in a 
very readable format.
Grant Angus Farrow, MD, FRCSC, 
FACS
Department o f  Surgery,
University o f Toronto.
Ste. 14-214,
Eaton Wing,
Toronto General Hospital,
Toronto, Ont.
BENIGN STRICTURES OF BILE 
DUCTS. Edward I. Galperin, Nikolai F. 
Kuzovlev and Suren R. Karagiulian. 
345 pp. Illust. International Universi­
ties Press, Inc., Madison, Conn., 1987. 
$60.00 (US). ISBN 0-8236-0494-2.
This book is written by experienced 
Russian surgeons who have made bili­
ary tract surgery their specialty. The 
text is, therefore, a review of the treat­
ment of benign biliary strictures, mostly 
from their own experience. It includes 
an overview of the literature on the 
subject with an emphasis on the Rus­
sian literature.
The problem with many translated 
texts is that the awkwardness of the 
language makes reading difficult as in 
this case. The print is clear and there 
are many excellent diagrams and draw­
ings to supplement the text.
The content flows logically from eti­
ology to clinical manifestations of be­
nign biliary stricture, from there to 
diagnostic maneuvers, preoperative 
preparation and finally to principles and 
practice of surgery for repair. The au­
thors cover many different surgical 
techniques and express personal prefer­
ences. Some areas are controversial, 
such as long-term stenting of biliary 
anastomosis; however, in the authors’ 
hands, the results appear to be good. In 
other parts of the book, such as that on
continued on page 384
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HOW I DO IT
Surgeon-Administered Local Anesthesia 
for Forefoot Surgery
A.A. Giachino, MD, FRCSC
O perating rooms are often not put to full use because of a 
shortage of anesthetists. However, 
in certain circumstances the sur­
geon can safely administer local 
anesthesia and perform major sur­
gery without complications as dem­
onstrated in this paper.
Method
Eighty-seven patients underwent 
147 procedures which were done on 
100 feet.
In all patients history-taking was 
thorough and physical examination 
included specific questions regard­
ing allergies to local anesthetic and 
family history of malignant hyper­
thermia. All procedures were per­
formed in a regular hospital operat­
ing room. In all patients, an intrave­
nous line was established and elec­
trocardiograms and blood pressure 
monitoring were supervised by the 
circulating nurse. Xylocaine was the 
only local anesthetic used and the 
dosage guidelines set forth in the 
product monograph (Xylocaine Par­
enteral Solutions; Astra Pharma­
ceuticals Canada Ltd., Mississauga, 
Ont.) were followed. The volume of
xylocaine without adrenaline did 
not exceed 4.5 m g/kg and 
xylocaine with adrenaline, 7 
mg/kg.
Technique
Ankle blocks are performed, be­
ginning on the posteromedial as­
pect. A 25-gauge needle is posi­
tioned posterior to the posterior 
tibial artery until paresthesia is pro­
duced in the region of the heel or 
forefoot; then 5 ml of local anes­
thetic is injected (Fig. 1). The sa­
phenous nerve is next anesthetized 
by palpating it next to the saphe­
nous vein and injecting around it. 
The deep peroneal nerve is blocked 
by depositing a small amount of 
xylocaine just superficial to the 
ankle joint capsule by way of the 
interval between extensor hallucis 
longus and tibialis anterior tendons 
(Fig. 2). The superficial peroneal 
nerves are palpated and blocked in a 
ring block fashion (Fig. 3). The 
sural nerve is palpated next to the 
peroneal tubercle and anesthetized 
by a local injection (Fig. 4), except 
in patients who are to undergo 
bunion surgery. For most proce­
dures a tourniquet is applied just 
proximal to the malleoli and the 
pressure adjusted to 100 mm Hg 
above systolic pressure.
Results
Seventy-one ankle blocks and 21 
local infiltrations or digital blocks 
were performed for a variety of 
procedures (Table I).
Only one patient, a hysterical 
teenage girl with a gonococcal 
infection of the great toe metatarso­
phalangeal joint needed conversion 
of the local anesthetic to a general 
anesthetic. There were no medical 
complications.
Use of an ankle tourniquet proxi­
mal to the area of anesthesia was 
not a problem. Major forefoot re­
construction such as a combination 
Fowler and Mayo metatarsal joint 
excisional arthroplasty and proxi­
mal joint fusions was carried out 
with a tourniquet applied for more 
than 1 hour and elicited no com­
plaints from the patients.
Comment
The surgeon can safely and suc­
cessfully administer local anesthesia 
for forefoot surgery. A paresthesia 
must be registered only from the 
posterior tibial nerve, and once the 
foot is prepared and draped and an 
ankle tourniquet applied, access to 
this nerve is markedly limited. To 
limit the volume, and thus possible
From the Division o f Orthopedic Surgery, University o f Ottawa, Ottawa General Hospital, 
Ottawa, Ont.
Presented at the annual meeting o f the Canadian Orthopaedic Association, Edmonton, Alta., 
June 1-5, 1986
Accepted for publication Feb. 2, 1988
Reprint requests to: Dr. A.A. Giachino, Ste. 206, 1929 Russell Rd., Ottawa, Ont. K1G 4G3
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toxicity, of the xylocaine, the sural 
nerve was not anesthetized in bun-
FIG 1. — Paresthesia produced in heel 
by injecting 5 ml of xylocaine posterior 
to posterior tibial artery.
are palpated then blocked.
ion surgery, and the patients were 
told that they would have sensation
FIG. 2 — Injection of xylocaine super­
ficial to ankle joint capsule will block 
deep peroneal nerve.
FIG. 4 — Sural nerve is palpated and 
blocked.
on the lateral aspect of the foot. 
When the sural nerve was blocked 
it was easily palpated and well local­
ized adjacent to the peroneal tuber­
cle. Until the surgeon achieves a 
high success rate in the administra­
tion of the block, a standby anes­
thetist should be available. ■
Table 1 -  Forefoo t P ro ced u res  Perfo rm ed
Procedure No.
U nila tera l
Fo refoo t reco n stru ctio n s 16
Bunion p ro cedures 13
M etatarsa l o steo to m ies 17
Bun ionette  e xc is io n s 3
Pro x im a l in terphalangeal jo in t 
fu s io n s 12
E xo ste c to m ie s 11
H allux rig idus p ro cedures 6
M edial se sam o id e cto m ies 4
M etatarsophalang eal jo in t 
syn o vec to m ie s 4
M orto n ’s  neurom a rese c tio n s 2
G anglion e xc is io n 1
R ad ica l toenail e xc is io n s 11
M isce llan e o u s 21
B ila te ra l
Fo refoo t reco n stru ctio n s 2
M etatarsa l o steo tom y 1
Bunion p ro cedures 2
C o m b inatio ns 8
BOOK REVIEWS
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preoperative care, there are insights 
into methods of treatment that would 
be foreign to most Canadian readers. 
One example of this is forced diuresis 
for endotoxemia. One is left wishing to 
know more about the results of such 
treatment.
This book will appeal to the subspe­
cialist surgeon or the general surgeon 
with a particular interest in the bile 
ducts. There is also a place for it on the 
shelves of the reference library.
R.J. Fairfull-Smith, MB, ChB, FRCSC
Division o f General Surgery,
Ottawa General Hospital,
Ottawa, Ont.
GENITOURINARY ULTRASOUND: A 
TEXT/ATLAS. Edited by Beverly G. 
Coleman. 542 pp. Illust. Igaku-Shoin 
Medical Publishers, Inc., New York; 
W.B. Saunders Company Canada Lim­
ited, Toronto, 1988. $95.75. ISBN 
0-89640-130-8.
Ultrasonography has become indispen­
sable in diagnosing and treating benign 
and malignant genitourinary disease as 
a result of the great improvement over 
the past decade in ultrasound tech­
niques and equipment. This atlas docu­
ments the various applications of ul­
trasonography in urinary tract disease. 
Each ultrasound image is accompanied
by a schematic anatomical reproduction 
and a line drawing to aid in its descrip­
tion and interpretation. The accompan­
ying text is concise and makes for easy 
viewing and, for the non-ultrasonogra- 
pher, a remarkably informative teaching 
tool.
The book covers all aspects of geni­
tourinary disease, including benign and 
malignant disease in both adults and 
children and illustrations of interven­
tional techniques. Although the images 
are well reproduced and extensive, the 
accompanying text is occasionally mis-
continued on page 412
3 8 4 VOL. 31, NO. 6 NOVEMBER 1988/CJS
ROYAL COLLEGE SYMPOSIUM
Symposium on Current Perspectives in 
the Management of Soft-Tissue Sarcoma
1. Incidence, Investigations and Staging of 
Soft-Tissue Sarcoma
Michael G. Rock, MD, FRCSC
Soft-tissue sarcomas account for only 1% of all malignant lesions. The Canadian 
Sarcoma Group encourages the investigation and management of these tumours at 
tertiary institutions, where a multidisciplinary team can handle the complex 
problems. Staging of these tumours implies accurate anatomic determination of the 
extent of disease, the histogenesis and grade of the tumours and the presence of 
regional or distant metastases. Arteriography, computed tomography and magnetic 
resonance imaging can accurately define the tumour before biopsy. The biopsy 
should be muscle-splitting to minimize contamination of additional compartments 
and should allow inclusion of the biopsy site at definitive surgical resection. It 
should be done at the institution where definitive management will be performed. 
Regional lymph-node involvement can be detected using magnetic resonance 
imaging or gallium scanning, whereas for distant metastases, specifically of lung, 
computed tomography is the method of choice.
To date no one staging system for soft-tissue sarcomas has been universally 
accepted. A hybrid, encompassing the advantages of each system, is being 
formulated.
A lthough no accurate statistics exist as to the incidence of 
soft-tissue sarcomas in Canada, it 
has been estimated that in the Unit­
ed States there are 5000 new cases 
annually.
Because of the need for specially 
trained units to manage the com ­
plex problems associated with these 
tumours, 50 referral centres have 
been identified in the United States. 
Unfortunately, this arrangement is 
not feasible in Canada. To manage 
150 to 200 cases a year, quoted as 
being the volume necessary to 
maintain expertise in treating these
Les sarcomes des tissus mous comptent pour seulement 1% de tous les cancers. Le 
Groupe canadien pour les sarcomes soutient la recherche et le traitement de ces 
tumeurs dans des institutions de troisieme ligne, ou des equipes multidisciplinaires 
peuvent prendre charge de problemes complexes. L’etablissement du stade evolutif 
de la maladie suppose la determination anatomique precise de l’etendue de la 
maladie, l’histogenese et le stade de la tumeur et la presence de metastases 
regionales ou eloignees. L’arteriographie, la tomodensitometrie et la resonance 
magnetique nucleaire permettent de definir clairement la tumeur avant la biopsie. La 
biopsie doit etre faite par voie intermusculaire afin de minimiser les risques de 
contamination de compartiments additionnels et doit permettre d’inclure le point de 
biopsie lors de la resection chirurgicale definitive. Elle doit etre pratiquee dans 
l’ institution ou le traitement final sera prodigue. Une atteinte des ganglions 
regionaux peut etre detectee par resonance magnetique nucleaire ou par scinti- 
graphie au gallium, alors que la tomodensitometrie demeure la methode de choix 
pour les metastases a distance, particulierement au poumon.
A ce jour, il n’existe pas de systeme universellement accepte pour determiner le 
stade evolutif des sarcomes des tissus mous. Un systeme hybride, reunissant les 
avantages de chacun, est en voie d’etre formule.
From the Division o f Orthopedic Surgery, 
University Hospital, London, Ont.
Presented as part o f a symposium on current 
perspectives in the management o f soft-tis­
sue sarcomas, by the Royal College in coop­
eration with the Canadian Oncology Society, 
the Canadian Orthopaedic Association and 
the Canadian Association o f Radiation On­
cology, at the 56th annual meeting o f the 
Royal College o f Physicians and Surgeons o f 
Canada, Winnipeg, Man., Sept. 12, 1987
Accepted for publication Apr. 25, 1988
Reprint requests to: Dr. M.G. Rock, Division 
o f Orthopedic Surgery, University Hospital, 
PO Box 5339, 339 Windermere Rd., Lon­
don, Ont. N6A 5A5
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tumours,1 all patients with soft-tis­
sue sarcomas presenting in Canada 
would have to be referred to three 
or four major institutions. Realisti­
cally, patients with these tumours 
will continue to be managed in 
university affiliated tertiary institu­
tions and by capable staff in other 
hospitals. Thus, all surgeons deal­
ing with these problems must be 
current in their knowledge of inves­
tigation and staging.
At meetings dedicated to the sub­
ject, the consensus has been that 
these tumours should be treated by 
a multidisciplinary team. Because 
surgery is the mainstay of manage­
ment, the surgeon should have the 
cooperation of radiologists, special­
ists in nuclear medicine, patholo­
gists, chemotherapists and radiation 
therapists. Before treatment, the 
team should identify the anatomic 
extension of the tumour, the histo- 
genic type and grade, anticipated 
response of the lesion to other 
treatments and patient priority re­
garding such plans.
Defining the Extent of Disease
Patients with soft-tissue tumours 
usually present because of the mass 
effect, which in itself may be 
asymptomatic, painful, compromise 
neurovascular structures, decrease 
mobility of contiguous joints or 
encroach upon or invade abdominal 
or pelvic viscera. It is essential to 
obtain a careful history since expo­
sure to chemical carcinogens such 
as phenoxyacids, chlorophenols, 
phenylchloride gas, or long-stand­
ing use of anabolic steroids have 
been known to induce soft-tissue 
sarcomas, especially hepatomas.2 
Exposure to radiation from outmod­
ed radiotherapy equipment or dur­
ing administration of variable dos­
age radiation can, after a long la­
tent period, result in sarcomatous 
transformation — as with the sec­
J.
ondary development of lymphangi- 
osarcomas in long-standing lym­
phedema after radical breast resec­
tion (the Stewart-Trieves syn­
drome). It is well recognized that 
patients with von Recklinghausen’s 
disease are predisposed to neurofi­
brosarcomas.
Laboratory analysis should in­
clude a complete blood count, mea­
surement of sedimentation rate, 
liver enzymes and alkaline phospha­
tase levels. With large soft-tissue 
sarcomas in which there is central 
necrosis and at times local he­
morrhage, it is not uncommon for 
the patient to have a low hemoglo­
bin value, slightly elevated leuko­
cyte count and a significantly ele­
vated blood sedimentation rate. Al­
though the lung is the preferred 
site of metastases for these tu­
mours, the liver may be involved, 
compromising heptic function. Al­
kaline phosphatase determination is 
necessary when the mass is close to 
osseous structures, with the poten­
tial to invade not only periosteum 
but also underlying cortex. A bone 
scan is mandatory in such cases as 
the area involved must be included 
in a definitive surgical excision.
Indium and gallium scans give 
valuable information. The latter is 
picked up predominantly by the 
reticuloendothelial system, allowing 
imaging of the liver and spleen and, 
more importantly, regional lymph 
nodes at the tumour site. Unlike its 
bone counterpart, some soft-tissue 
sarcomas, notably rhabdomyosar­
coma, synovial sarcoma and malig­
nant fibrous histiocytoma will dis­
seminate to regional nodes in 20% 
to 25% of cases. The indium scan is 
much more selective for infection, 
so any mass whose density on other 
radiologic investigations appears 
consistent with abscess or hemato­
ma may be more effectively identi­
fied.
Dual plain x-ray films are insuffi­
cient to identify essential character­
istics of the tumour (Fig. 1). Distor­
tion of soft-tissue planes, compart­
ment distortion or even scalloping 
of underlying bony structures indi­
cating invasion may be noted, but 
these findings are inadequate when 
deciding on treatment. Similarly, 
ultrasonography, although effective 
in identifying the presence of the 
mass, will not determine its size, 
extension or proximity to various 
muscle groups or neurovascular 
structures. The most useful infor­
mation can be obtained from arteri­
ography, computed tomography
FIG. 1 — Plain x-ray film of thigh of 
35-year-old woman, known to have 
neurofibromatosis. Ill-defined soft-tis­
sue mass is present medially.
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and magnetic resonance imaging. 
Arteriography is indicated when 
soft-tissue tumours adjoin major 
vascular channels. The early phase 
of the arteriogram will allow assess­
ment of anatomic or vessel distor­
tion and indicate the vascularity of 
the lesion; if it appears to be highly 
vascular it may be prudent to carry 
out selective embolization of feed­
ing vessels 24 to 48 hours before 
resection of the mass. The late 
venous phase allows appreciation of 
tumour size and its reactive zone, 
representing the host’s attempt to 
wall off the rapidly growing lesion 
with a zone of hypervascularity, 
fibrous tissue and inflammatory 
cells. This is important information 
because satellite lesions, having 
penetrated the pseudocapsule, will 
sometimes extend into the reactive 
layer from the principal tumour. 
This appearance is erroneously con­
ceived by many surgeons as an 
effective barrier to tumour migra­
tion. This surrounding contaminat­
ed reactive zone may be left behind 
in a marginal excision or shelling- 
out procedure.
With computed tomography it is
possible to define the anatomical 
extension, compromised tissue com­
partments, consistency of the tu­
mour and its proximity to vital 
structures (Fig. 2). This is particu­
larly true of intrapelvic and retro­
peritoneal sarcomas that are ex­
tremely difficult to define anatomi­
cally by means other than computed 
tomography or magnetic resonance 
imaging. Because of the long inter­
val between onset and detection, it 
is not surprising that 15% of pa­
tients have chest metastases at the 
time of initial presentation.6 Com­
puted tomography has also revolu­
tionized the assessment of chest 
metastases among sarcoma patients 
(Fig. 3), and it now plays one of the 
principal roles in the staging of 
these tumours. When taken 5 mm 
apart, a 3-mm nodule can be im­
aged with the scanner, giving a 
sensitivity that is an improvement 
on the 6-mm pick-up with whole 
lung tomography. However, the se­
lectivity of the latter is much more 
accurate. Lesions that are question­
ably granulomatous necessitate ad­
ditional tomography to assess the 
presence of calcification thus fa­
FIG. 2 — This 28-year-old man presented with enlarging mass in left buttock. 
Computed tomography shows large soft-tissue tumour which on open biopsy was 
identified as high-grade malignant fibrous histiocytoma.
vouring granuloma rather than me­
tastasis.
Magnetic resonance imaging rep­
resents a marked improvement, 
even on the information available 
from computed tomography (Fig. 
4). From both axial and coronal 
cuts, the presence of the tumour 
and its relationship to surrounding 
anatomy is much better appreciat­
ed. Magnetic resonance imaging is 
also accurate in identifying fatty 
tumours that may be malignant and 
the presence of extra-abdominal de­
smoid tumours, which have proven 
difficult to identify with convention­
al computed tomography because 
the signals between muscle and 
tumour are similar. Our current 
philosophy for extremity, pelvic and 
retroperitoneal soft-tissue tumours 
is to favour magnetic resonance 
imaging while recognizing that 
computed tomography is more ac­
curate in detecting chest metasta­
ses.
Defining Histogenic Type and 
Grade
After appropriate investigations 
have delineated possible tumour ex­
tension, the histogenic type and
FIG. 3 — Preoperative staging studies 
of patient from Fig. 2 included comput­
ed tomography of chest revealing soli­
tary chest metastasis.
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grade of the tumour must be de­
fined. An adequate biopsy must be 
performed, if possible by the sur­
geon who will ultimately do the 
definitive resection. Undoubtedly, 
there will be situations where exci- 
sional biopsies will be performed for 
what was thought to be a benign 
lesion, but histologically was 
proved to be malignant. If there is 
any suggestion of malignancy, 
evoked by the size, rapid appear­
ance or symptom complex of the 
tumour, the patient should be re­
ferred, before biopsy, to a centre 
where the required expertise and 
ancillary services are available. A 
recent survey by the Musculoskele­
tal Tumor Society3 compared the 
efficacy of performing a biopsy on a 
sarcoma in the referring centre and 
in the treating centre. They found 
that biopsy related problems oc­
curred three to five times more 
frequently when performed at a re­
ferring institution. The Society 
members strongly recommended 
that all aspects of treatment of 
sarcomas be conducted in a recog­
nized facility capable of managing 
such patients.45 If this is not feasi­
ble, the following guidelines should 
be observed to minimize the num­
ber of confusing biopsy findings:
•  In the extremities, flank and 
pelvic area, place the biopsy skin 
incision in line with the underlying 
muscle fibres to avoid compromis­
ing subsequent definitive surgical 
procedures.
•  Transverse incisions can make 
skin coverage difficult after defini­
tive surgical excision. The approach 
to the underlying tumour should be 
of muscle-splitting orientation to 
minimize compartment contamina­
tion and hemorrhage, which should 
be accurately controlled before clo­
sure. Representative tissue, which 
can be determined from preopera­
tive magnetic resonance imaging, 
should be obtained and confirmed 
by a pathologist before the biopsy 
wound is closed.
•  Aerobic and anaerobic swabs 
should be taken at the same time as 
the biopsy to exclude the possibility 
of central necrosis with infection in 
the tumour or the presence of an 
unrecognized abscess.
•  In the recovery room ice 
packs should be placed around the 
biopsy area and activity minimized 
for 24 hours to discourage tracking 
of hematoma along fascial planes.
The biopsy can be performed by 
fine needle, needle, excisional or 
incisional techniques, but the inci­
sional method is preferred. Needle- 
biopsy material demands that the 
pathologist makes a diagnosis on 
cytologic examination alone; this is 
a very difficult proposition, and de­
finitive histogenic classification is 
often impossible. It is also more 
difficult to obtain truly representa­
tive sections, to identify the needle 
tract which must be incorporated in 
the excision of the tumour, because 
of contamination. Excisional biopsy 
leaves residual tumour in the 
wound with possible contamination 
of surrounding tissue.
By electron microscopy and im- 
munohistochemical testing a defini­
tive histogenic type and grade of 
the biopsy specimen can be deter­
mined. This is of more than aca­
demic interest because the natural 
history of the various sarcomas is 
quite different, necessitating altered 
forms of adjuvant therapy.
Staging of Disease
Possibly the most contentious 
and currently debated aspect of 
soft-tissue sarcomas is the means of 
staging. The American Joint Com­
mittee for Cancer Staging and End 
Results Reporting has attempted to 
extrapolate the TNM system, pri-
Fig. 4a Fig. 4b Fig. 4c
FIG. 4 — (a) Computed tomogram of lesion from patient in Fig. 1 revealed solid tumour deep to adductor muscles extending to 
underlying femur, (b) Magnetic resonance imaging, coronal cut. Proximity of tumour to superficial femoral vessels and sciatic 
nerve are better demonstrated. Pseudocapsule and reactive zone around tumour appear more clearly, allowing more accurate 
preoperative determination of contaminated tissues, (c) Magnetic resonance imaging, sagittal cut. Actual longitudinal extension 
of tumour. Neurofibrosarcoma was ultimately removed with wide margins.
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marily used for carcinoma, to soft- 
tissue sarcomas. When the prog­
nostic importance of grade became 
evident it was included into the 
staging system which became the 
GTNM staging system. To physi­
cians managing a large volume of 
soft-tissue sarcomas it became obvi­
ous that the extended TNM classifi­
cation was not applicable to these 
tumours. Members of the Musculo­
skeletal Tumor Society pointed out 
that there was no link between it 
and treatment planning. Inconsis­
tencies arose in prognosis, associat­
ed with overlap of the various 
stages, and the nodal metastases 
introduced at stage III of the dis­
ease implied a better prognosis than 
usually seen with distant lymph- 
node metastases. Moreover, the ma­
jority of physicians managing soft- 
tissue sarcomas also deal with osse­
ous sarcomas, and the proposed 
TNM classification for the former is 
not applicable to the latter. There­
fore, the Musculoskeletal Tumor 
Society proposed an alternative 
staging system for sarcomas,1'6 rec­
ognizing that surgery was the de­
finitive mode of treatment and thus 
the staging system should have 
direct influence on surgical man­
agement. Furthermore, it was sub­
sequently proven that there was no 
intrinsic difference between his- 
togenically similar lesions in soft 
tissue and bone.
The present staging system used 
by most orthopedic surgeons deal­
ing with soft-tissue sarcomas is the 
one subsequently formulated, which 
maintains simplicity for universal 
application and clinical correlation 
with the natural history of these 
tumours. Briefly, it is a three-stage 
system based on the grade of the 
tumour (low G1 or high G2) and 
whether the tumour is intracom- 
partmental (Tl) or extracompart- 
mental (T2). The concept of com- 
partmentalization is important be­
cause it has a direct impact on the 
subsequent surgical management 
and because most anatomical areas 
fall within specific compartments. 
At times (5% of cases), confinement 
within a given compartment proves 
difficult and the classification is not 
as effective. Stage III disease im­
plies distant or nodal metastases, 
recognizing that both carry a poor 
prognosis. This three-stage system 
has been applied to thousands of 
soft-tissue and bone sarcomas with 
reproducible prognoses. The ortho­
pedic community and the interna­
tional Musculoskeletal Tumor Soci­
ety have universally accepted the 
Enneking system because of its sim­
plicity and accuracy of prognosis.
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2. The Role of Chemotherapy in 
Multimodality Therapy
Vivien H.C. Bramwell, PhD, MB, BS, FRCPC
The role of chemotherapy in adult soft-tissue sarcomas is controversial. In this 
review, the author examines the effectiveness of single-agent and combination 
chemotherapy to manage advanced disease and the role of adjuvant combination 
chemotherapy to control primary tumours and prevent the spread of the disease.
Doxorubicin (Adriamycin) is still considered the most effective single agent for 
advanced soft-tissue sarcoma. Ifosfamide has given similar results and may have 
greater potential in combination therapy than cyclophosphamide. A current study 
using trimetrexate shows early positive results.
Doxorubicin, cyclophosphamide, vincristine and dacarbazine is currently the most 
efficacious combination.
The efficacy of adjuvant chemotherapy remains to be established. The majority of 
studies indicate some benefit with chemotherapy, particularly in the relapse-free 
survival rate, but no consistent improvement in overall survival has been noted.
A lthough chemotherapy is of proven benefit in embryonal 
rhabdomyosarcomas of childhood, 
its role in adult soft-tissue sarcomas 
is more controversial. This review 
examines the activity of single and 
combination cytotoxic drugs in ad­
vanced disease. The potential con­
tribution of adjuvant chemotherapy 
in providing local control of primary 
tumours and preventing metastasis 
is analysed.
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Le role de la chimiotherapie dans le sarcome des tissus mous de l’adulte est 
discutable. Cette revue porte sur l’efficacite de la mono et de la polychimiotherapie 
dans le traitement des cancers a un stade avance et du role de la polychimiotherapie 
adjuvante dans la maltrise des tumeurs primitives et dans la prevention de la 
dissemination de la maladie.
La doxorubicine (Adriamycine) est toujours consideree comme le medicament qui, 
utilise seul, est le plus actif contre les sarcomes des tissus mous au stade avance. 
L’ifosfamide a donne des resultats comparables a ceux de la doxorubicine, et semble 
presenter de plus grandes possibility en polychimiotherapie que la cyclophosphami­
de. Une etude presentement en cours avec le trimetrexate laisse prevoir des resultats 
positifs.
Actuellement, la cyclophosphamide, la vincristine et la dacarbazine represented 
l’association la plus active.
L’interet de la chimiotherapie adjuvante reste a etre demontre. La majorite des 
etudes indique qu’elle peut etre d’un certain apport, particulierement en ce qui a 
trait a la survie sans recidive, mais aucune amelioration notable dans la taux de 
survie n’a ete note.
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Advanced Disease
Single Agents
Of the anthracyclines, dox­
orubicin (Adriamycin [ADR]), intro­
duced into clinical practice in the 
early 1970s, is generally acknowl­
edged as the most active single 
agent in the treatment of adult 
soft-tissue sarcomas. A review of 
relevant studies containing more 
than 25 patients,1-8 showed an aver­
age response rate of 24% (range 
from 16% to 41%) in 930 patients. 
An intensive search to identify an­
thracyclines that retain the anti­
tumour efficacy of ADR with less 
toxicity, especially cardiotoxicity, 
has been disappointing; Car- 
minomycin,9 deoxydoxorubicin,10 
Aclacinomycin1112 and demethoxy- 
daunorubicin,13 each showed insig­
nificant activity. When given at 
identical doses (75 m g/m 2 every 3 
weeks) in a study performed by the 
European Organisation for Re-
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search and Treatment of Cancer 
(EORTC), Epiadriamycin was less 
toxic than ADR, but the response 
rate was lower — 15 of 84 (18%) 
versus 21 of 83 (25%) for ADR.14 
This difference was not statistically 
significant, but it is unlikely that 
Epiadriamycin, even if used at a 
dose equitoxic to ADR, will be more 
active.
With respect to alkylating 
agents, ifosfamide, an interesting 
analogue of cyclophosphamide, was 
synthesized in Germany in 1967. 
Reported response rates are avail­
able on 218 patients treated with a 
variety of doses and schedules of 
ifosfamide.15 The average rate of 
28% (range from 18% to 38%) is 
remarkably similar to that for 
ADR.16 However ifosfamide has 
been evaluated in considerably 
fewer patients, and characteristical­
ly the response rate of a new drug 
is inversely proportional to the 
number of patients in which it is 
evaluated. Nevertheless, ifosfamide, 
in contrast to ADR, has been used 
more frequently as second-line che­
motherapy. Response rates in an 
EORTC study comparing ifosfamide 
with cyclophosphamide were 18% 
and 8% respectively17 and provided 
the only single-agent data for cyclo­
phosphamide. Ifosfamide produced 
two responses in 28 previously 
treated patients and three responses 
in 31 patients crossed over after 
failure of cyclophosphamide. The 
response rates for patients who had 
never received chemotherapy were 
10 of 40 (25%) for ifosfamide and 5 
of 38 (13%) for cyclophosphamide. 
Although the rates were not signifi­
cantly different by conventional sta­
tistical analysis, ifosfamide caused 
less myelosuppression than cyclo­
phosphamide, suggesting greater 
potential in combination.
Of other single agents, it is gen­
erally accepted that dacarbazine 
(DTIC) shows limited activity in 
soft-tissue sarcomas,1819 the aver­
age response rate in accumulated 
series (97 patients) being 18% 
(range from 15% to 25%). Cis- 
platinum is very active in osteosar­
coma and has been extensively test­
ed in soft-tissue sarcoma.2'3'5 An 
average response rate of 9% in 150 
patients does not warrant inclusion 
in combination chemotherapy, par­
ticularly as it is a very toxic and 
expensive drug. The data on metho­
trexate are intriguing. A study from 
the United Kingdom20 reported a 
response rate of 25% in 62 patients. 
A variety of doses, routes and
schedules were used in this trial. A 
later EORTC study was unable to 
demonstrate any activity for metho­
trexate given intravenously every 
week in previously treated pa­
tients.21 Although high-dose metho­
trexate has been used in several 
small series,1 there is no evidence 
that its activity is increased, and no 
group has repeated the studies of 
conventional-dose methotrexate. 
The Canadian Sarcoma Group, in 
conjunction with the National Can­
cer Institute of Canada, is currently 
performing a phase II study using 
trimetrexate, a methotrexate ana­
logue, and responses have been 
seen.
Combination Chemotherapy
The drug combination most com­
monly used to treat adult soft-tissue 
sarcomas is CYVADIC (Table I). It 
consists of cyclophosphamide (500 
m g/m 2), vincristine (1.4 m g/m 2, 
day 1), ADR (50 m g/m 2) and dacar­
bazine (250 m g/m 2, days 1 to 5).1-8 
The two most active single agents 
(ADR and dacarbazine) have also 
been used fairly extensively in com­
bination,26 but the response rate 
(Table I) seems lower than that of 
CYVADIC. Other ADR combina­
tions have activity in the same 
range, but none are better than 
CYVADIC.1-8
The addition of ifosfamide to 
ADR2223 has been disappointing 
(Table II). In the EORTC study22 of 
178 patients treated with ADR and 
ifosfamide, the overall response rate 
of 36% was similar to that reported 
for CYVADIC (39%). However, 
nearly half the patients receiving 
CYVADIC manifested disease pro­
gression, whereas the correspond­
ing figure for ADR and ifosfamide 
was 19%. The addition of dacarba­
zine seemed to improve the re­
sponse rate.24 However, this partic­
ular regimen was very myelosup-
Table 1 -  Response to Combination Chemotherapy
Combination No. of patients Response, %
CYVADIC* 750 48 (15-68)
ADR/DTIC 592 27.5 (20-42)
CYCL0/VCR/ADR 70 19
CYCL0/ADR/DTIC 80 35
CYCLO/VCR/ADR/DACT 199 40
CYCL0/ADR/MTX 100 36
‘ Cyclophosphamide, vincristine, Adriamycin, dacarbazine.
ADR =  Adriamycin, DTIC =  dacarbazine, CYCL0 =  cyclophosphamide, VCR =  vincristine, DACT
=  actinomycin D, MTX = methotrexate.
Table II -  Combination Chemotherapy Including Ifosfamide
No. of Response,
Series Combination patients %
Wiltshaw and associates, 198623 ADR +  IF0S 47 36
Schutte and associates, 198622 ADR +  IF0S 178 36
Elias and Antman, 198624 ADR +  IF0S +  DTIC 65 52
ADR =  Adriamycin, IF0S =  ifosfamide, DTIC =  dacarbazine.
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pressive; there was a 23% incidence 
of granulocytopenic fever. A central 
venous line had to be inserted in all 
patients and treatment was given by 
intravenous infusion for 5 days 
every 3 weeks.
The EORTC is currently compar­
ing ADR, CYVADIC and ADR plus 
ifosfamide in a three-arm study; 
393 patients have been entered in 
22 months and the accrual should 
be complete within 6 months. Com­
parative response rates are not yet 
available, but should be very inter­
esting as ADR has never been di­
rectly compared with CYVADIC. 
This study should also clarify the 
value of ifosfamide used in combi­
nation.
The Canadian Sarcoma Group is 
performing a pilot study of the
combination of ADR, ifosfamide and 
dacarbazine, using a shorter, more 
convenient schedule than the Bos­
ton group. The Boston group is 
comparing their schedule of this 
combination with ADR alone.
Primary Management
Intra-arterial Chemotherapy
To improve local control, chemo­
therapy has been given intra-arteri­
ally in conjunction with surgery and 
radiotherapy. There have been no 
randomized studies comparing this 
route of therapy with other meth­
ods for local control, such as radical 
surgery or limited surgery plus ra­
diotherapy. Investigators claiming
superiority for intra-arterial therapy 
have generally compared their re­
sults with historical controls from 
their own centre or results reported 
in the literature, both of which have 
obvious flaws.
Another method of primary man­
agement has been that of isolation 
perfusion with or without hyper­
thermia. Most studies using this 
method were performed between 
1960 and 1980 with drugs such as 
melphalan, actinomycin D and ni­
trogen mustard, whose activity in 
soft-tissue sarcomas is minimal. 
The results of several of these se­
ries25"28 are compared in Table III 
with the results reported by Lind- 
berg and colleagues29 from a group 
of patients treated by surgery and 
radiotherapy in a major centre. 
Limb salvage, local recurrence and 
ultimate outcome in terms of over­
all survival, show little advantage 
for the complex, expensive and 
cumbersome technique of isolation 
perfusion.
The intra-arterial use of ADR 
with or without radiotherapy preop- 
eratively has been reported (Table 
IV).30-32 EUber’s group3334 has the 
most extensive experience and their 
rates of limb salvage and local con­
trol are impressive. However, com­
plications, including pathologic 
fracture of long bones, led them to 
reduce the dose of radiotherapy in
Table III -  Isolation Perfusion With Melphalan, Actinomycin D and Nitrogen Mustard Plus 
Hyperthermia Compared With Surgery Plus Radiotherapy
Series
No. of 
patients
Limb
salvage,
%
Local
recurrence,
"/o
Metastases,
%
Overall
survival,
%
Chemotherapy 
Stehlin and associates, 
198425 65 94 NS NS 73
Lehti and associates, 
198626 64 83 11 33 67
McBride, 197627 85 89 15 23 68
Krementz and associates, 
197728 73 90 25 30 64
No chemotherapy 
Lindberg and associates, 
198129 200 85 20 25 69
NS =  not stated.
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Table IV -  Intra-arterial Adriamycin With Radiotherapy Compared With Preoperative and Postoperative Radiotherapy Without Chemotherapy
Series
No. of 
patients
Follow-up,
mo.
Limb
salvage,
%
Local
recurrence,
%
Metastases,
%
Overall
survival,
"/o
-
Chemotherapy
Mantravadi and associates, 198430 32 15 91 3 25 70 A
Denton and associates, 198431 15 24 80 6 NS 79
Goodnight and associates, 198532 17 32 88 0 35 82
Eiiber and associates, 198433
198534 
Protocol 2 77 60 96 4 NS 64
Protocol 3 105 24 97 8 NS 95
No chemotherapy
Karakousis and associates, 198635 85 >24 96 13 NS 68
Abbatucci and associates. 198636 89 60 93 14 NS 66
NS =  not stated.
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protocol 3 (from 3500 rad in 10 
fractions to 1750 rad) and this 
doubled the local recurrence rate. 
Judging from the results of proto­
col 2, the rate of metastasis was not 
affected by improved local control 
and the survival rate may not be 
better. Protocol 3 still has a very 
short follow-up. When the results 
of preoperative and postoperative 
irradiation as in the studies by 
Karakousis and associates35 and Ab- 
butucci and colleagues,36 are used 
for comparison (Table IV), the local 
recurrence rates with radiotherapy 
only are slightly higher, but the 
outcome is otherwise similar, again 
casting doubt on the value of intra­
arterial chemotherapy. Eilber’s 
group is currently conducting a 
randomized trial comparing intra­
arterial versus intravenous preoper­
ative chemotherapy, and it may be 
that the theoretical advantages of 
intra-arterial chemotherapy will not 
be clinically evident.
Systemic Adjuvant Chemotherapy
Since the frequency of soft-tissue 
sarcoma is approximately 2 in 
100 000, the difficulties of perform­
ing good randomized studies of 
adjuvant chemotherapy in this het­
erogeneous group of tumours are 
obvious. Most studies published or 
in progress are flawed.
To examine the role of adjuvant 
ADR, the results of five randomized 
studies37-41 are summarized (Table 
V); each of them compares a che­
motherapy group with a random­
ized control group treated only by 
surgery with or without radiothera­
py. The Scandinavian study of Alve- 
gard40 is the largest but has been 
reported only in abstract form and 
the follow-up is relatively short. 
Nevertheless, it has the greatest 
power to detect differences between 
the two arms, and the various prog­
nostic factors are more likely to be 
evenly distributed. The Bos- 
ton/ECOG study of Wilson and 
colleagues41 has much longer fol­
low-up than the other studies, and 
although there was a slight delay in 
the appearance of metastases in the 
ADR arm, there have been no sig­
nificant differences in disease-free 
survival or overall survival for all 
patients or those with extremity 
sarcomas only.
The only study giving positive 
results, that of Gherlinzoni and col­
leagues from Bologna,37 has been 
severely criticized.42 The number of 
patients was relatively small and 
there were three different surgical 
groups. These factors, combined 
with a poor randomization tech­
nique, led to considerable imbalance 
in prognostic factors between the 
arms. A recent update of this 
study,43 involving 77 patients (33 
receiving ADR and 44 controls), 
demonstrated improvement in re- 
lapse-free and overall survival for 
the ADR treated group, but the 
median duration of follow-up was 
not stated.
At present there is no firm evi­
dence that adjuvant single-agent 
ADR affords any substantial benefit 
in soft-tissue sarcomas. However, 
delay in the appearance of metasta­
ses in some studies suggests that 
more aggressive chemotherapy may 
be worth pursuing.
Randomized studies of various 
types of combination chemotherapy 
versus control are depicted in Table
V J .« - 4 8
The first study was performed by 
Lindberg and colleagues at the
Table V -  Randomized Studies of Adjuvant Adriamycin
Series
No. of 
patients
Median 
follow-up, mo Outcome
Gherlinzoni and associates, 198637 59 28 RFS p < 0.005 
in favour of 
ADR. No data on 
overall survival
Antman and associates, 198738 64 20 NS
Eilber and associates, 198639 114 30 NS
Alvegard, 198640 146 36 NS
Wilson and associates, 198641 75 49 NS
RFS =  reiapse-free survival, NS = not significant.
Table VI -  Randomized Studies of Adjuvant Combination Chemotherapy
Series Combination
No. Of 
patients
Median
follow-up,
mo Outcome
Edmonson and associates 
(Mayo Clinic), 198444
VCR/DACT/CYCL0 
alternating 
VCR/ADR/DTIC 
12 mo
61 64 NS
Lindberg and associates 
(M.D. Anderson 
Hospital), 197645
Benjamin and associates 
(M.D. Anderson 
Hospital), 198746
VCR/ADR/CYCLO
VCR/DACT/CYCL0 
24 mo
43 120 RFS, p =  0.04 in 
favour of 
chemotherapy OS 
NS
Rosenberg and associates 
(National Cancer 
Institute), 198547
ADR/CYCLO/HDMTX 
14 mo
65 60 RFS and OS, p =  0.04 
in favour of 
chemotherapy
Bramwell and associates, 
198748
CYVADIC 
8 mo
317 37 RFS, p =  0.01 in 
favour of 
chemotherapy OS 
NS
NS =  not significant, OS =  overall survival, HDMTX =  high-dose methotrexate.
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M.D. Anderson Hospital and Tumor 
Institute in the early 1970s and 
reported after 18 months’ follow­
up.45 At that time, the chemothera­
py group was doing slightly, al­
though not significantly, worse. Re­
cently this study has been rea­
nalysed after 10 years’ follow-up.46 
The relapse-free survival now fa­
vours the chemotherapy group, but 
although overall survival is better 
for that group, the difference is not 
significant. Local recurrence was 
lower in the chemotherapy arm (two 
versus eight), but metastases oc­
curred with similar frequency — 
45% (9 of 20) in the chemotherapy 
group versus 48% (11 of 23) in 
controls.
Because the early results of the 
M.D. Anderson Hospital study were 
negative, the trial from the United 
States National Cancer Institute 
was the first randomized study47 to 
suggest benefit for adjuvant chemo­
therapy. It should be emphasized 
that this study had serious flaws — 
the number of patients was very 
small, increasing the likelihood of 
imbalance of known and, more im­
portantly, unknown prognostic fac­
tors between the arms; the control 
group has done worse than expect­
ed when compared with results re­
ported by other centres, thus mag­
nifying the difference between the 
two arms. Because the ADR dose 
was pushed to tolerance there was a 
30% incidence of subclinical cardi­
omyopathy detected by nuclear 
medicine scans, and three patients 
suffered congestive heart failure. 
Benefit was observed only in ex­
tremity sarcomas; the same chemo­
therapy had no effect in head, neck 
and trunk sarcomas. The most re­
cent analysis,49 with median follow­
up of 7 years, no longer demon­
strates improved survival for the 
chemotherapy group (p = 0.124).
Building on the results of their 
previous study,47 and dismayed by 
the high incidence of cardiomyopa­
thy, Rosenberg and colleagues com­
pared their “standard” chemothera­
py with an abbreviated course of 
treatment, giving much lower total 
doses of ADR and cyclophospha­
mide and omitting high-dose me­
thotrexate.49 There were no signifi­
cant differences between the two 
treatments, in terms of 5-year dis­
ease-free (72%) and overall (75%) 
survival. In view of the lack of 
efficacy of ADR as an adjuvant, and 
the minimal activity of cyclophos­
phamide in advanced disease, it 
would be surprising if this combina­
tion proves to be effective.
A Mayo Clinic study44 did not 
demonstrate any benefit for adju­
vant chemotherapy, but the inci­
dence of local recurrence (30%) was 
high in this trial, perhaps because 
radiotherapy was not used. In addi­
tion, the chemotherapy used was 
inadequate — the vincristine, acti- 
nomycin D, cyclosphosphamide 
combination is inactive in advanced 
disease, and as vincristine, ADR, 
dacarbazine was only alternated 
every 6 weeks with the first combi­
nation, patients received active 
drugs only every 12 weeks, and at a 
low dose intensity.
For all patients in the EORTC 
study,48 there was a significant im­
provement in relapse-free survival in 
the CYVADIC arm (p = 0.01), 
although this is of borderline signif­
icance on subgroup analysis by site, 
for both limb sarcomas (p = 0.06) 
and those of the head, neck and 
trunk (p = 0.09). However, there 
was no benefit for any group in 
terms of overall survival. In fact, 
the improvement in relapse-free sur­
vival was entirely accounted for by 
reduced local recurrence in the CY­
VADIC arm (p = 0.005) whereas 
distant metastases occurred with 
equal frequency in both arms (p = 
0.28). It is intriguing that the re­
duction in local recurrence seems to 
be occurring in head, neck and 
trunk tumours.
Conclusions
Although the majority of studies 
suggest some limited benefit for 
adjuvant chemotherapy, the optimal 
regimen and timing of such therapy 
remain to be established. The con­
clusions of the National Institutes 
of Health Consensus Development 
Conference on Bone and Soft-Tis­
sue Sarcomas, 1984, remain rele­
vant — “the efficacy of adjuvant 
systemic chemotherapy for high 
grade sarcomas remains to be estab­
lished within the context of pro­
spective clinical trials.”50
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SESAP V Question
Items 253-255
A 54-year-old man has noted an increase in the size of his left thigh over the last 18 months. Physical 
examination reveals a fairly well-circumscribed, rubbery, nontender, 9.0- X 5.0-cm mass on the medial aspect of 
the thigh, noticeably more prominent with the knee extended. The patient has no history of trauma or recent 
infection.
253. The procedure LEAST likely to aid in management of this patient is
(A) conventional roentgenography of the thigh
(B) angiography
(C) ultrasonography of the thigh
(D) computed tomography of the thigh
(E) lymphangiography
254. A soft tissue mass is demonstrated in a subfascial plane of the thigh. The most appropriate method for 
determining the histopathology would be
(A) multiple percutaneous aspiration needle biopsies
(B) incisional biopsy
(C) “ core"’ needle biopsy
(D) enucleation of the lesion for biopsy
(E) wide local excision
255. Pathologic examination shows liposarcoma. Definitive treatment might include each of the following 
EXCEPT
(A) wide anatomic soft-part resection
(B) adjuvant postoperative radiotherapy
(C) adjuvant postoperative chemotherapy
(D) preoperative radiation therapy
(E) preoperative systemic chemotherapy
For the incomplete statements above, select the one completion for each that is best of the five given.
For the critique of Items 253-255 see page 426.
(Reproduced by permission from SESAP V Syllabus: Surgical Education and Self-Assessment Program No. 5. 
For enrolment in the Surgical Education and Self-Assessment Program No. 5, please apply to the American 
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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3. Limb-Sparing Management in Extremity 
Soft-Tissue Sarcomas in the Adult: the 
Radiation Oncologist’s Viewpoint
Brian O’Sullivan, MB, FRCPC
Current management of extremity soft-tissue sarcomas achieves local control in a 
high proportion of patients. This paper describes the local methods to conserve limb 
function that have largely replaced traditional approaches of ablative surgery. 
Frequently, these methods employ conservative surgery with preoperative or 
postoperative radiotherapy. An understanding of the biology and behaviour of these 
rare tumours is necessary to optimize the goals of limb conservation without 
compromising local control. Appropriate surgical and radiotherapy techniques are 
facilitated by planned pretreatment staging methods and communication between the 
surgical and radiation oncology teams. Although a high rate of local control can be 
expected, distant metastases continue to be a problem. Future strategies should be 
directed towards scheduling of optimal local treatments with the investigation of 
adjuvant systemic methods to reduce the rate of distant metastases.
Le traitement actuel des sarcomes des tissus mous des membres assure une cure 
locale chez un grand nombre de malades. Cet article decrit les moyens utilises 
localement pour conserver la fonction du membre, lesquels ont largement remplace 
l’approche traditionnelle de chirurgie ablative. Souvent, ces methodes ont recours a 
une chirurgie conservatrice accompagnee d’une radiotherapie pre- et postoperatoire. 
II est necessaire de bien connaitre la biologie et le comportement de ces tumeurs 
rares, si Ton veut optimiser l’objectif de conserver le membre sans compromettre la 
cure locale. Les techniques chirurgicales et radiotherapeutiques appropriees sont 
rendues plus faciles par une planification des methodes employees avant traitement 
pour evaluer le stade evolutif de la maladie, et par une bonne communication entre 
les equipes de chirurgie et de radiotherapie. Meme si on peut s’attendre a un bon 
taux de cures locales, les metastases a distance demeurent un probleme. Dans 
l’avenir, les strategies devront viser a etablir un programme des traitements locaux 
optimums, tout en cherchant les therapies adjuvantes systemiques destinees a 
reduire le taux des metastases a distance.
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Thirty years ago Cade1-2 noted that radiotherapy combined 
with surgery was of greater value 
than surgery alone in treating soft- 
tissue sarcoma of the extremities. 
Because of a long-standing miscon­
ception that these tumours were 
resistant to radiotherapy,3 the main­
stay of management continued to 
be radical surgical excision, often 
consisting of limb amputation, and 
only recently have Cade’s observa­
tions been widely accepted. An un­
derstanding of certain biologic, 
technical and behavioural features 
of these lesions and their treatment 
has resulted in a modified philoso­
phy toward management. This dis­
cussion focuses on some of these 
issues, provides evidence for the 
efficacy of adjuvant radiotherapy in 
a conservative surgical approach 
and describes the radiotherapy op­
tions and methods of administra­
tion.
Biologic Issues of Importance 
for Radiotherapy
The Compartmental Nature of 
Soft-Tissue Sarcomas
Soft-tissue sarcomas typically re­
spect fascial boundaries, intermus­
cular septae, bones, tendons and 
joint capsules. As a result, tum our 
enlargement in most cases remains 
confined to the compartment of
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origin and occurs centifugally along 
fascial planes. Extracompartmental 
spread by direct invasion is uncom­
mon but may be seen in very large 
or neglected lesions. Usually it re­
sults from an extracompartmental 
origin de novo or from diagnostic 
(biopsy) or therapeutic (resection) 
interventions, which have breached 
a fascial boundary. Lesions arising 
de novo in intercompartmental 
spaces (extracompartmentally) pose 
specific problems for both surgeon 
and radiation oncologist in their 
choice of appropriate resection or 
radiation volumes. Such sites in­
clude the femoral triangle, popliteal 
fossa and antecubital fossa, axilla 
and subcutaneous tissues where 
distinct barriers to tumour spread 
are not present. Management of 
compartmental lesions, on the other 
hand, can make use of the localized 
nature of the tumour, thereby spar­
ing unnecessary resection. Local 
treatment must be planned with 
knowledge of the precise localiza­
tion of the tumour and the areas at 
risk for subclinical disease. Where 
available, magnetic resonance imag­
ing and computed tomography help 
to identify the anatomic extent of 
the disease and also any important 
structures that may be involved in 
the dissection. Together with the 
operative and pathology reports,
FIG. 1 — Gross specimen of fibrosar­
coma after compartmental resection. 
Tumour is growing into surrounding 
muscle (A) on most of surface where it 
has formed pseudocapsule. Fascial 
layer contains growth (B) in remaining 
area.
initial imaging information is also 
useful when planning subsequent 
postoperative radiotherapy fields.
Regional Node Involvement
Regional lymph nodes are in­
volved in only 3% to 5% of adults 
with an extremity lesion,4 an excep­
tion being epithelioid sarcoma, for 
which rates approaching 50% have 
been quoted for synchronous and 
metachronous nodal disease.5 How­
ever, regional node dissections and 
deliberate inclusion of nodes within 
radiation treatment portals are not 
routine. To do this would com­
pound the technical problems in­
volved in providing optimal preser­
vation of limb function because of 
complications relating to surgery 
and radiotherapy.
The Capsule or Pseudocapsule
Unfortunately there is no defined 
anatomic capsule to provide a local 
barrier to tumour spread. On the 
contrary, the apparent “capsule” is 
nothing more than a layer of com­
pressed normal tissue created by 
the rapid centrifugal expansion of 
tumour. This layer is invaded by 
microaggregates of tumour as is 
the surrounding reactive zone of 
peripheral normal tissue (Figs. 1
Fig. 2a
and 2). Similar microaggregates can 
be expected to exist some distance 
from the margins of gross tumour 
and may form tumour satellites or 
micrometastases in higher grade le­
sions. Furthermore, if the pseudo­
capsule has been penetrated during 
surgery, areas around the dissection 
site or involved in residual hemato­
ma will likely harbour tumour 
cells.6 This explains local failure 
after both conservative and radical 
procedures involving marginal tu­
mour removal. For the same rea­
sons, if gross tumour is visible 
within the wound it can be accepted 
that tumour seeding has occurred, 
even if the affected area is subse­
quently totally resected through 
the same incision. These concepts 
also explain “field edge” local 
failures after postoperative radio­
therapy, when tumour cells may 
have migrated some distance along 
fascial planes during the dissection, 
in postsurgical hematoma or pri­
marily as micrometastases.6
Specific Pathologic Details
There is agreement that similar 
management approaches are re­
quired for the individual histologic 
subtypes of soft-tissue sarcoma. Al­
though different histologic sub- 
types may occur more commonly in
Fig. 2b
FIG. 2 — (a) Part of pseudocapsule shows tumour cells infiltrating and 
interdigitating between muscle fibres, (b) Fascial area shows tumour contained by 
true barrier to tumour spread (hematoxylin and eosin, original magnification X 
200) .
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certain age groups or anatomic 
sites, their behaviour is more close­
ly linked to tumour size and grade. 
Indeed, alterations in management 
have been suggested, depending on 
the grade of the lesion; higher 
doses and larger volumes are fa­
voured for higher grade lesions.7 
Microscopic findings of incomplete 
removal are indications for further 
treatment; further surgical removal 
should be attempted when feasible 
and is usually combined with adju­
vant preoperative or postoperative 
radiotherapy. In surgical resections 
that included radical margins of 
healthy tissue (minimum 2 cm), the 
benefit of radiotherapy is unproven.
Adjuvant Radiotherapy
Goals o f Treatment
Table I4-8 describes the expected 
outcome of surgery as the only 
treatment. The terms used conform 
to accepted terminology8 for proce­
dures ranging from intralesional, 
marginal and wide excisions to 
more radical forms of surgery with 
variable amounts of tumour residu­
um. Both local and ablative surgical 
excisions may be described by these 
terms. An ablative operation includ­
ing a radical margin of healthy 
tissue is expected to provide at least 
80% local control of the primary 
lesion; if such margins cannot be 
obtained this level of control cannot 
be achieved and the tumour may be 
better managed by using combined 
approaches. Satisfactory outcomes 
for conservative limb-sparing sur­
gery alone or in combination with 
adjuvant radiotherapy should pre­
serve limb function at an acceptable 
level of risk and also retain local 
control and survival rates similar to 
those of ablative surgery.
Principles in Adjuvant Radiotherapy
Gross tumour can be controlled 
by radiotherapy alone, but the re­
sults are inferior to those achieved
by conventional approaches.9 Sur­
gery alone necessitates radical mar­
gins (2 cm minimum); if lesser mar­
gins are planned, adjuvant radio­
therapy should be considered. In 
any treatment decision, it should be 
realized that a satisfactory function­
al result may be achieved by conser­
vative resection with preoperative 
radiotherapy instead of postopera­
tive radiotherapy for an ablative 
procedure with inadequate margins. 
In the latter case, the patient has 
received combined modality treat­
ment without the benefits of limb 
conservation.10
Strategies for the combined use 
of radiotherapy and surgical resec­
tion include preoperative,1011 post­
operative,12-14 intraoperative10 and 
brachytherapy techniques.15 Preop­
erative radiotherapy has been com­
bined with intra-arterial chemother­
apy,1617 and frequently postopera­
tive “boosts” are included. Altered 
fractionation regimens have also 
been described for both preopera­
tive (with16 and without chemother­
apy18) and postoperative sched­
ules.19 The method of administra­
tion of radiotherapy is governed by 
a combination of factors, including 
referral pattern, institutional poli­
cies and the available resources.
Table II demonstrates pooled 
data for the use of adjuvant radio­
therapy compared with radical sur­
gery. The important feature demon­
strated is the excellent local control 
achieved regardless of the adjuvant 
treatment used. Survival outcome is 
not prejudiced by conservative com­
bined modality approaches com­
pared with radical surgery.20
Table III illustrates the relative 
merits of preoperative and postoper­
ative radiotherapy. In general, a 
smaller volume of normal tissue 
requires treatment if the therapy is 
administered preoperatively; postop­
erative treatment must include a 
margin of normal tissue beyond the 
limit of surgical dissection. Thus,
T a b le  1 -  Local Control After Surgery as the Sole Modality*
Local
P ro c e d u re t D efin ition C onsequences fa ilu re , %
Intralesional Incision through 
pseudocapsule
Residual gross tumour. 
All tissues 
contaminated
9 0 -1 0 0
Excisional
(marginal)
Pseudocapsule removed “ Shell-out":
microscopic tumour 
remains
8 0 - 9 0
Wide Removal with “ normal" 
tissue
Frequently leaves 
microscopic tumour
50
Radical Removal with
uninvolved anatomic 
barrier (>  2 cm)
No residual tumour 0 - 2 0
‘ Data from Simon and Enneking® and Leibel.4
tTerminology describes features of surgical margin not technique of removal.
T a b le  II -  Patterns of Failure for Radical Surgery Alone and Conservative Surgery with 
Postoperative Radiotherapy
No. of 
cases
Local fa ilu re  
and d is tan t 
m e ta s ta s e s , %
D is tan t
m e tas tases , %
Radical surgery and/or amputation 
alone
464 18.1 31.5
Conservative surgery and postop 
radiotherapy
416 18.3 22.6
‘ Data from Suit and colleagues.10
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all skin incisions and tissue planes 
that have been disrupted during the 
procedure are at risk from contami­
nation by tumour satellites and skip 
lesions and require inclusion within 
the zone of irradiation. This may 
necessitate treatment to otherwise 
uninvolved regions including joints, 
an entire limb circumference or ex­
tensive length of an extremity. Fur­
thermore, a planned preoperative 
course assists communication be­
tween treating surgeons and radia­
tion oncologists; surgical proce­
dures are discussed beforehand with 
knowledge of the proposed tissues 
to be irradiated, and the topography 
of surgical scars can be planned 
with precision. Radiation treatment 
portals can be reviewed in conjunc­
tion with the diagnostic x-ray films 
and histologic findings. In this man­
ner difficult management issues can 
be minimized.
Postoperative referral for radio­
therapy may be associated with pro­
cedures that counteract the goals of 
limb-sparing treatment. If preopera­
tive imaging has not documented 
the tumour location and if the pa­
tient has not been assessed before­
hand by the radiation oncologist, 
irradiation volumes tend to be ex­
cessive. Unplanned surgical ap­
proaches may result in transverse 
incisions crossing from involved to 
uninvolved compartments, and 
drain sites positioned in unsatisfac­
tory locations; these may signifi­
cantly expand the potential regions 
of contamination and the width of 
limb requiring treatment. Conse­
quent irradiation can result in pain­
ful fibrosis, distal edema and loss of 
function, which may ultimately lead 
to limb amputation. Another con­
sideration is the availability of a 
final pathology report when using 
postoperative radiotherapy. This is 
a theoretical advantage because the 
management approach should be 
determined beforehand based on the 
initial incisional biopsy. Rarely,
wound healing may be delayed by 
preoperative therapy and after ex­
tensive or complicated surgery in 
the absence of radiotherapy. In the 
latter situation, one is faced with 
the dilemma of an unhealed wound 
that may contain active tumour, 
and the need to delay therapy to 
allow the wound to mature. Since 
active tumour seedings will be pres­
ent at the tumour margins, preoper­
ative treatment allows combined 
therapy to be completed in the 
shortest time and problems of 
wound healing can be considered 
knowing the threat of tumour re­
growth is less.
Finally, preoperative and postop­
erative radiotherapy, although 
providing essentially similar rates of 
local control, are not truly compara­
ble. Suit and associates10 showed 
that their patients who received 
preoperative therapy had a greater 
number of lesions larger than 10 
cm in dimension (43% versus 18% 
for postoperative therapy). Al­
though prospective comparison may 
present a useful clinical exercise, its 
feasibility would be affected by the 
number of “inoperable” cases that 
could not be managed in a postop­
erative regimen, requiring preopera­
tive treatment as the only realistic 
approach and thereby rendering in­
terpretation of the results difficult.
Technical Factors and Radiotherapy
For the radiation oncologist, soft- 
tissue sarcomas present challenging 
but time-consuming treatment
plans. Management of other forms 
of malignant disease usually utilizes 
standard treatment, involving radia­
tion fields determined by variations 
around conventional anatomic land­
marks. In contradistinction, extrem­
ity soft-tissue sarcomas are atypical, 
and therapy is outlined according to 
the principle of sparing a maximum 
volume of normal tissue while en­
compassing an acceptable target 
volume.
Optimal dose delivery usually in­
volves the use of several beams and 
different qualities of radiation (i.e., 
photons, electrons or interstitial im­
plants). Beam configurations should 
be assessed initially on a simulator 
(a diagnostic-like x-ray unit de­
signed to mimic the precise geome­
try of the chosen therapy machine). 
Fluoroscopy and roentgenography 
to demonstrate beam arrangements 
are additional features of this proc­
ess. Verification port films on the 
treatment machine are then taken 
before treatment begins. In general, 
the goal of the therapy is the 
administration of a moderate dose 
(e.g., 50 Gy in 25 treatments) to a 
volume judged to contain micro­
scopic amounts of tumour. This 
volume will differ, depending on 
whether the situation is preopera­
tive or postoperative. Most authors 
recommend margins ranging from 5 
to 10 cm beyond involved tissues 
and advise the larger volumes for 
high-grade lesions.7 21 Higher doses 
are administered by reduced portals 
to tissues at higher risk (the surgi­
cal bed and scars) to provide mini-
Table III -  Is s u e s  in P re op e ra tive  and P os to pe ra tive  R a d io th e ra p y  S ch e d u lin g
Issue Preoperative Postoperative
In te rsp e c ia lty  c o m m u n ic a tio n E xce llen t F re q u e n tly  ab se n t
T u m o u r co n tro l p ro b a b ility E xce lle n t V e ry  good
“ In o pe rab le ”  d ise ase S tanda rd P reop  requ ired
W o u n d  hea ling P o te n tia l de lay A ffe c te d  s o le ly  by su rg ica l 
e x te n t
R ad io the rapy  v o lu m e M in im u m D e te rm in e d  by su rg ica l 
e x te n t
P a th o log y  d e ta ils B io p sy  o n ly Fu ll sp e c im e n
Functiona l o u tc o m e S m a ll ra d ia tion  v o lu m e  m ay 
enhance
A cce p ta b le
v-
u .
V
r ' '
V r
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mum tumour doses of 60 Gy in 30 
treatments for low-grade lesions 
and 66 Gy in 33 treatments for the 
higher grade lesions.7
The initial volume should include 
all surgical scars and the tumour 
area determined clinically and by 
computed tomography and magnet­
ic resonance imaging. Postoperative 
treatment is facilitated by surgical 
clips inserted at the tumour site 
(Fig. 3). Radiotherapy planning is 
assisted by computerized dosimetry 
interphasing with computed tomo­
graphic images of the patient in the 
treatment position. This allows the 
optimal choice of radiotherapy vol­
ume (Fig. 4). As far as possible, a 
generous longitudinal strip of the 
limb circumference is protected dur­
ing treatment to avoid circumferen­
tial fibrosis and distal edema. Immo­
bilization of the limb may enhance 
repetition of the daily treatment
Fig. 3a
plan. Beam modification by com­
pensators and wedge filters may 
contribute to a more uniform distri­
bution of dose within the chosen 
region by correcting for irregulari­
ties in patient contour. Other beam 
modifiers include shields, which ex­
clude tissues from the treatment 
volume, and a tissue-like bolus me­
dium, which allows the dose to be 
placed on the surface of scars and 
grafted regions when using skin­
sparing megavoltage (greater than 
1 MeV) photon and electron beam 
treatment.
Brachytherapy
Excellent local control has been 
reported at Memorial Sloan Ketter­
ing Center15 by combining conser­
vative limb-sparing surgery with 
postoperative tumour bed irradia­
tion using iridium-192. The proce-
Fig. 3b
dure involves the postoperative in­
sertion of iridium sources into the 
tumour bed 72 hours after loading 
catheters are positioned, 1 cm 
apart, at the time of surgery. Doses 
of approximately 40 Gy are admin­
istered over 4 to 5 days and have 
shown local control rates approach­
ing 100%.15 The method offers an 
alternative effective means of spar­
ing the limb, but because it involves 
a commitment to brachytherapy 
techniques including technical ex­
pertise and necessary cooperation 
between a large group of different 
specialties, it is not practised in 
many centres.
Indications for Radiotherapy
Although “close” or positive 
margins of surgical resection repre­
sent indications for radiotherapy, 
there is no uniform agreement that 
radiotherapy should be carried out 
in all such cases. Further surgical 
resection may be indicated before 
radiotherapy is administered if the 
margins of resection are indeed in­
adequate.
In their study, the Roswell Park 
Group12 omitted radiotherapy in pa-
FIG. 4 — Preoperative radiotherapy 
treatment plan for malignant fibrous 
histiocytoma in lateral compartment of 
lower leg. Surgeon believed lesion 
could not be resected without entering 
all three compartments of leg. Preop­
erative treatment permits anterior 
compartment to be spared. This would 
have been impossible postoperatively. 
(Field arrangement: two opposed co- 
balt-60 beams 10 X 15 cm.)
FIG. 3 — (a) Patient in prone position receiving postoperative radiotherapy for 
tumour originating in left deltoid region. Megavoltage photons are directed to 
spare medial side of left upper arm. (Field is defined by light field of treatment 
unit.) Note longitudinal scar positioned in lateral deltoid area, (b) Simulator film. 
Clips define surgical bed. Shield is to be introduced after dose of 40 Gy to protect 
humoral head and shoulder joint.
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tients whose tumours were resected 
with a minimum margin of 2 cm. 
The 5-year local control rates for 
this group (83%) compared favoura­
bly (93%) with a group who re­
ceived postoperative radiotherapy 
after tumour resection in which the 
margins were less than 2 cm. De­
tails of prognostic factors (grade 
and size for both groups and micro­
scopic residuum for the group with 
margins less than 2 cm) were not 
provided for the two groups sepa­
rately. These data suggest that a 
2-cm margin may be safe for resec­
tion alone, although, in the absence 
of information to the contrary, cau­
tion should still be exercised for 
large and high-grade lesions.
At the other extreme of patients 
having tumour resection with 
“close” margins, is the patient with 
microscopic involvement of resec­
tion margins. Leibel and associ­
ates13 suggested that postoperative 
radiotherapy can effectively sterilize 
“microscopic or small amounts of 
visible tumour at the margin” . De­
spite this report, postoperative ra­
diotherapy, after incomplete sur­
gery, has had an adverse effect on 
local control in several reports, in­
cluding a retrospective series (Bell 
RS, O’Sullivan B: Unpublished data, 
1988) from The Princess Margaret 
Hospital in Toronto (Fig. 5). Four 
groups were identified according to 
whether the margins of resection 
were microscopically involved, and 
whether the margins were achieved 
by a single or multiple surgical 
procedures (excluding biopsy). For 
the combined group with micro­
scopic involvement of resection 
margins, the 5-year actuarial local 
control rate was 50% and the out­
come for the two subsets was not 
significantly altered by the number 
of surgical procedures. For the 
group with clear margins, regard­
less of how close these were, the 
Figure was 92% and remained unin­
fluenced by a second procedure per­
formed to obtain negative margins. 
The detrimental effect of involved 
surgical margins on local control 
was independent of other known 
adverse factors, including tumour 
grade and size.
Two series10-20 reported unfavou­
rable local control rates when dis­
ease was present in the margins of 
resection. Incomplete surgery and 
postoperative radiotherapy for le­
sions staged IIB, IIIB, and IVA 
provided 5-year actuarial local con­
trol of 58%, compared with 75% for 
similar-stage recurrent disease and 
83% for complete resection.10 Ro­
senberg and colleagues20 reported 
greater likelihood of local recur­
rence if resection margins were pos­
itive than if they were negative (p < 
0.0001), despite the use of radio­
therapy postoperatively.
Normal Tissue Effects After 
Limb-Sparing Treatment
Criteria for assessing limb func­
tion have varied between series and 
the literature contains no confident 
statements based on prospective 
data. Nevertheless, acceptable func­
tion can be expected in 80% to 90% 
of patients after radiotherapy and 
surgical resection, although this 
rate will vary depending on the 
nature of the underlying disease 
process, the extent of surgical re­
section and the volume of radiation 
administered. Series in which preop­
erative radiotherapy was used1016’17 
had higher complication rates (more 
than 10%) than those in which 
postoperative radiotherapy was 
used (6.5%).14 This may be because 
of delayed wound healing after the 
former but is more likely owing to 
larger tumours requiring more ex­
tensive surgery.
Conclusions
Extremity sarcomas represent a 
rare group of malignant lesions. 
The combined efforts of many dif­
ferent medical disciplines have suc­
ceeded in improving management 
over the past 20 years, mainly in 
the area of local control where 
similar rates of control and survival 
have been achieved by limb-sparing 
methods and by ablative surgery. 
Unfortunately metastases still devel-
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op rapidly in high-risk patients. 
Future efforts should be directed 
toward more effective systemic ad­
juvant therapy —  innovations are 
needed in scheduling radiotherapy 
and chemotherapy to integrate 
these two modalities with surgery. 
In this manner, patient survival may 
be enhanced without danger of 
compromising local control and 
functional outcome.
References
1. Cade S: Soft tissue tumours: their natu­
ral history and treatment; president’s 
address. Proc R Soc Med 1951; 44: 19- 
36
2. Idem: Tumours of bone and soft tissue. 
Sarcoma of bone and soft tissue. In 
Carling ER, W indeyer BW, Smithers 
DW (eds): British Practice in Radiother­
apy, Butterworth, London, 1955: 407- 
422
3. Paterson R, Tod M, Russell M: Com­
mentary on tumours of connective tis­
sue. In: The Results o f Radium and 
X-Ray Therapy in Malignant Disease: 
Being the Third Statistical Report from 
The Radium Institute, The Christie Hos­
pital and Holt Radium Institute, Man­
chester, Years 1940 to 1944 Inclusive 
Assessed at 5 Years and 1934 to 1938 
Assessed at 10 Years, E. & S. Living­
stone Ltd., Edinburgh, 1950: 59
4. Leibel SA: Soft tissue sarcomas: thera­
peutic results and rationale for conser­
vative surgery and radiation therapy. In 
Phillips TL, Pistenmaa DA (eds): Radia­
tion Oncology Annual, Raven, New 
York, 1984: 153-177
5. Shimm DS, Suit HD: Radiation therapy 
of epithelioid sarcoma. Cancer 1983; 52: 
1022-1025
6. Ennekinc WF, Spanier SS, Malawer 
MM: The effect of the Anatomic setting 
on the results of surgical procedures for 
soft parts sarcoma of the thigh. Cancer 
1981; 47: 1005-1022
7. Lindberg RD: Soft tissue sarcoma. In 
Fletcher GH: Textbook o f Radiothera­
py, 3rd ed, Lea & Febiger, Philadelphia, 
1980: 922-942
8. Simon MA, Enneking WF: The manage­
ment of soft-tissue sarcomas of the 
extremities. J Bone Joint Surg [Am] 
1976; 58: 317-327
9. Tepper JE, Suit HD: Radiation therapy 
alone for sarcoma of soft tissue. Cancer 
1985; 56: 475-479
10. Suit HD, Mankin HJ, Wood WC, et al: 
Preoperative, intraoperative, and postop­
erative radiation in the treatment of 
primary soft tissue sarcoma. Cancer 
1985; 55: 2659-2667
11. Atkinson L, Garvan JM, Newton NC: 
Behaviour and management of soft con­
nective tissue sarcomas. Cancer 1963; 
16;1552-1562
12. Karakousis CP, Emrich LJ, Rao U, et al: 
Feasibility of limb salvage and survival 
in soft tissue sarcomas. Cancer 1986; 
57: 484-491
13. Leibel SA, Tranbauch RF. W ara WM, 
et al: Soft tissue sarcomas of the ex­
tremities: survival and patterns of failure 
with conservative surgery and postoper­
ative irradiation compared to surgery 
alone. Cancer 1982; 50: 1076-1083
14. Lindberg RD, Martin RG, Romsdahl 
MM, et al: Conservative surgery and 
postoperative radiotherapy in 300 adults 
with soft-tissue sarcomas. Cancer 1981; 
47:2391-2397
15. Hilaris BS, Shiu MH, Dattatreyudu N, 
et al: Limb-sparing therapy for locally 
advanced soft-tissue sarcomas. En- 
docurietherapy/Hyperthermia Oncology 
1985; 1: 17 -24
16. Giuliano AE, Eilber FR: The rationale 
for planned reoperation after unplanned 
total excision of soft-tissue sarcomas. J 
Clin Oncol 1985; 3: 1344-1348
17. Goodnicht IE jr, Barcar WL, Voegeli 
T, et al: Limb-sparing surgery for ex­
tremity sarcomas after preoperative in­
traarterial doxorubicin and radiation 
therapy. Am J Surg 1985; 150: 109- 
113
18. Bryant M, Martinez A, Pritchard D, et 
al: Soft tissue sarcomas of the extremi­
ties: morbidity of combined radiation 
and limb salvage with special emphasis 
on twice a day fractionation (abstr). Int J 
Radiat Oncol Biol Phys 1985; 11 (suppl 
1): 87
19. Ashby MA, Ago CT, Harmer CL: Hypo- 
fractionated radiotherapy for sarcomas. 
Int J Radiat Oncol Biol Phys 1986; 12: 
13-17
20. Rosenberg SA, Tepper J, Glatstein E, 
et al: The treatment of soft-tissue sarco­
mas of the extremities: prospective ran­
domized evaluations of (1) limb-sparing 
surgery plus radiation therapy compared 
with amputation and (2) the role of 
adjuvant chemotherapy. Ann Surg 
1982; 196: 305-315
21. Tepper J, Rosenberg SA, Glatstein E: 
Radiation therapy technique in soft tis­
sue sarcomas of the extremity — poli­
cies of treatment at the National Cancer 
Institute. Int J Radiat Oncol Biol Phys 
1982; 8: 263-273
BOOKS RECEIVED
This list is an acknowledgement of 
books received. It does not preclude 
review at a later date.
The Basic Science of Vascular Sur­
gery. Edited by Joseph M. Giordano, 
Hugh H. Trout, III and Ralph G. DePal- 
ma. 773 pp. Iilust. Futura Publishing 
Co., Inc., Mount Kisco, New York, 
1988. $89.00 (US). ISBN 0-87993- 
321-6.
Breast Cancer. Collaborative Manage­
ment. Edited by Jay K. Harness, Harold 
A. Oberman, Allen S. Lichter, Dorit D. 
Adler and Robert L. Cody. 390 pp. 
Iilust. Lewis Publishers, Inc., Chelsea, 
Mich., 1988. $69.95 (US). ISBN
0-87371-106-8.
Essential Surgical Practice. 2nd edi­
tion. Edited by A. Cuschieri, G.R. Giles 
and A.R. Moosa. 1438 pp. Iilust. But­
terworth International Edition, Stone- 
ham, Mass., 1988. $125.00 (US). ISBN 
0-7236-1127-0.
Metabolic Complications of Acute Ar­
terial Occlusions and Related Condi­
tions (Myonephropathic-Metabolic 
Syndrome). Henry Haimovici. 328 pp. 
Iilust. Futura Publishing Co., Inc., 
Mount Kisco, New York, 1988. $45.00 
(US). ISBN 0-87993-324-0.
Obstetric Anesthesia: the Complicated 
Patient. Edited by Francis M. James, 
III, A. Scott Wheeler and David M. 
Dewan. 577 pp. Iilust. F.A. Davis Com­
pany, Philadelphia, 1988. $79.00 (US). 
ISBN 0-8036-4914-2.
Operative Ultrasonography During 
Hepatobiliary and Pancreatic Surgery.
Edited by B. Deixonne and F-M. Lopez. 
134 pp. Iilust. Springer-Verlag, Berlin; 
Springer-Verlag New York, Inc., Secau- 
cus, NJ, 1988. $89.50 (US). ISBN 
0-387-17630-6.
Perspectives in Radiology. Edited by 
Clyde A. Helms. 166 pp. Iilust. Quality 
Medical Publishing, Inc., St. Louis, 
Mo., 1988. $171.00. ISSN 0896-873-X.
continued on page 454
VOL. 31, NO. 6 NOVEMBER 1988/CJS 403
ROYAL COLLEGE SYMPOSIUM
4. Role of the Pathologist in the 
Management of Soft-Tissue Sarcomas
A.J. Worth, MD, FRCPC
The contribution of the pathologist to the management of soft-tissue sarcomas is 
threefold. First, and most important, is to establish the correct pathological 
diagnosis which should include the histologic type, subtype and grade of the 
tumour. This information, correlated with the size, site, clinical and radiologic 
presentation, is the key factor in determining the biologic behaviour of the tumour. 
As soft-tissue sarcomas frequently demonstrate histologic variability from one area 
to another, biopsy with computed tomography or radiologic guidance and adequate 
sampling is essential.
Second, careful marking of the surgical resection margins in consultation with 
the surgeon is necessary to determine the completeness of excision.
Third, examination of the resected specimen may also provide useful information 
on the sensitivity of the sarcoma to any previous radiation or chemotherapy which 
the patient may have received.
The pathologist’s contribution to the management of patients 
with soft-tissue sarcomas is in mak­
ing the correct diagnosis and ex­
pressing the characteristics of the 
tumour in such a way that the 
management team has a clear un­
derstanding of its biologic potential. 
An appreciation of the local region­
al growth patterns and the potential 
of metastatic spread are essential in 
planning the type and sequence of 
the various treatments.
La contribution du pathologiste au traitement des sarcomes des tissus mous se fait 
sentir a trois niveaux. En premier lieu, contribution la plus importante, il y a 
l’etablissement d’un diagnostic precis, comprenant le type et le sous-type 
histologiques, ainsi que le stade evolutif de la tumeur. Cette information, mise en 
correlation avec la taille, la localisation et le tableau clinique et radiologique, est 
primordiale pour determiner le comportement biologique de la tumeur. Comme les 
sarcomes des tissus mous manifestent souvent une variabilite histologique d’une 
region a l’autre, il est essentiel de pratiquer sous controle tomodensitometrique ou 
radiologique, une biopsie avec prelevement adequat.
Second apport, la delimination soigneuse de la marge de resection chirurgicale, 
etablie en collaboration avec le chirurgien, est necessaire pour permettre une 
excision complete.
Troisiemement, l’examen du materiel reseque peut aussi fournir une information 
utile sur la sensibilite du sarcome aux traitements radiologiques ou chimio- 
therapeutiques qu’aurait pu recevoir le malade, prealablement.
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Behaviour
To evaluate the behaviour of a 
soft-tissue sarcoma, one needs to 
know the cell type, grade, mitotic 
rate, size, depth and site. These 
factors, considered together, are the 
most useful prognostic indicators. 
In general, the smaller and the 
more superficial the tumour is, the 
less likelihood there is that metasta- 
ses will develop. Similarly, tumours 
located distally tend to metastasize 
less frequently than more proximal 
lesions that frequently are deeply 
placed, large and of high grade.1-4 
It is not surprising that tumours 
situated deep within the soft tissues 
tend to be larger at the time of 
diagnosis as they are less likely to 
be noticed by the patient and fre­
quently are misinterpreted initially 
as being reactive processes. Failure 
to consider a soft-tissue sarcoma in 
the initial differential diagnosis is
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surprisingly common.5 This may re­
sult in an inappropriately placed 
biopsy incision or an incomplete 
local incision, both of which may 
compromise the subsequent defini­
tive surgery and increase the 
amount of potentially contaminated 
normal tissue that must be removed 
to ensure adequate margins.
Soft-tissue sarcomas are rare­
ly truly encapsulated but may 
be surrounded by pseudocapsule 
of compressed normal tissues and 
a reactive zone, giving a clinical 
impression of encapsulation. They 
usually display infiltrating mar­
gins with tongues of tumour which 
may, on occasion, extend several 
centimetres beyond the palpable 
disease. Malignant fibrous histi­
ocytoma and dermatofibrosarcoma 
protuberans are examples of such 
tumours; both tend to grow along 
fascial planes in a diffuse perme­
ative fashion that the surgeon may 
not notice.12 This accounts for the 
multiple recurrences frequently 
seen adjacent to or within scars of 
previous incomplete excisions. A 
superficially placed malignant fi­
brous histiocytoma that has not 
penetrated the fascia seldom metas­
tasizes.1’2 Multiple recurrences may 
lead eventually to dedifferentiation 
or recurrence of the higher grade 
components of the tumour which 
precede metastatic spread.67 At­
tempted enucleation or piecemeal 
excision of soft-tissue sarcomas 
usually fails, but when a carefully 
planned excision is undertaken with 
preoperative evaluation of the tu­
mour by computed tomography or 
magnetic resonance imaging and a 
knowledge of the pathologic fea­
tures and pattern of spread, local 
control is achieved in the majority 
of patients without amputation.
Typing
Many sarcomas may be subtyped
according to their histologic pat­
tern. The subtypes frequently corre­
late with the nuclear grade of the 
tumour. For example, within the 
liposarcoma category, a low-grade 
well-differentiated lipoma-like sub- 
type, a moderate-grade myxoid lipo­
sarcoma or high-grade pleomorphic 
or lipoblastic subtype may be recog­
nized.12 The first two subtypes in­
frequently metastasize, whereas the 
pleomorphic or round-cell lipoblast­
ic type of liposarcoma frequently 
does.1’2 Sarcomas are often hetero­
geneous, a single lesion presenting 
with a variety of subtypes and vari­
able histologic grade.12 It is impor­
tant to realize this, as a single-nee­
dle core or aspirate may not be 
representative of the entire lesion. 
Focal necrosis may also be present.
The usual metastatic pattern of 
spread of a sarcoma is to lung and 
bone, with infrequent involvement 
of regional nodes.12 For example, 
the histologic pattern reflects the 
pattern of metastatic spread as well 
as the metastatic potential. In con­
trast to the usual metastatic spread, 
synovial sarcomas may metastasize 
to the regional lymph nodes in 
approximately 20% of cases and 
have a tendency to spread along 
tenosynovial and aponeurotic planes 
in a discontinuous fashion.12 The 
surgeon must understand their be­
haviour and carefully examine the 
regional lymph nodes and the te­
nosynovial plane resection margins 
to ensure completeness of excision. 
A preoperative computed tomogram 
may be helpful, as may frozen sec­
tions from the resection margins at 
the time of definitive surgery. Em­
bryonal and alveolar rhabdomyosar­
comas also frequently metastasize 
to regional nodes,12 whereas the 
adult pleomorphic type infrequently 
does.1’2 Some soft-tissue sarcomas 
may have an unusual metastatic 
pattern, such as epithelioid sarco­
mas which may metastasize to the 
soft tissue of the scalp.12 Although
locally aggressive, many soft-tissue 
sarcomas are late to invade the deep 
fascial planes and tend to displace 
the neurovascular bundles;1-2 both 
these features may be delineated on 
the computed tomogram. High- 
grade small cell tumours, such as 
lymphomas and neuroepithelioid le­
sions, are more permeative, sur­
rounding and less frequently dis­
placing neurovascular bundles, than 
the large cell pleomorphic sarcomas 
such as liposarcomas and fibrous 
histiocytomas.12
Diagnosis
The differential diagnosis of soft- 
tissue sarcomas depends on the site 
of the lesion and the age of the 
patient;12 it is much more likely 
that the soft-tissue sarcoma in a 
child will be a small-celled high- 
grade one such as an embryonal 
sarcoma, neuroblastoma, lymphoma 
or Ewing’s sarcoma than in an 
adult in whom such lesions, apart 
from lymphomas, are infrequent.12 
For a precise diagnosis and correct 
evaluation of biologic potential, it is 
important that the tumour be ade­
quately sampled. This can best be 
achieved by consultation between 
the radiologist, surgeon and pathol­
ogist, who together can evaluate 
the radiologic appearance of the 
tumour and plan the areas to be 
sampled, choosing areas of different 
texture, both close to the “capsule” 
and deep within the tumour, so that 
the biopsy material obtained is rep­
resentative of the entire lesion.
Tumour Sampling
Various techniques may be used 
to obtain a sample of tumour. Fine- 
needle aspiration may be helpful 
initially in determining whether the 
lesion is a soft-tissue tumour rather 
than an abscess or a reactive proc-
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ess. Great caution is required, how­
ever, in interpreting such aspirates, 
because highly mitotic, highly cellu­
lar reactive proliferative lesions 
such as necrotizing fasciitis, pseu- 
dosarcomatous fasciitis and myosi­
tis ossificans may be easily misinter­
preted as a high-grade malignant 
lesion. Needle biopsies that yield 
generous cores of tissue or open 
biopsies are preferred for diagnosis 
because they allow better histologic 
evaluation of the tumour. In addi­
tion to the routine processing of 
tumours, electron microscopy, im­
munologic staining, including mo­
noclonal stains, flow cytometry and 
chromosomal analysis may all be 
helpful in arriving at a definitive 
diagnosis. In order to utilize these 
techniques, a variety of fixatives 
may be desirable. The surgeon 
should alert the pathologist of the 
time of biopsy and the pathologist 
should either obtain the specimen 
directly from the operating room in 
an unfixed state or have the speci­
men sent immediately in transport 
medium to the laboratory for pro­
cessing. If this is not possible, the 
pathologist should be consulted as 
to the desired fixative or fixatives to 
be used in each case.
Evaluation of Resection 
Margins
Similarly, there should be close 
cooperation between the surgeon 
and pathologist in the evaluation of 
the resection margins of the excised 
specimen. In order to do this thor­
oughly, it will help if the surgeon 
orients the specimen for the pathol­
ogist, indicating the resection mar­
gins of greatest concern. It should 
be remembered that when fascial 
planes are incised by the surgeon, 
the fascial tissues tend to retract, 
exposing adjacent muscular or fatty 
tissues which did not constitute the 
true excision margin. If the pathol­
ogist cannot evaluate this and does 
not have the surgeon’s assistance 
to do so, he may inappropriately 
mark margins that are thought to 
represent excision margins. A vari­
ety of solutions may be used to 
mark the excision margins; these 
include India ink, silver nitrate and 
laundry bluing, the latter being 
nontoxic and easy to handle.
Radiotherapy and 
Chemotherapy
Additional information as to the 
extent of residual disease and lym­
phatic, vascular or neural invasion 
may help to determine the need for 
further therapy. If radiotherapy or 
chemotherapy have already been ad­
ministered, a comparison of the 
degree of tumour necrosis, residual 
viable disease and persistent mitotic 
activity relative to the original spec­
imen may provide an estimate of the 
degree of effectiveness of the thera­
py that the patient received. Vari­
ous grading systems to evaluate cell 
damage have been proposed and 
have been reported to be useful in 
evaluating osteogenic sarcomas. 
The effect of the treatment on the 
adjacent normal tissues can also be 
evaluated, although morphologic 
evidence of the vascular damage, 
which is so important in determin­
ing long-term radiation reactions, 
often is not perceptible until 3 
months or more after the initiation 
of radiotherapy.
Summary
The pathologist has an important 
role to play in both the diagnosis 
and management of patients with 
soft-tissue sarcoma. Optimally, 
there should be consultation be­
tween the radiologist, pathologist, 
surgeon and oncologist starting be­
fore the initial biopsy investigation 
so that the biopsy and subsequent 
surgical management can be well 
planned and chemotherapy and ra­
diotherapy appropriately integrated 
into the overall treatment regimen.
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Announcing a  
transform ation 
o f parenteral antibiotic 
therapy
PRIMAXINu
^  (imipenem and cilastatin sodium for injection)
41
.. Trademark the first caihapenem antibiotic
PRIMAXIN
(imipenem and cilastatin sodium for injection)
LV pH
*Yt?
A carbapenem, representing a totally new class of antibiotics
The broadest spectrum  
single-agent antibiotic
possessing bactericidal activity against a great 
m ajority of clinically significant pathogens
PRIM AXIN* offers the activity of
the penicillins against gram-positive aerobes -  
including coverage of Streptococcus faecalis
plus
the aminoglycosides and 3rd generation cephalosporins
against gram-negative aerobes -
including coverage of Pseudomonas aeruginosa
plus
the antianaerobic agents -  
including coverage of Bacteroidesfragilis
u
\\
PRIMAXIN* is not active against Corynebacterium group JK, Fusobacterium varium, Mycobacterium spp., 
Chlamydia spp, Streptococcus faecium, Pseudomonas maltophilia, and some strains of: P. cepacia,
P. pseudomallei, methicillin-resistant staphylococci, and Flavobacterium spp.
Single-agent antibiotic for 
documented and empiric
therapy in many important 
infections
□ infections usually treated with combination 
therapy
□ infections complicated by underlying 
disease
□ nosocomial infections
Imipenem and cilastatin sodium are present in a 1:1 ratio in PRIMAXIN* I.V. 
Imipenem is the sole antibacterial component. The role of cilastatin sodium is to 
prevent the inactivation of imipenem in the kidney and obtain antibacterial 
concentrations of imipenem in the urine.
tCaused by organisms susceptible to PRIMAXIN* I.V.
,
PRIMAXIN
(im ipenem  and cilastatin sodium for injection) *
IV
Clinical efficacy in many important infections'
EFFICACY IN INTRA-ABDOMINAL INFECTIONS'
91% cure or 
improvement
in  164 evaluable patients
1. Kager, L., Nord, C.E.: Im ipenem / 
cilastatin in the treatment of intra­
abdominal infections: A review of 
worldwide experience, Rev Infect Dis 
7 (Suppl 3): S518-S521, July-August 
1985.
EFFICACY IN LOWER RESPIRATORY TRACT 
INFECTIONS2
85% cure or 
improvement
in 204 evaluable 
patients
2. Acar, J.F.: Therapy for lower 
respiratory tract infections with 
imipenem/cilastatin: A review of 
worldwide experience, Rev Infect Dis 
7 (Suppl 3): S513-S517, July-August 
1985.
+Caused by organisms susceptible to PRIMAXIN* I.V.
EFFICACY IN BACTERIAL SEPTICEMIA3
90%  cure or 
improvement
in 135 evaluable 
patients
3. Eron, L.J.:
Imipenem/cilastatin 
therapy of bacteremia,
Am J Med 78 (Suppl 6A): 
95-99, June 7, 1985.
EFFICACY IN GYNECOLOGICAL
INFECTIONS4
97%  cure or 
improvement
in 72 evaluable 
patients
4. Sweet, R.L.: Imipenem/ 
cilastatin in the treatment 
of obstetric and gynecologic 
infections: A review of 
worldwide experience,
Rev Infect Dis 7 (Suppl 3):
S522-S527, July-August 1985.
PRIMAXIN
(imipenem and cilastatin sodium for injection)
IV
PRIMAXIN* LV. offers management 
advantages over combination therapy 
that includes an aminoglycoside
Generally well tolerated -  
safety profile
sim ilar to cefazolin' ’
EU 1723 patients, including the severely ill, have received therapy in clinical trials.
The incidence of the most common adverse experience (nausea) was no greater 
than 2%.
0 Avoids the potential nephrotoxicity or ototoxicity experienced with 
aminoglycosides.
□ Avoids the potential hypoprothrombinemia and clinical bleeding experienced 
with cephalosporins with MTTf side chain.
□ Avoids the potential disulfiram-like effect experienced with metronidazole and v 
cephalosporins with MTT side chain.
Convenience of a single agent
The broadest spectrum  single­
agent antibiotic representing 
a transformation of parenteral 
antibiotic therapy
5. Calandra G.B., Ricci F.M., Wang C., Brown K.R.: Safety and 
tolerance comparison of imipenem/cilastatin to cephalothin and 
cefazolin, J  Antimicrob Chemother 12(supplD): 125-131,1983.
f Certain antibiotics which possess, as part of their molecular structure, the l-methyl-5-thiotetrazole (MTT) 
group have been associated with hypoprothrombinemia (and in some cases, clinical bleeding) and with 
a disulfiram-like effect.
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PRIMAXIN*
(imipenem and cilastatin sodium 
for injection)
« Antibiotic
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CNS adverse experiences such as myoclonic 
activity, confusional states, or seizures have 
been reported with PRIMAXIN’ especially when 
recommended dosages based on renal function 
and body weight were exceeded. These exper­
iences have occurred most commonly in patients 
with CNS disorders (e.g., brain lesions or 
history of seizures) and/or who have compro­
mised renal function. However, there were rare 
reports in which there was no recognized or 
documented underlying CNS disorder. Close 
adherence to recommended dosage schedules 
is urged, especially in patients with known factors 
that predispose to seizures.
^  ACTION
Imipenem exerts a bactericidal action by inhibiting 
cell wall synthesis in aerobic and anaerobic gram- 
positive and gram-negative bacteria.
PRIMAXIN* consists of two com ponents: 
** (1) imipenem, a derivative of thienamycin, a 
carbapenem antibiotic; and (2) cilastatin sodium, a 
*. -'specific inhibitor of dehydropeptidase-l a renal 
enzyme w hich metabolizes and inactivates 
imipenem. Cilastatin blocks the metabolism of 
imipenem in the kidney, so that concomitant 
administration of imipenem and cilastatin allows 
j  antibacterial levels of imipenem to be attained in the 
urine.
-i Inhibition of cell-wall synthesis is achieved in gram­
negative bacteria by the binding of imipenem to 
penicillin binding proteins (PBPs). In the case of 
*■ ' E sch e rich ia  c o l i  and se lec ted  s tra in s  of 
Pseudomonas aeruginosa, imipenem has been 
- shown to have highest affinity for PBP-2, PBP-1a 
and PBP-1 b, with lower activity against PBP-3. The 
preferential binding of imipenem on PBP-2 and 
PBP-1 b leads to direct conversion of the individual 
cell to a spheroplast resulting in rapid lysis and cell 
death without filament formation. When imipenem 
M is removed prior to complete killing of gram­
negative species, the remaining viable cells show a 
4 measurable lag, termed a “post-antibiotic effect" 
(PAE), prior to resumption of new growth.
-4 INDICATIONS AND CLINICAL USE
PRIMAXIN* (imipenem and cilastatin sodium for 
* injection) may be indicated in the treatment of 
serious infections when caused by sensitive strains 
of bacteria. Where considered necessary, therapy 
’’  may be initiated on the basis of clinical judgment 
before results of sensitivity testings are available, 
v Continuation of therapy should be reevaluated on 
the basis of bacteriological findings and of the 
patient’s clinical condition.
Imipenem is active in vitro against a wide range of 
yy gram-positive and gram-negative aerobic and 
anaerobic bacteria, including most strains which 
are beta-lactamase producing. Patients have 
responded while under treatment with PRIMAXIN* 
for single or mixed infections of the following body 
systems, when they were associated with a number 
of pathogenic species and strains of the genera
listed
1. Lower Respiratory Tract Infections
2. Urinary Tract Infections
YW 3. Intra-Abdominal Infections
4. Gynecological Infections
! 5. Septicemia
r 6’Endocarditis caused by Staphylococcus aureus
L  7. Bone and Joint Infections
8. Skin Structure Infections
-  -i Gram-positive Aerobes
• Listeria monocytogenes
* • Nocardia asteroides
• Staphylococcus (excluding many strains 
which are methicillin resistant)
^  • Streptococcus (excluding S. faecium)
+ Gram-negative Aerobes
• Acinetobacter
* Citrobacter
• Enterobacter
• Escherichia coli
* • Haemophilus influenzae
• Haemophilus paraintiuenzae
• Klebsiella
• Morganella morganii
•  Neisseria
•  Proteus (indole positive and indole negative 
strains)
•  Providencia
•  Pseudomonas aeruginosa
•  Serratia marcescens
Gram-positive Anaerobes
•  Clostridium (excluding C. difficile)
•  Peptococcus
•  Peptostreptoccus
Gram-negative Anaerobes
•  Bacteroides fragilis
•  Bacteroides (non-fragilis)
CONTRAINDICATIONS
PRIMAXIN* (imipenem and cilastatin sodium for 
injection) is contraindicated in patients who have 
shown hypersensitivity to either component of this 
product.
WARNINGS
PRIMAXIN* (imipenem and cilastatin sodium for 
in jec tio n ) SHOULD BE ADMINISTERED WITH 
CAUTION TO ANY PATIENT WHO HAS DEMONS­
TRATED SOME FORM OF ALLERGY, PARTICULARLY 
TO STRUCTURALLY-RELATED DRUGS. IF AN 
ALLERGIC REACTION TO PRIMAXIN* OCCURS, 
DISCONTINUE THE DRUG. SERIOUS HYPER­
S EN S IT IV ITY  REACTIONS MAY REQUIRE 
EPINEPHRINE AND OTHER EMERGENCY 
MEASURES.
Pseudomembranous colitis
Pseudomembranous colitis has been reported with 
the use of PRIMAXIN*. Therefore it is important to 
consider this diagnosis in patients who develop 
diarrhea during or after therapy. This colitis may 
range from mild to life threatening in severity.
Mild cases of pseudomembranous colitis may 
respond to drug discontinuance alone. In more 
seve re  cases, m anagem ent may in c lu d e  
sigm o idoscopy, appropria te  bacte rio log ica l 
studies, flu id, electrolyte and protein supple­
mentation, and the use of a drug such as oral 
vancomycin, as indicated. Other causes of colitis 
should also be considered.
PRECAUTIONS
General
Prolonged use of PRIMAXIN* (imipenem and 
cilastatin  sodium for in jection) may result in 
overgrowth of resistant organisms. Repeated 
evaluation of the patient’s condition is essential. If 
superinfection occurs during therapy, appropriate 
measures should be taken.
CNS adverse experiences such as myoclonic 
activity, confusional*states, or seizures have been 
reported with PRIMAXIN* especially when recom­
mended dosages based on renal function and body 
weight were exceeded. These experiences have 
occurred most commonly in patients with CNS 
disorders (e.g., brain lesions or history of seizures) 
and/or who have compromised renal function. 
However, there were rare reports in which there was 
no recognized or documented underlying CNS 
disorder. Close adherence to recommended dosage 
schedules is urged especially in patients with 
known factors that predispose to seizures (see 
DOSAGE AND A D M IN IS T R A T IO N ). A n t i­
convulsant therapy should be continued in patients 
with a known seizure disorder. If focal tremors, 
myoclonus, or seizures occur, patients should be 
evaluated neurologically and placed on anti­
convulsant therapy if not already instituted. If CNS 
symptoms continue, the dosage of PRIMAXIN* 
should be decreased or discontinued.
Use in Patients with Impaired Renal Function
Dosage in patients with impaired renal function is 
based on the severity of infection but the maximum 
daily dose varies with the degree of renal functional 
im pa irm en t (see DOSAGE AND A D M IN IS­
TRATION - Dosage in Patients w ith Renal 
Insufficiency).
Use in Pregnancy
The use of PRIMAXIN* in pregnant women has not 
been studied, therefore, PRIMAXIN* should be used 
during pregnancy only if clearly needed. Use of this 
drug in women of childbearing potential requires 
that the anticipated benefits be weighed against 
possible hazards.
Reproduction studies with bolus I .V. doses suggest 
an apparent intolerance to PRIMAXIN* (including 
emesis, inappetence, body weight loss, diarrhea
and death) at doses equivalent to the average 
human dose in pregnant rabbits and cynomolgus 
monkeys that is not seen in non-pregnant animals in 
these or other species. In other studies, PRIMAXIN* 
was well tolerated in equivalent or higher doses (up 
to 11 times the average human dose) in pregnant 
rats and mice (see REPRODUCTION STUDIES 
under TOXICOLOGY in the complete monograph).
Nursing Mothers
It is not known whether PRIMAXIN* is excreted in 
milk. If the use of PRIMAXIN* is deemed essential, 
the patient should stop nursing.
Pediatric Use
Efficacy and tolerability in infants under the age of 
3 months have not yet been established; therefore, 
PRIMAXIN* is not recommended in the pediatric 
age group below the age of 3 months.
Drug Interactions
Concomitant administration of PRIMAXIN* and 
probenecid results in only minimal increases in 
plasma levels of imipenem and plasma half-life. It is 
not recommended that probenecid be given with 
PRIMAXIN*.
PRIMAXIN* should not be mixed with or physically 
added to other antibiotics. PRIMAXIN* has been 
administered concomitantly with some antibiotics, 
such as aminoglycosides.
There is no evidence to suggest that association of 
PRIMAXIN* with any other beta-lactam antibiotics 
has any therapeutic advantage.
ADVERSE REACTIONS
PRIMAXIN’ (imipenem and cilastatin sodium for 
injection) is generally well tolerated. The following 
adverse reactions were reported on 1,723 patients 
treated in clinical trials. Many of these patients were 
severely ill and had multiple background diseases 
and physiological impairments, making it difficult to 
determ ine causal relationship of adverse ex­
periences to therapy with PRIMAXIN*.
Local Adverse Reactions
Adverse local clinical reactions that were reported 
as possibly, probably or definitely related to therapy 
with PRIMAXIN* were:
Incidence (%)
Phlebitis/thrombophlebitis 1.7
Infused vein pain 0.6
Vein induration 0.2
Infused vein infection 0.1
Systemic Adverse Reactions
Adverse clinical reactions that were reported as
poss ib ly , p robab ly , or de fin ite ly re lated to
PRIMAXIN* were:
Incidence (%)
Gastrointestinal
nausea 2.0
diarrhea 1.7
vomiting 1.6
tongue papillar hypertrophy 0.2
pseudomembranous colitis
(see WARNINGS) 0.1
hemorrhagic colitis <0.1
gastroenteritis <0.1
abdominal pain <0.1
glossitis <0.1
heartburn <0.1
pharyngeal pain <0.1
increased salivation <0.1
CNS
fever 0.4
dizziness 0.3
seizures 0.2
(see PRECAUTIONS)
somnolence 0.2
confusion 0.2
myoclonus 0.1
vertigo 0.1
headache 0.1
encephalopathy <0.1
paresthesia <0.1
Special Senses
transient hearing loss in
patients with impaired hearing <0.1
tinnitus <0.1
Respiratory TABLE 1 Dosage in Infants and Children
dyspnea 0.1
hyperventilation <0.1
thoracic spine pain <0.1
Cardiovascular
hypotension 0.4
palpitations 0.1
tachycardia <0.1
Renal
oliguria/anuria <0.1
polyuria <0.1
Skin
rash 0.9
pruritus 0.3
urticaria 0.2
skin texture changes 0.1
candidiasis 0.1
erythema multiforme <0.1
facial edema <0.1
flushing <0.1
cyanosis <0.1
hyperhidrosis <0.1
pruritus vulvae <0.1
Body as a whole
polyarthralgia <0.1
asthenia/weakness <0.1
Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug 
relationship, that were reported during clinical trials 
were:
Hepatic: Increased SGPT, SGOT, alkaline phospha­
tase, bilirubin and LDH,
Hemic: Increased eosinophils, positive Coombs 
test, decreased WBC and neutrophils, increased 
WBC, increased platelets, decreased platelets, 
decreased hemoglobin and hematocrit, increased 
monocytes, abnormal prothrombin time, increased 
lymphocytes, increased basophils.
Electrolytes: Decreased serum sodium, increased 
potassium, increased chloride.
Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red 
blood cells, urine white blood cells, urine casts, 
urine bilirubin, and urine urobilinogen.
TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN* (imipenem and cilastatin sodium for 
injection) is cleared by hemodialysis.
DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN* 
(imipenem and cilastatin sodium for injection) 
represent the quantity of imipenem to be ad­
ministered by I.V. infusion only. An equivalent 
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN* should be determined by 
the severity of the infection, renal function, body 
weight, the antibiotic susceptibility of the causative 
organism(s) and the condition of the patient. Doses 
cited are based on body weight of 70 kilos.
The median duration of treatment with PRIMAXIN* 
in clinical trials for infections of the various body 
systems ranged from 6 to 10 days except for 
endocarditis and bone and joint infections for which 
the median duration of treatment was 4 weeks.
Dosage in Adults
The recommended daily dose is 1 to 2 g adminis­
tered in equally divided doses every 6 to 8 hours 
(see Table 1).
Dosage in Elderly Patients
The recommended dosage of PRIMAXIN* in elderly 
patients with normal renal function is the same as 
given for adults above. Renal status of elderly 
patients may not be accurately portrayed by 
measurement of BUN or creatinine alone. Deter­
mination of creatinine clearance is suggested to 
provide guidance for dosing in such patients.
ADULT DOSAGE OF PRIMAXIN*
I.V. Adm inistration
Severity 
of infection
Dose
(m g of im ipenem )
Dosage
Interval
Daily
Dose
Mild 250 mg 6 h 1.0 g
Moderate 500 mg 8 h 1.5 g
Severe (fully 
susceptible)
500 mg 6 h 2.0 g
Severe* infections 
due to less 
susceptible 
organisms 
or life threatening 
conditions
1000 mg 
1000 mg
8 h 
6 h
3.0 g
4.0 g
* Primarily some strains of Ps. aeruginosa.
The recommended total daily dosage of PRIMAXIN* 
in children and infants 3 months of age and older is 
60 to 100 mg/kg of body weight divided into 4 equal 
doses given at six hour intervals. The higher 
dosages should be used for infants and young 
children. The total daily dosage should not exceed *  
2 grams. C lin ica l data are in s u ff ic ie n t to 
recommend an optimum dose for infants and *  
children with impaired renal function.
Administration *--•
CAUTION: CONTENTS OF VIALS NOT FOR . 
DIRECT INFUSION. *
Each reconstituted 250 mg or 500 mg dose should 
be given by intravenous infusion over twenty to *  
th irty minutes. Each 1000 mg dose should be 
infused over 40 to 60 minutes. In patients who ,» 
develop nausea during the infusion, the rate of 
infusion may be slowed.
RECONSTITUTION
The maximum daily dose should not exceed 4 g or 
50 mg/kg, which ever is less.
Dosage in Patients with Renal Insufficiency
P a tie n ts  w ith  c re a t in in e  c le a ra n c e s  o f 
<5 mL/min/1.73m2 (<0.08 mL/s/1.73m2) should 
not receive PRIMAXIN* unless hemodialysis is 
instituted within 48 hours. Both imipenem and 
cilastatin are cleared from the circulation during 
hem odia lys is . The pa tien t sho u ld  receive 
PRIMAXIN* after hemodialysis and at 12 hour 
intervals timed from the end of that hemodialysis 
session. Dialysis patients, especially those with 
background CNS disease, should be carefully 
m o n ito re d ; fo r pa tien ts  on hem od ia lys is , 
PRIMAXIN* is recommended only when the benefit 
outweighs the potential risk of seizures (see 
PRECAUTIONS). Currently, there are inadequate 
data to recommend the use of PRIMAXIN* in 
patients undergoing peritoneal dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN*
IN RELATION TO RENAL FUNCTION
RENAL
FUNCTION
CREATININE
CLEARANCE
mL/min/1.73 m2 
(mL/s/1.73 m2)
DOSE
(g)
DOSAGE
INTERVAL
(h)
MAXIMUM
TOTAL
DAILY
DOSAGE
(9)
Mild
impairment 3 1 -7 0
(0 .52-1 .17 )
0.5 6 - 8 1 .5 -2
Moderate
impairment 2 1 -3 0  
(0.35 - 0.50)
0.5 8 - 1 2 1 -1 .5
Severe*
impairment 0 - 2 0
(0 -0 .3 3 )
0 .2 5 -0 .5 12 0.5 -1 .0 * *
Patients w ith  creatin ine  c learance of 6 to 
20 mL/min/1.73 m2 (0.1 -0.3 mL/s/1.73 m2) should 
be treated with 250 mg (or 3.5 mg/kg whichever is 
lowed every 12 hours for most pathogens. When 
the 500 mg dose is used in these patients, there may 
be an increased risk of seizures.
x* The highest dose is only recommended for 
infections due to less susceptible organisms 
primarily some strains of Ps. aeruginosa.
When only the serum creatinine level is available, 
the following formula (based on sex, weight, and 
age of the patient) may be used to convert this value 
into creatinine clearance (mL/min). The serum 
creatinine should represent a steady state of renal 
function.
Males: Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL) 
Females: 0.85 x above value.
When using the International System of units (SI), 
the estimated creatinine clearance (mL/s) in males 
can be calculated as follows:
(lean body weight, kg) x (140 - age, years) x 1.4736 
(72) x (serum creatinine concentration, pmol/L)
and in females the estimated creatinine clearance 
(mL/s) is:
(lean body weight, kg) x (140 - age, years) x 1.2526 
(72) x (serum creatinine concentration, pmol/L)
PRIMAXIN* is cleared by hemodialysis. After each 
dialysis session the dosage schedule should be 
restarted.
Contents of the 13 mL vials must be suspended and -r* 
transferred to 100 mL of an appropriate infusion 
solution.
¥
A suggested procedure is to transfer approximately 
10 mL from the 100 mL of the appropriate infusion 
solution to the vial (see list of diluents under 
COMPATIBILITY AND STABILITY). Shake well. 
Return the resulting 10 mL of suspension to the*--* 
remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to *'• 
ensure complete transfer of the contents of the vial 
to the infusion solution.
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5. Definitive Surgical Management for 
Soft-Tissue Sarcomas
The surgical management of soft-tissue sarcomas, a seemingly heterogeneous group 
of malignant tumours, depends on the circumstances (e.g., untreated primary 
tumour, inadequately resected primary tumour, local recurrence, metastasis) and 
site.
The basic steps in managing a primary tumour include using the correct method 
to establish a diagnosis, obtaining adequate tumour-free resection margins and 
giving consideration to adjuvant radiotherapy or chemotherapy, or both. Local 
recurrences and metastatic lesions require a multidisciplinary approach.
The relative rarity of this group of sarcomas and the low survival rate associated 
with them make it mandatory that such patients be treated in centres able to provide 
specialized care from the beginning.
Le traitement chirurgical des sarcomes des tissus mous, un groupe apparemment 
heterogene de tumeurs malignes, depend des circonstances (qu’il s’agisse d’une 
tumeur primaire non traitee ou non suffisamment resequee, d’une recidive locale ou 
d’une metastase) et du foyer.
La marche a suivre dans le traitement d’une tumeur primaire commence par 
1’utilisation de la methode diagnostique appropriee, et se poursuit par l’obtention 
d’une marge de resection exempte de tumeur adequate en considerant la possibility 
d’avoir a utiliser une radiotherapie ou un chimiotherapie d’appoint. Les recidives 
locales et les metastases exigent une approche multidisciplinaire.
La rarete relative de ce groupe de tumeurs et le faible taux de survie qui y est 
rattache obligent que les patients qui en sont frappes soient traites dans des centres 
capables de fournir des soins specialises des le debut.
H.R. Shibata, MD, FRCSC, FACS
W ith increasing knowledge of the biology of soft-tissue sar­
comas, their surgical management, 
as with other human cancers, has 
slowly evolved from conservative to 
radical techniques and back to con-
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servative combined with other mo­
dalities.
The surgeon’s objective in man­
aging patients with soft-tissue sar­
comas is cure. Risk factors that are 
important in determining the out­
come in the patient with a soft-tis­
sue sarcoma are: the size of the 
tumour, site or tissue of origin, and 
histopathologic grading of the tu ­
mour. The smaller the tumour, the 
better are the chances for margins 
of resection that are free of tumour 
and therefore give better overall 
results. Sarcomas that originate in 
the extremities, both upper and 
lower, afford a much better survival 
rate than those arising in the head 
and neck, trunk, retroperitoneal 
space and viscera. The importance 
of obtaining a good history and 
physical examination, appropriate 
laboratory investigations, including 
angiography, computed tomogra­
phy and magnetic resonance imag­
ing, and a carefully planned biopsy 
have already been emphasized. 
These measures provide informa­
tion essential in planning the defini­
tive surgical procedure.
Surgical Treatment
The surgical procedure must be 
adapted to the circumstances (an 
untouched primary, inadequately re­
sected primary, local recurrence, 
metastasis) and site (extremities, 
trunk, head and neck, retroperito­
neal space, viscera) of the tumour.
Primary Tumour
Because local recurrence after 
simple excision (“shelling o u t”) 
ranges from 65% to 90%, the goal 
of the surgeon must be surgical
From the Department o f  Surgery, Royal Victoria Hospital, McGill University, Montreal, PQ
Presented as part o f a symposium on current perspectives in  the management o f  soft-tissue 
sarcomas, by the Royal College in cooperation with the Canadian Oncology Society, the 
Canadian Orthopaedic Association and the Canadian Association o f  Radiation Oncology, at the 
56 th annual meeting o f  the Royal College o f Physicians and Surgeons o f  Canada, Winnipeg, 
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resection with tumour-free margins. 
Although the local recurrence rate 
may still be as high as 28% to 36% 
for high-grade lesions, this may be 
reduced by adjuvant therapy.1-2
Soft-tissue sarcomas of the ex­
tremities can be managed by four 
types of resection: local, wide local, 
compartmental and amputation.
•  Local resection is limited to a 
very small margin of normal tissue. 
At times, this may be called an 
excisional biopsy, and, unfortunate­
ly, no further local procedure is 
performed for better local control.
•  Wide local resection is the 
treatment of choice for superficial 
smaller lesions. Frozen-section ex­
amination should be carried out 
whenever possible at the time of 
surgery to ensure tumour-free mar­
gins.
•  Compartmental resection 
should be used for deeper tumours. 
This procedure involves removal of 
all the muscles in the particular 
compartment containing the tu­
mour, from their origin to insertion. 
Adequate margins may be obtained 
easily in a longitudinal axis, but the 
distance from adjacent bone, nerves 
and vessels may be quite small and 
may be the limiting factor.3
•  Amputation may be necessary 
when the tumour is large and deep- 
seated, compromising major ves­
sels, nerves or bone. However, the 
modern trend is toward limb sal­
vage procedures with adjuvant ra­
diotherapy or chemotherapy.4 In the 
pattern of care survey of adult 
soft-tissue sarcomas carried out by 
the American College of Surgeons 
in the United States for the periods 
1977 to 1978 and 1983 to 1984, 
little change was demonstrated in 
operative procedures; 6.4% and 
8.2% of patients underwent primary 
amputation respectively (Table I).1
For tumours in other parts of the 
body, the relation of the tumour to 
vital structures will determine how 
radical the excision must be. In­
traoperative biopsy with frozen-sec­
tion examination may help to 
achieve tumour-free margins of re­
section but does not guarantee free­
dom from local recurrence. Howev­
er, the 5-year survival figures are 
approximately 10% better if biopsy 
proven tumour-free margins are 
achieved.
Five-year survival rates are close­
ly linked to site, being highest for 
extremity tumours, intermediate for 
head and neck and visceral tu­
mours, and lowest for those in the 
mediastinum or retroperitoneum.
Inadequately Resected Tumours
If the sarcoma is superficial or of 
low grade, or both, further wide 
local excision may be adequate. 
However, patients with poorly dif­
ferentiated sarcomas are at risk for 
greater local recurrence and dissem­
ination because of previous tissue 
contamination, and in such patients 
adjuvant therapy should be consid­
ered after further resection.
Local and Regionally Recurrent 
Tumours
Most tumour recurrences occur 
within 2 years of primary manage­
ment. Distant metastases from 
poorly differentiated sarcomas also 
develop during this time. If there is 
no evidence of metastatic disease, 
further resection following the 
same principles as outlined for pri­
mary tumours are appropriate, but 
adjuvant treatments such as radio­
therapy and chemotherapy are 
highly recommended.
Metastases
If metastatic lesions are confined 
to regional nodes, radical lym- 
phadenectomy is recommended, but 
the long-term prognosis is poor.5 
Resection of pulmonary metastases 
in selected patients whose tumour 
has a slow doubling time may sal­
vage 20% of such patients.6 Occa­
sionally, resection of other meta­
static sites, such as the liver, may 
be appropriate.
Combination Therapy
Figure 1 suggests an algorithm 
that could be followed in the man­
agement of soft-tissue sarcomas. 
After a soft-tissue mass has been 
diagnosed as a sarcoma by the 
different methods outlined in the 
second box, it can be classified into 
subsets by age, site and stage of 
disease. The primary resection can 
then be performed; the possible 
choices are a radical or a limited 
local resection. The surgeon should 
determine whether the margins of 
resection are free of tumour or 
involved, because this will influence 
the postoperative treatment. The 
grading and localization of the tu­
mour can also be used to subdivide 
management.
If the tumour is of low grade and 
localized to the primary site and the 
margins of resection are adequate,
Table 1 -  T y p e  o f S u rg ica l P ro ce d u re s  U sed  in  S a rco m a  P a tie n ts  W ith o u t M e ta s tase s  at T im e
o f D ia g n o s is
1977-1978 1983--1984
Procedure No. % No. %
W ide  loca l re se c tio n 8 7 9 5 2 .4 1412 5 6 .7
L im ite d  lo c a l re sec tion 4 5 5 27.1 583 2 3 .4
A n a to m ic  co m p a rtm e n ta l re se c tio n 168 10 .0 249 10 .0
A m p u ta tio n 108 6 .4 138 5 .5
M ore  th a n  one  type 69 4.1 108 4 .3
T o ta ls 1 6 7 9 249 0
4
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then the patient should be followed 
up carefully with no further thera­
py. If the margins are inadequate, 
then repeat resection must be car­
ried out; in this case, postoperative 
options are radiotherapy or observa­
tion. If the tumour is of high grade 
(poorly differentiated and still local­
ized), radiotherapy must be given 
postoperatively; following this, ad­
juvant chemotherapy is optional.
If distant metastases are identi­
fied and localized, then surgical 
resection should be attempted fol­
lowed by systemic therapy of some 
type. If the metastases are multiple 
and multiorgan in nature, then che­
motherapy is indicated.
Discussion
It is interesting that there was 
very little improvement in the surgi­
cal management of soft-tissue sar­
comas in North America during two 
separate 2-year periods (1977 to 
1978 and 1983 to 1984) surveyed 
by the American College of Sur­
geons. Although their survey did 
not indicate the reasons for this 
lack of improvement, it appeared 
that many North American sur­
geons did not adhere to the basic 
principles of good surgical manage­
ment from the time of surgical 
diagnosis to local and regional con­
trol (Table I).
Because of the rarity of soft-tis­
sue sarcomas, they should ideally 
be managed at tertiary care centres 
which can carry out multidiscipli­
nary treatment. The correct tech­
niques for making a surgical diag­
nosis should be taught in all surgi­
cal training programs and the im­
pression made that surgical resec­
tion should be performed in the
majority of patients by a surgeon 
with expertise and experience in the 
field, who also acts as a vital mem­
ber of the oncology team. Improve­
ment in local control as well as 
overall survival can only be 
achieved in this manner.
There is an urgent need to inform 
practising surgeons of all disci­
plines involved in the management 
of this type of cancer that multidis­
ciplinary management and par­
ticipation in clinical trials are neces­
sary.
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Guidelines for the Surgical Management of Soft-Tissue Sarcoma. Report of the Canadian Sarcoma Group
W.J. Temple, MD, FACS, FRCSC;* V. Bramwell, PhD, MB, BS, FRCPC;t E. Eisenhauer, MD, FRCPC;| 
R D.T. Jenkin, MB, FRCR, FRCPC;§ F. Langer, MD, FRCSC;1 A.J. Worth, MD, FRCPCH
The Canadian Sarcoma Group was formed in 1985 by interested surgeons, 
oncologists and pathologists. In the evaluation of new protocols, standard surgical 
guidelines have been developed which incorporate the concepts of multimodality 
therapy, particularly radiotherapy and chemotherapy. Also defined are the 
procedures performed: biopsy, marginal resection, wide local excision, radical 
resection and the principles to be considered when doing a diagnostic biopsy and a 
curative resection, particularly with limb salvage in mind. To optimize local control 
of the disease, centres treating sarcomas should have access to computed 
tomography, radionuclide scanning, to radiation and medical oncologists, and 
members of other surgical specialties. This team approach increases survival by 10% 
and also provides the best circumstances in which to study adjuvant therapy. 
Surgical guidelines are also essential in order to compare the results of different 
clinical trials.
En 1985, des chirurgiens, oncologues et pathologistes interesses formerent le 
Groupe canadien pour les sarcomes. A 1’evaluation des protocoles, des directives 
chirurgicales standard furent elaborees, lesquelles enveloppent des concepts de 
therapie multimodale comprenant radiotherapie et chimiotherapie. Les interventions 
pratiquees ont aussi ete definies: biopsie, resection de marge, excision locale 
etendue, resection radicale et les principes devant etre consideres quand on effectue 
une biopsie de diagnostic ou une resection a visee curative, particulierement quand 
on envisage la conservation d’un membre. Afin d’optimiser le controle local de la 
tumeur, les etablissements oil Ton traite les sarcomes doivent disposer de la 
tomodensitometrie, de la scintigraphie isotopique, de radiotherapeutes et d’oncol- 
ogues, en plus des membres des diverses specialites chirurgicales. Cette approche 
d’equipe augmente la survie de 10% et offre des conditions ideates pour etudier les 
therapies adjuvantes. Des directives chirurgicales sont aussi essentielles pour 
pouvoir comparer les resultats de differentes etudes cliniques.
From The Canadian Sarcoma Group (CSG) affiliated with the National Cancer Institute o f 
Canada and the Canadian Musculoskeletal Society
*Tom Baker Cancer Centre, Foothills Hospital, University o f Calgary, Calgary, Alta.
fLondon Regional Cancer Centre, University o f  Western Ontario, London, Ont.
tO ntario  Cancer Foundation, Kingston General Hospital, NCIC Clinical Trials Group, Queen’s 
University, Kingston, Ont.
§Ontario Cancer Foundation, Toronto Bayview Regional Cancer Centre, University o f Toronto, 
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UCancer Control Agency o f  British Columbia, University o f British Columbia, Vancouver, BC
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In 1985 the Canadian Sarcoma Group (CSG) was formed by in­
terested general surgeons, orthope­
dic surgeons, medical oncologists, 
radiation oncologists and patholo­
gists, supported by the National 
Cancer Institute of Canada (NCIC) 
Clinical Trials Group. Its purpose is 
to develop national protocols and to 
initiate or participate in internation­
al protocols for sarcoma treatment. 
One essential component of the 
program is a set of surgical guide­
lines to assure adequate local treat­
ment. In workshops with the Cana­
dian Orthopaedic Association and 
the NCIC Clinical Trials Group spe­
cific guidelines have been accepted 
as a basis for any ongoing or future 
adjuvant trials in which the CSG 
participates. These guidelines em­
brace modern concepts of limb sal­
vage surgery for soft-tissue sarco­
ma and define minimum criteria for 
the eligibility of patients in primary 
management multicentre trials. It 
is our premise that optimum local 
control not only reduces morbidity 
but contributes to the overall cure 
rate in as many as 10% of patients.1
A standard set of definitions has 
been adopted to describe a surgical 
procedure.
•  Biopsy is removal of a portion 
of the tumour for diagnosis.
•  Intralesional resection is exci­
sion through the pseudocapsule 
leaving gross tumour.
•  Marginal resection is incom­
plete excision, when gross and his­
tologically negative tumour margins 
are present, but the periphery of the
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tumour is very close to the resec­
tion edge (as close as 1 mm) in one 
or more planes.
•  Wide resection is excision of 
the tumour and at least one layer of 
uninvolved fascia or 2 cm gross 
distance between tumour and resec­
tion edge, proven histologically.
•  Radical resection is a compart- 
mental excision involving removal 
of muscle groups from origin to 
insertion and one fascial plane be­
yond the tumour.2
Biopsy Technique
All deep or large soft-tissue mass­
es must be considered sarcomas 
until proven otherwise. They should 
be approached in two stages — a 
diagnostic, incisional biopsy fol­
lowed by therapeutic excision once 
the diagnosis is determined histo­
logically.3 The error of doing two 
operations for a benign soft-tissue 
lesion is less serious than removing, 
in one stage, an unsuspected sarco­
ma without appropriate planning. 
Poor biopsy planning may result in 
unnecessary loss of limb.4
Physical examination and com­
puted tomography or nuclear mag­
netic resonance imaging help to 
localize the tumour and permit the 
most direct approach to biopsy. A 
longitudinal incision is preferred to 
a transverse incision so that the 
residual scar can be included in the 
en-bloc excision of the sarcoma. To 
avoid tumour extension the ap­
proach to the lesion should be 
intra- not intercompartmental. The 
adequacy of the specimen may be 
verified by frozen-section examina­
tion. If a drain is used, it should be 
brought through the wound at a 
site that will be excised en bloc with 
the tumour. Once a precise diagno­
sis has been made and the search 
for metastatic disease completed, 
the patient can be treated appropri­
ately.
Definitive Surgery
The prerequisite for successful 
sarcoma surgery is to obtain a 
microscopically clear margin around 
the tumour, through normal tissue, 
not through or near the reactive 
pseudocapsule. The fact that mega­
voltage irradiation can eradicate mi­
croscopic residual disease means 
that margins smaller than those 
required for radical resection or 
amputation may be adequate. How­
ever, because of the nature of local 
spread of sarcomas along tissue 
planes and into unexpected areas, it 
is useful arbitrarily to define a wide 
surgical margin: a fascial plane sep­
arating the tumour from normal 
tissue is considered to be the mini­
mum acceptable margin. For the 
above reasons only basic guidelines 
for resection of sarcomas can be 
proposed, and these will change 
somewhat according to the size of 
the tumour and its location. When 
these guidelines are followed, opti­
mal local control rates should be as 
high as 90%.
Guidelines for definitive surgical 
resection of sarcoma are as follows:
•  When possible a 2-cm margin 
of normal tissue should be obtained 
around the sarcoma. When an unin­
volved fascial plane intervenes, a 
margin less than 2 cm is acceptable 
but the fascial plane must be includ­
ed in the specimen.
•  Using frozen sections, the sur­
geon must document all margins of 
resection as being tumour free at 
the time of surgery. The sections 
are best taken from the residual 
tissue defect in the patient rather 
than from the specimen itself. The 
closest margin should be checked 
by at least two samples and the 
other four margins checked with 
one sample each. The margins 
should include deep, lateral, medial, 
caudad and cephalad sites. If the 
skin is also infiltrated, frozen sec­
tions of its margins should also be
obtained. The best sites for biopsy 
include fascial planes involved by 
the tumour which are often areas of 
microscopic extension. Clinical ex­
perience has shown that a minimum 
tissue margin of 2 cm around the 
gross specimen is associated with 
the highest chance of a histological­
ly disease-free margin and a low 
risk of inadvertently exposing the 
tumour. If the tumour is not re­
moved intact, the chance of local 
control of disease is thought to be 
reduced. When larger margins can 
be achieved without substantially 
sacrificing limb function, so much 
the better.
•  Intraoperatively, the patholo­
gist and surgeon together should 
cut the specimen and locate areas 
where tumour is close to the mar­
gins. The corresponding areas in 
the resection defect should then be 
checked by frozen-section examina­
tion before the operation is com­
pleted.
•  When the skin is not involved, 
any previous biopsy or excision scar 
should be removed with approxi­
mately 2 cm of tissue en bloc with 
the tumour. If the skin is involved, 
then margins should be larger and 
frozen-section examination is neces­
sary to confirm the tumour-free 
margins.
•  When an amputation is re­
quired, the distance from the tu­
mour to the transection level should 
be recorded if the sarcoma is in the 
same limb segment; this also ap­
plies to disarticulation. When the 
amputation is performed more than 
one joint above the tumour, then 
the distance to the tumour need not 
be recorded.
•  Metal clips should be placed in 
the margins of excision, because 
many of these patients will require 
adjuvant radiotherapy postopera- 
tively.
•  These guidelines for sarcomas 
apply to local excisions, marginal 
excisions, compartmental excisions
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and high- and low-grade tumours 
when adjuvant radiotherapy is used. 
In low-grade lesions not requiring 
pre- or postoperative radiation, a 
wide margin of healthy tissue is 
essential to reduce the risk of local 
recurrence.
•  Radiotherapy may be used 
preoperatively to assist limb salvage 
procedures, facilitating dissection of 
the tumour from adjacent major 
structures, especially for high-grade 
or large sarcomas.
•  After resection of high-grade 
or large sarcomas by wide local 
excision or amputation in the same 
limb segment, postoperative radia­
tion is advisable.
•  These guidelines are applica­
ble not only to limb sarcomas but 
also to head and neck, trunk and 
chest wall sarcomas and retroperito­
neal sarcomas.
BOOK REVIEWS
continued from page 384
leading. For example, there is a valu­
able chapter on renal masses, which 
contains an excellent discussion of renal 
cysts. However, in dealing with solid 
renal masses, the value of ultrasonogra­
phy is underemphasized. In my clinical 
experience, ultrasonography is the most 
valuable aid for screening and diagnos­
ing solid renal masses, yet the author 
tends to downplay its role as compared 
with intravenous pyelography and com­
puted tomography. There are some 
minor criticisms of the book’s organiza­
tion and content. The long chapter on 
the malfunctioning kidney tends to be 
repetitive and dull, since there are very 
few diagnostic features to differentiate 
the many intrinsic renal diseases. The 
chapter on prostate ultrasonography is 
slightly outdated owing to the rapid 
advances made in the last 2 years. The 
machines available now produce much 
better images than those presented in 
this book and also allow for very accu-
Summary
Optimal primary sarcoma surgery 
usually takes place in a tertiary care 
facility where access to computed 
tomography, angiography and a 
staff of neurosurgeons, vascular 
and plastic surgeons, medical on­
cologists, radiation oncologists, pa­
thologists and physiotherapists are 
available to support the primary 
orthopedic or general surgeon. Op­
timal local control rates should be 
80% to 90% when these specific 
guidelines are followed. We expect 
the implementation of these guide­
lines in limb salvage surgery will 
reduce the morbidity and mortality 
associated with local recurrence of 
the sarcoma. The true value of 
adjuvant local or systemic treat­
ments such as radiotherapy or che­
motherapy may then be accurately
determined. We hope that the ma­
jority of sarcoma patients will be 
treated in the context of prospective 
trials by experienced teams acquir­
ing information and thereby im­
proving the rate of cure.
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rate transrectal (as opposed to trans- 
perineal) biopsy techniques which are 
not discussed in this text.
Two of the more interesting chapters 
are those on interventional ultrasonog­
raphy and ultrasonography of the fetal 
genitourinary system. As well as being 
thorough and accurate, these chapters 
make fascinating reading.
This is an excellent atlas (not a 
textbook) of genitourinary ultrasound 
imaging. As well as being a reference 
aid for the ultrasonographer, it is also 
an excellent learning tool for the non­
radiologist who is involved in the diag­
nosis and treatment of genitourinary 
disease.
David R. Mador, MD, FRCSC
Assistant Clinical Professor,
Royal Alexandra Hospital,
University o f Alberta,
Edmonton, Alta.
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GROWTH FACTORS AND OTHER 
ASPECTS OF WOUND HEALING. 
BIOLOGICAL AND CLINICAL IMPLI­
CATIONS. Edited by Adrian Barbul, 
Eli Pines, Michael Caldwell and Thom­
as K. Hunt. 342 pp. Illust. Alan R. 
Liss, Inc., New York, 1988. $68.00. 
ISBN 0-8451-5116-9.
This book presents concise and infor­
mative chapters on the proceedings of 
the second international symposium of 
tissue repair, held at the Innisbrook 
Resort, Tarpon Springs, Florida in May 
1987; the symposium brought together 
world-class researchers in this field. The 
editors are leaders in the field of wound 
repair and wound healing and they 
report the results of the researchers 
consistently and extensively. The 
book’s format of grouping together the
continued on page 440
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Unusual Gastric Foreign Body: a Case 
Report
William M. Kuzon, Jr., MD, MSc; Craig A. McFadyen, MD; Frederick L. Moffat, MD, FRCSC
Ingestion of foreign bodies, either intentionally or accidentally, is quite common. 
The authors report an unusual case in which a 32-year-old man deliberately 
assembled a large metallic aggregate in his stomach by swallowing magnets and 
coins in order to relieve epigastric discomfort. The collection was retrieved by 
laparotomy and gastrotomy; a gastric ulcer was also found and it was oversewn. 
Management of this patient is discussed and the principles of treatment for ingested 
foreign bodies are reviewed.
L’ingestion intentionnelle ou accidentelle de corps etrangers est assez frequente.
Les auteurs signalent un cas etrange, celui d’un homme de 32 ans qui, deliberement, 
assembla dans son estomac un important aggregat metallique par l’absorption 
d’aimants et de pieces de monnaie. Cet assemblage fut retire par laparotomie et 
gastrotomie; un ulcere gastrique fut egalement decouvert et suture. Le traitement de 
ce patient est commente et les principes de traitement lors de l’ingestion de corps 
etrangers sont passes en revue.
D eliberate or accidental inges­tion of foreign bodies is rela­
tively common, and there have been 
numerous reports1-5 of strange and 
bizarre objects that have found 
their way into the gastrointestinal 
tract. We describe the case of a man 
who deliberately accumulated a 
large metallic mass in his stomach 
by swallowing magnets and coins; 
ultimately he required surgery to 
remove the mass.
Case Report
A 32-year-old man was seen in 
the emergency department com­
plaining of epigastric discomfort. 
He said he had been ingesting for­
eign material for over 2 years to 
remedy the vague pain. He had a 
known history of psychiatric illness, 
which included two suicide attempts 
(drug overdoses), and was consid­
ered to have a schizoid-type person­
ality. Initially, his self-administered 
treatment relieved his pain, but with 
time the “therapy” became less 
effective, and he was again troubled 
by nondescript upper abdominal dis­
comfort. He had noted the passage 
of coins in his stool.
About 5 months before he pre­
sented at our hospital, he began to
swallow small magnets in addition 
to coins, believing that if he could 
retain the coins in his stomach 
longer, they would “do more 
good” . His abdominal pain persist­
ed and he sought medical attention 
because the magnets and coins had 
not passed in his stool.
There was no history of gastroin­
testinal bleeding or of obstructive 
symptoms. His abdominal pain was 
epigastric in location, moderate in 
intensity and was relieved some­
what by meals. He could feel a 
heavy mass in his abdomen which 
shifted with changes in position.
He was an asthenic young man. 
He wore an excessive amount of 
jewellery; both forearms were en­
tirely covered by metal bracelets of 
various types and he wore over 50 
necklaces. The areolae of both 
breasts had been pierced and held 
metal ringlets.
On abdominal examination there 
was a large, firm, mobile mass in 
the left upper quadrant; it was best 
palpated in the epigastrium with the 
patient on his hands and knees. 
There was no abdominal distension 
or tenderness and no other abnor­
mal physical signs.
Routine laboratory investigations 
gave normal results; hemoglobin 
concentration 158 g /L  and serum 
amylase 162 U/L (normal range 
from 0 to 400 U/L).
X-ray films with the patient su­
pine showed a large, irregular, radi­
opaque mass in the right upper 
quadrant; with the patient in the
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left lateral decubitus position the 
mass was shown in the left lower 
quadrant (Fig. 1).
Flexible esophagogastroduodeno- 
scopy performed the day after ad­
mission to hospital revealed a con­
glomerate of small magnets and 
coins in the stomach. Superficial 
gastric erosions were also noted, 
but the entire stomach was not 
visualized due to the size of the 
collection. Attempts to fragment 
the mass with the endoscope were 
unsuccessful. The esophagus and 
duodenum appeared normal.
At laparotomy, the stomach, py­
lorus and duodenum appeared nor­
mal. Through a mid-body gastroto- 
my the mass of coins and magnets 
was removed from the stomach 
(Fig. 2).
A careful inspection of the gastr­
ic mucosa, pylorus and duodenum 
revealed a small gastric ulcer, ap­
proximately 1.0 cm in diameter, on 
the lesser curve 4.0 cm proximal to 
the cardiac incisure of the stomach. 
The ulcer had a fibrinous base 
suggesting chronicity. The overly­
ing serosa was normal. The ulcer 
was excised down to the deep layers 
of the muscularis mucosae and the 
resulting partial thickness defect 
closed with 2-0 silk sutures. Micro­
scopic examination of the ulcer re­
vealed no evidence of malignant 
disease.
The patient recovered without 
complications and was discharged 
from hospital on postoperative day 
7, taking ranitidine for his gastric 
ulcer. He is currently undergoing 
psychiatric treatment.
The mass removed from the pa­
tient’s stomach weighed 585 g and 
contained 66 Canadian nickels, 23 
button magnets (2 cm in diameter 
and 0.5 cm in length), 2 cylindrical 
magnets (1 cm diameter and 2 cm 
in length), 2 iron spheres (1 cm 
diameter), 1 small square magnet (1 
X 0.5 cm) and 12 irregular iron 
fragments of various sizes and
shapes (Fig. 3). Some of the irregu­
lar fragments were pieces of larger 
magnets that had been broken up.
Discussion
The management of ingested for­
eign bodies relates to the type of 
patient, the nature and size of the 
objects, their location in the gas­
trointestinal tract and the presence 
or absence of complications. Several 
authors6"8 have presented algo­
rithms useful in the management of 
these patients.
The problem is usually found in 
children, psychiatric patients, men­
tally impaired persons, prisoners, 
drug and alcohol abusers, denture 
wearers, or those engaged in cer­
tain occupations.2'49-11 In children 
and workers in particular occupa­
tions, the object is usually swal­
lowed accidentally when placed in 
the mouth during play or work. In 
substance abusers and those wear­
ing dentures, diminished palatal 
sensation or gag reflex may contrib­
ute to the accidental ingestion. In 
prisoners, mentally retarded individ-
FIG. 1 — Supine plain film showing 
large, multisurfaced, radiopaque mass 
in right upper quadrant.
uals or psychiatric patients, foreign 
bodies may be swallowed deliberate­
ly and repeatedly.2'11
The nature of the ingested object 
is important in determining the ap­
propriate management. Sharp ob­
jects may perforate the gut; large 
objects or conglomerations can 
cause intestinal obstruction.71213 
The object itself may be corrosive 
or contain toxic substances, making 
immediate removal mandatory.8'1114 
Usually, small blunt objects, such 
as the coins ingested by our patient, 
can be managed conservatively, es­
pecially if they have reached the 
stomach.711
There is general agreement that 
any object lodged in the pharynx or 
esophagus must be removed ur- 
gently6'715"17 because complications 
associated with foreign-body impac­
tion above the diaphragm are seri­
ous. The complications include air­
way obstruction or pulmonary aspi­
ration, esophageal perforation, me- 
diastinitis, esophageal obstruction,
FIG. 2 — Conglomerate of small mag­
nets and Canadian nickels removed 
from stomach by gastrotomy.
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FIG. 3 — Individual components of 
mass.
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and, rarely, aortoesophageal fis- 
tula.610'1618-20 Objects usually be­
come lodged in the esophagus at 
the three anatomic points of nar­
rowing: the cricopharyngeal mus­
cle, the aortic impression or the 
gastroesophageal junction.616 Car­
cinoma or strictures of the esopha­
gus predispose to impaction of for­
eign bodies, especially in cases of 
the food bolus “ cafe coro­
nary” .6’10-16 Although the use of 
papain to digest a meat bolus is no 
longer recommended, in some cases 
relaxation of the smooth muscle of 
the esophagus using intravenous 
glucagon and sedation can cause 
the object to pass into the stom­
ach.6 Blunt objects at this level can 
be removed endoscopically3’6’10’16 or 
with a Foley catheter.21 Metallic 
objects may sometimes be removed 
using a magnet mounted in the end 
of a nasogastric tube.8 Sharp ob­
jects generally require endoscopic 
removal; surgery is rarely neces­
sary.3’61016 Using an endoscope, the 
object may be pushed into the 
stomach in order to turn it around 
before extraction or in the hope it 
will eventually pass in the feces.6
If the foreign body has reached 
the stomach, as in our patient, 
small- or medium-sized objects, 
even sharp ones, usually will be 
evacuated without complication in 
80% to 90% of cases.6 711 However, 
obstruction, ulceration, pressure 
necrosis, perforation, steatorrhea, 
protein-losing enteropathy, gas­
trointestinal bleeding, diarrhea and 
obstructive jaundice have all been 
described.1’3’6’9’12-13’22 In specific cir­
cumstances, including symptoms of 
pain, fever, obstruction, jaundice, 
persistent diarrhea and bleed­
ing,7’91215'22 removal of a foreign 
body from the stomach or gut is 
warranted. Long, slender objects 
should be removed from the sto­
machs of children under 2 years of 
age due to the high incidence of 
duodenal impaction and perfora­
tion.15 Pre-existing disease, such as 
pyloric stenosis, is also a relative 
contraindication to a conservative 
approach.23 If the object is in the 
stomach or proximal duodenum, an 
attempt at endoscopic removal is 
recommended,3’6’1016 but if the ob­
ject is located more distally and is 
producing symptoms, laparotomy is 
required.
The management of asymptomat­
ic retained foreign bodies in other­
wise healthy adults is more contro­
versial. Aboral progress may be ar­
rested at the pylorus, duodenal 
sweep, ligament of Treitz, ileocecal 
valve, appendix, sigmoid or rec­
tosigmoid colon.13 22 Some reports1’7 
recommend intervention if the ob­
ject is within reach of the endo­
scope or if x-ray films indicate that 
impaction has occurred or is likely 
to occur because of the object’s 
size. Others211 prefer a conservative 
approach. Since it is difficult to 
assess the likelihood of complica­
tions associated with foreign-body 
ingestion, management decisions in 
asymptomatic patients will likely re­
main controversial.
Our patient had a personality 
disorder and displayed a tendency 
toward self-mutilation, both of 
which are characteristic of individu­
als who repeatedly swallow foreign 
objects.2 However, his motivation 
was quite lucid and most unusual in 
that he consciously produced his 
bezoar for the purpose of treating 
abdominal symptoms. The result 
was a large, blunt, gastric conglom­
eration of magnets and nickels 
(which are magnetic). Although 
there was no evidence of bleeding 
or obstruction, laparotomy was in­
dicated because of the size of the 
mass and his abdominal pain. In 
retrospect, it cannot be determined 
with certainty whether the gastric 
ulcer was the cause of his original 
symptoms or secondary to the 
mass. Therefore, removal of the 
mass with partial thickness excision
since this was a gastric foreign 
body, a more aggressive attempt to 
dislodge and remove the compo­
nents of the mass endoscopically 
should have been attempted first. 
As mentioned, the first gastroscopic 
examination indicated that this 
would not likely succeed, so a lapa­
rotomy was judged to be safer. 
Vagotomy and pyloroplasty were 
considered when the ulcer was 
found, but because of known surgi­
cal complications of this procedure, 
and since the ulcer would likely 
respond to medical management we 
elected not to perform a gastric 
resection or an acid-reducing proce­
dure once intraoperative frozen-sec­
tion examination had ruled out neo­
plasia.
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Uterine Leiomyosarcoma With Cardiac 1
Metastases
Fredrick Hoy, MD, FRCSC; Robert Boucher, MD; Anthony Brody, MD, FACS
Leiomyosarcoma metastatic to the heart is rare and is usually fatal. The authors 
present the case of a 58-year-old woman who had a history of uterine 
leiomyosarcoma. Echocardiography and cardiac catheterization revealed a large 
right ventricular mass. Computed tomography confirmed the presence of the mass 
which extended into the pulmonary artery. The inferior vena cava was free of 
disease. At operation, a large tumour originating in the right ventricle and 
protruding through the pulmonary valve was found. Histologically, it was a 
leiomyosarcoma. Because there were numerous septal and intramural foci of tumour, 
complete resection was impossible, but palliative resection was performed 
successfully and the patient was alive and active 1 year after operation.
Les leiomyosarcomes avec metastases cardiaques sont rares et habituellement fatals. 
Les auteurs decrivent le cas d’une femme de 58 ans ayant des antecedents de 
leiomyosarcome uterin. Une echocardiographie et un catheterisme cardiaque 
revelerent une importante masse au ventricule droit. La tomodensitometrie confirma 
la presence de cette masse qui s ’etendait jusqu’a l’artere pulmonaire. La veine cave 
inferieure n’etait pas touchee. A Toperation, on decouvrit une grosse tumeur 
partant du ventricule droit et faisant saillie a travers la valvule pulmonaire. A 
l’histologie, on identifia un leiomyosarcome. Comme il y avait plusieurs foyers 
tumoraux sur et a l’interieur de la paroi, il fut impossible d’effectuer une resection 
complete. Une resection palliative fut pratiquee et la patiente etait toujours vivante 
et active un an apres Toperation.
L eiomyosarcoma is a common primary malignant lesion of the 
heart, but metastatic to the heart it 
is a rare, highly invasive and usual­
ly fatal lesion. A review of the 
literature revealed only four detailed 
reports of uterine leiomyosarcoma 
metastatic to the heart. We present 
a fifth, but only the third to report 
an antemortem diagnosis and surgi­
cal palliation.
Case Report
A 58-year-old woman was admit­
ted to hospital complaining of exer­
tional dyspnea that had developed 3 
days earlier. Six months before, she 
had undergone total abdominal hys­
terectomy and bilateral salpingo- 
oophorectomy for a stage III poorly 
differentiated uterine leiomyosar­
coma with metastases to the right
ovary. Whole lung tomography at 
that time revealed two nodules, 
each less than 1 cm in diameter, in 
the left lung, believed to represent 
metastatic disease. Postoperatively, 
the patient had received chemother­
apy with doxorubicin.
On examination, the woman was 
mildly tachypneic. There was a 
grade III/VI systolic murmur heard 
diffusely along the right sternal 
border. Her chest film showed no 
evidence of congestive heart failure. 
2D echocardiography demonstrated 
a large mass attached to the right 
ventricular free wall. Cardiac cathe­
terization revealed a mean right 
atrial pressure of 16 mm Hg and a 
right ventricular pressure of 70/20 
mm Hg. A large filling defect occu­
pied most of the right ventricle 
(Fig. 1), extending through the pul­
monary valve. In addition, there was 
a filling defect in the right atrium. 
Computed tomography (Figs. 2 and 
3) confirmed these findings. Lei­
omyosarcoma metastatic to the 
heart was diagnosed and a palliative 
tumour resection was undertaken.
The right ventricle was markedly 
enlarged and a firm mass occupied 
the chamber of the entire right 
ventricle, the right ventricular out­
flow tract and extended into the 
pulmonary artery. Under cardiople- 
gic arrest, the right atrium was 
incised and an organized thrombus 
removed from the appendage. No 
tumour was present. The pulmo­
nary artery was then opened longi­
tudinally revealing a large friable 
mucoid tumour protruding through
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UTERINE LEIOMYOSARCOMA
the pulmonary valve. When the 
right ventricle was opened a tumour 
was found occupying most of the 
right ventricular chamber and was
densely adherent to the septal, ante­
rior and inferior aspects. Multiple 
septal and intramural areas of tu­
mour foci made complete resection
impossible, but the major portion of 
the tumour mass was excised. A 
large organized thrombus was also 
removed from the right ventricle. 
The patient recovered without com­
plications. The central venous pres­
sure decreased to 8 cm H20  from 
16 cm H20  and her symptoms were 
alleviated. She was discharged 8 
days postoperatively.
She was started on a second 
course o f chemotherapy but tolerat­
ed this poorly. Five months postop­
eratively, she had some recurrence 
of dyspnea and peripheral edema. A 
2D echocardiogram showed recur­
rence o f the tumour or thrombus in 
the right ventricle. She is alive and 
moderately active 1 year after the 
palliative resection.
Pathological Features
Specimens removed at operation 
were friable, gelatinous, myxoid 
masses with multifocal areas o f he­
morrhage. Fragments o f myocardi­
um adherent to the tumour revealed 
extensive necrosis and infiltration 
by a malignant neoplasm showing 
large pleomorphic nuclei and nu­
merous mitotic figures consistent 
with metastatic leiomyosarcoma.
Discussion
Cardiac metastases occur in 5% 
to 20% of patients who die of 
malignant disease.1 Secondary car­
diac tumours are 16 to 50 times 
more common than primary ones;2 
75% to 90% of them arise from 
tumours of the breast, bronchus, 
lymphoid tissue or skin. These sec­
ondary tumours are rarely the sole 
metastases3 and are symptomatic in 
15% to 30% of patients.1
Sarcomas metastasize to the 
heart more frequently than car­
cinomas.2 Cardiac metastases from 
leiomyosarcomas of the uterus are 
extremely rare — 6 out of 2600
FIG. 1 — Ventriculogram demonstrates filling defect in right ventricle.
FIG. 2 — Contrast computed tomogram of thorax shows filling defect in right 
atrium and right ventricle.
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patients in one series.4 Most neo­
plastic lesions of the heart are si­
lent; symptoms result from im­
pingement on adjacent structures 
and include arrhythmias, conduc­
tion disturbances, effusion, embo­
lism, valve dysfunction, angina, ob­
struction of blood flow and conges­
tive heart failure. Cardiac dysfunc­
tion in a patient with a known 
neoplasm should arouse suspicion 
of a cardiac metastasis. Survival 
from the onset of symptoms is 
usually short.2 Of patients whose 
cardiac involvement is symptomatic, 
80% die of cardiac complications.3
Uterine leiomyosarcomas are 
rare, constituting less than 3% of 
all tumours, and are associated with 
an incidence of 0.6 per 100 000 
females.5 Metastases are usually to 
liver and lung. Cardiac metastases 
from leiomyosarcomas of the uterus 
are extremely rare, only 6 out of 
2600 cases being reported in one 
series.4 A review of the literature 
revealed only four other cases in
which clinical data were available. 
Symptoms developed 1 to 12 years 
after resection of the uterine lei­
omyosarcoma. Two patients died 
before a diagnosis was made.46 
Both had large tumour masses orig­
inating in the right ventricle. In one 
who underwent surgery for pericar­
dial effusion, a tumour mass at­
tached to the myocardium by a 
pedicle 2 cm in diameter was found 
arising from the surface of the right 
ventricular outflow tract. This was 
resected with a large disk of right 
ventricular wall and the patient was 
well 15 months postoperatively.7 
Diagnosis of an intracardiac tumour 
was made preoperatively in the 
fourth patient. She underwent pal­
liative resection of the right ventric­
ular tumour, but died of low cardiac 
output 48 hours postoperatively.8 
The diagnosis and operative man­
agement of our patient were aided 
by the use of 2D echocardiography 
and computed tomography. The pa­
tient’s symptoms were caused by
low right-sided cardiac output due 
to obstruction of blood flow by the 
tumour mass and by thrombus sec­
ondary to stasis. The tumour inter- 
digitated with the tricuspid valve 
and trabeculae of the right ventricle 
so that only palliative resection 
could be performed. Postoperative­
ly, the mean central venous pres­
sure decreased markedly and the 
patient was symptomatically much 
improved. The highly malignant na­
ture of her tumour is attested to by 
the disappointing early return of 
symptoms and recurrence of tu­
mour. Cardiac symptoms in patients 
with known metastasis should sug­
gest the possibility of an intracar­
diac metastasis. Since the survival 
from the onset of symptoms is 
usually short, palliative resection is 
justified. The diagnosis can be 
greatly aided by noninvasive tech­
niques and prolonged symptom-free 
survival may be obtained in patients 
with tumours of lower-grade malig­
nancy or those that are more re­
sponsive to chemotherapy or radio­
therapy.
References
1. Birmingham CL, Peretz DI: Metastatic 
carcinoma presenting as obstruction to 
the right ventricular outflow tract. Report 
of a case and review of the literature. Am 
Heart J 1979; 97: 229-232
2. Greenwald EF, Breen JL, Gregori CA: 
Cardiac metastases associated with gyne­
cologic malignancies. Gynecol Oncol 
1980; 10; 75-83
3. Malaret GE, Aliaca P: Metastatic disease 
to the heart. Cancer 1968; 22: 457-466
4. Rosenblatt WH, Featherston WP: 
Metastatic leiomyosarcoma of the heart. 
Am J Cardiol 1960; 6: 672-675
5. Christopherson WM, W illiamson EO, 
Gray LA: Leiomyosarcoma of the uterus. 
Cancer 1972; 29: 1512-1517
6. Nicol AG, McAndrew GM: Cardiac lei­
omyosarcoma: primary or secondary? Br 
Heart J 1968; 30: 432-435
7. Martin JL, Boak JG: Cardiac metastasis 
from uterine leiomyosarcoma. J Am Coll 
Cardiol 1983; 2: 383-386
8. Keir P, Keen G: Secondary leiomyosar­
coma of the right ventricle. A surgical 
report. Br Heart J  1978; 40: 328-330
FIG. 3 — Contrast computed tomogram of thorax demonstrates filling defect in 
pulmonary artery.
420 VOL. 31, NO. 6 NOVEMBER 1988/CJS
ORIGINAL ARTICLES
N ormoglycemia After Implantation of 
Purified Islet Cells in Dogs
G.L. Warnock, MD, MSc, FRCSC;* M.S. Cattral, MD;* R.V. Rajotte, BSc, MSc, PEng, PhDt
A major problem that limits the effectiveness of clinical trials of islet transplantation 
is the inability to isolate sufficient pure viable islets from a single pancreas. The 
authors have evaluated this problem, using dogs rendered diabetic by total 
pancreatectomy. An average of 123 ± 11 X 103 highly purified islets (mean graft 
weight 0.75 ± 0.1 g) were implanted as splenic allografts (seven dogs), splenic 
autografts (six dogs) or liver autografts (six). In the autograft recipients, fasting 
normoglycemia was maintained during follow-up to 10 months; onset of 
hyperglycemia was delayed in three liver recipients and one splenic autograft 
recipient at 1.5, 2, 8 and 10 months respectively. The K values (decline in glucose 
levels in %/min) during intravenous glucose tolerance testing were more than 1.0. 
Six recipients of allografts and cyclosporine (CsA) were normoglycemic when CsA 
trough serum levels were greater than 300 pg/L, although the fasting plasma 
glucose level was higher than that in autograft recipients. These data show that 
purified islets isolated from a large mammal will maintain fasting normoglycemia for 
prolonged periods after auto- or alloimplantation.
Un probleme majeur limite l’efficacite des essais cliniques de greffes d’llots de 
Langerhans, soit l’incapacite d’isoler suffisamment d’ilots purs et viables d’un seul 
pancreas. Les auteurs ont etudie ce probleme chez des chiens rendus diabetiques par 
pancreatectomie totale. Une moyenne de 123 ± 11 X 103 ilots hautement purifies 
(poids moyen de la greffe: 0.75 ± 0.1 g) ont ete greffes sous forme d’allogreffes 
spleniques (sept chiens), d’autogreffes spleniques (six chiens) ou d’autogreffes 
hepatiques (six chiens). Chez les receveurs d’autogreffes, une normoglycemie a jeun 
s’est maintenue durant une periode de controle de 10 mois; une hyperglycemie 
d’apparition retardee est survenue chez trois receveurs de greffes hepatiques et chez 
un receveur d’autogreffe splenique apres, respectivement, 1.5, 2, 8 et 10 mois. Les 
valeurs de K (la baisse de la glycemie en %/min) durant les epreuves d’hypergly- 
cemie provoquee par voie intraveineuse ont toutes ete superieures a 1.0. Six 
porteurs d’allogreffes, qui recevaient de la cyclosporine (CsA), sont demeures 
normoglycemiques alors que les concentrations plasmatiques minimums de CsA 
etaient inferieures a 300 ng/L, bien que leur glycemie a jeun ait ete superieure a 
celle des receveurs d’autogreffes. Ces donnees demontrent que des ilots purifies, 
preleves chez un grand mammifere peuvent maintenir une normoglycemie a jeun 
pendant une periode prolongee apres une auto- ou une allogreffe.
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Fifteen years have elapsed since the initial report1 of a cure for 
experimentally induced diabetes in 
rodents by implanting free grafts of 
insulin-producing tissue. Further 
studies2 showed that islet cell trans­
plantation prevents or reverses the 
complications of diabetes mellitus. 
These procedures have been less 
successful in large mammals and 
humans, casting doubts on their 
feasibility. As with other organ 
grafts, islet allografts are subject to 
rejection, but a major problem has 
been the inability to isolate suffi­
cient pure, viable islet cells from a 
single pancreas. Although the yield 
can be increased by collecting islet- 
containing pancreatic microfrag­
ments,3 their implantation results in 
severe portal hypertension.4
Recent advances in islet cell isola­
tion suggest that a technique may 
soon be available for clinical trials. 
Alejandro and colleagues5 isolated 
sufficient purified islets to reverse 
diabetes in pancreatectomized dogs; 
however, delayed graft failures oc­
curred, suggesting that a marginal­
ly adequate islet mass had failed. 
We have combined the methods of 
collagenase perfusion by way of the 
ducts,6 gentle trituration of tissue7 
and density gradient centrifugation8 
to separate purified islets from the 
canine pancreas. Our studies 
showed that more than 5000 is- 
le ts /k g  body weight (average endo­
crine particle size 122 nm) consis­
tently induced normoglycemia.9 In 
this study, we subjected these high­
ly purified grafts to prolonged fol­
low-up and evaluated the effects of 
allograft implantation and cyclospo­
rine (CsA) immunosuppression.
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Materials and Methods
Pancreatectomy
Under general anesthesia with so­
dium pentobarbital (30 m g/kg 
body weight), the pancreas in 29 
adult mongrel dogs (weight range 
from 13 to 25 kg) was mobilized. 
The major vascular connections 
were preserved until just before 
excision. Cannulas (20 gauge) were 
inserted into both main branches of 
the pancreatic duct and into the left 
duct by a cutdown 5 cm from the 
tip of the gland. After excision of 
the pancreas the abdomen was 
closed in three dogs (controls), the 
seven dogs that provided islets for 
allografts were subjected to eutha­
nasia while under anesthesia and 
the remaining 19 dogs were main­
tained under general anesthesia 
while the islets were being prepared 
for implantation (about 3 hours).
Islet Isolation
The cannulas were perfused (300 
mm Hg) with Hanks’ solution (Gib- 
co, Chagrin Falls, Ohio) at 4°C for 
10 minutes. The perfusate was then 
changed to a solution of collage- 
nase (type XI or V; Sigma Chemical 
Co., St. Louis, Miss.) at a concen­
tration of 1600 U/ml in Hanks’ 
solution at 37°C. For six isolations, 
the collagenase solution (1100 
U/ml) was perfused immediately 
after excision of the pancreas, with­
out preliminary flushing with 
Hanks’ solution. Perfusion was con­
tinued at 37 °C until the gland 
became mucoid (25 minutes for 
type V, 12 minutes for type XI 
collagenase). The digested tissue 
was dissociated by teasing and tritu­
ration,7 weighed and resuspended at 
4°C to a total volume of 120 ml in 
Medium-199 with 25 mmol/L 
Hepes (Gibco, Chagrin Falls, Ohio), 
10% fetal calf serum (vol/vol, Gib­
co, Grand Island, NY), penicillin
100 U/m l.and streptomycin 100 
Mg/ml. Aliquots of 4 ml were re­
moved to 50-ml tubes, suspended in 
a mixture of 4.3 ml of 5X Medi­
um-199 and 16.7 ml of Ficoll (den­
sity 1.125, Sigma) and overlaid with 
5 ml each of Ficoll with densities of 
1.085, 1.075 and 1.045.5 The tubes 
were centrifuged at 550 X g for 25 
minutes at 22°C. Tissue was col­
lected from the interface of the 
1.045/1.075 and 1.075/1.085 lay­
ers, washed, recombined, weighed 
and resuspended to a final volume 
of 30 ml in culture medium.
Islet Counts and Size
Ten samples, each containing 20 
pL of freshly-isolated islets, were 
placed on a microscope slide and 
protected with a coverslip. Slides 
were viewed through a stereomicro­
scope at 25X magnification with 
side illumination from a fiberoptic 
light source; islets were identified 
by their rounded shape, opalescent 
blue colour and finely granular tex­
ture. Islets and islet fragments more 
than 60 /tm in greatest dimension 
were counted, and the total was 
estimated from the sample mean. 
An additional aliquot was examined 
without a coverslip; the greater and 
lesser diameter of 10 randomly se­
lected islets of minimum size 60 nm 
was measured with a graticule and 
the average islet diameter deter­
mined. Purity was estimated by 
comparing the ratio by volume of 
islet to exocrine tissue.
Implantation
In each case of autografting, the 
suspended purified islets from the 
pancreas were either refluxed into 
the splenic veins (six dogs, group 1) 
or embolized by way of the portal 
vein to the liver (six dogs, group 2). 
Portal venous pressure was mea­
sured by connecting the infusion 
catheter to a manometer before and
immediately after infusion of the 
islets. Postoperatively exocrine en­
zyme supplements (12 capsules) of 
Cotazym (Organon Canada Ltd., 
Montreal, PQ) were provided daily 
for all 19 dogs. Recipients of sple­
nic allografts (seven dogs, group 3) 
received CsA (Sandoz Pharmaceuti­
cal Co., Basle, Switzerland) intra­
muscularly daily; the initial daily 
dose of 20 m g/kg was tapered to 5 
mg/kg.
Blood Indices
Blood samples were taken preop- 
eratively, postoperatively during 
glucose tolerance testing, then daily 
postoperatively for 1 week and sub­
sequently once a week for the dura­
tion of follow-up. Fasting plasma 
glucose (mg/dl) was measured with 
a Beckman 2 analyser (glucose oxi­
dase; Beckman Instruments, Fuller­
ton, Calif.). The level of im- 
munoreactive insulin (IRI, mU/L) 
was determined by double-antibody 
radioimmunoassay,10 using Phar­
macia RIA kits and human insulin 
standards (Pharmacia, Uppsala, 
Sweden). For glucose tolerance 
testing, saphenous veins were can- 
nulated, glucose (0.5 g /kg  body 
weight) was injected intravenously 
and blood was collected at 0, 1, 5, 
10, 15, 30, 60 and 90 minutes for 
assay of glucose. The K value (de­
cline in glucose level [%/min]) was 
determined from glucose levels at 5, 
10, 15 and 30 minutes.11 Glucose 
tolerance testing was repeated at 1 
and 3 months in normoglycemic 
recipients. Trough levels of CsA 
were measured daily by radioim­
munoassay.
Data Analysis
Numbers of islets per kilogram 
implanted, plasma glucose levels 
and K values for dogs that received 
liver and splenic autografts were 
compared using Student’s t-test for
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paired data. The values of plasma 
glucose in splenic autografts versus 
allografts were compared using Stu­
dent’s f-test for unpaired data. Val­
ues were considered significant at p 
< 0.05.
Results
Grafts
The mean tissue weight after 
purification with Ficoll was 0.75 ± 
0.1 g (±SD). An average of 123 ± 
11 X 103 (range from 78 to 188 X 
103) islets and islet fragments were 
recovered per pancreas. Most of the 
islets were completely free of at­
tached exocrine cells and the aver­
age diameter was 122 ±  5 /in> 
(range from 60 to 240 /urn). By 
estimating the relative amount of 
islet to nonislet tissue, the islets 
appeared to be 80% to 90% pure.
Autografts
The number of islets adminis­
tered into the liver (4763 ± 
537/kg [±SD]) was similar to that 
for the spleen (5446 ± 689, p > 
0.05). After infusion of islets into 
the portal vein the mean increase in 
portal pressure was 3.7 ± 0.9 cm 
H20; the pressure returned to base­
line values within 10 minutes. All 
recipients maintained their preoper­
ative weight. These dogs became 
normoglycemic immediately after 
implantation (Fig. 1) and normo- 
glycemia was maintained at 1 
month; plasma glucose values were 
then 89 ±  6 mg/dl in group 1 and 
85 ± 3 mg/dl in group 2 (p > 
0.05). Delayed failures in graft 
function occurred in three group 2 
dogs at 1.5, 2 and 8 months respec­
tively and a single graft failed in 
group 1 at 10 months after implan­
tation. The remaining dogs conti­
nue to be normoglycemic. To prove 
conclusively that endocrine function 
was provided by the graft in the 
splenic site, two group 1 dogs were 
subjected to splenectomy; the insu­
lin level in the splenic vein was 20 
± 4 mU/L versus 4 ± 1 mU/L in
the artery. Hyperglycemia ensued 
rapidly after splenectomy. Postoper- 
atively, the K value declined from 
3.6 to 1.8 at 1 month in group 1 
(Fig. 2a) and from 3.9 to 1.6 in 
group 2 (Fig. 2b), but had not 
declined significantly more at 1.7 
and 1.4 respectively after 3 months. 
The insulin levels were reduced in 
all dogs postoperatively and the 
peak response was delayed after 
islet implantation into the spleen.
Allografts
Doses of 8645 ± 1149 islets/kg 
were refluxed into the spleens of 
seven dogs. In one recipient with 
initial CsA levels less than 300 
iug/L the graft failed at 9 days. 
Figure 3 shows the results for six 
dogs that had initial CsA levels of 
more than 300 /xg/L. Compared 
with apancreatic dogs, the allograft 
recipients showed immediate fasting 
normoglycemia, which was main­
tained for more than 30 days. The 
fasting plasma glucose value was 
always higher with allografts than 
autografts (p < 0.05).
Discussion
Large mammals are the most 
suitable models for studying the 
clinical application of islet cell 
transplantation. The compact pan­
creas in these species requires three 
key steps in islet separation: ade­
quate intralobular disruption of the 
connective tissue stroma, avoidance 
of mechanical trauma to the islets 
and density gradient purification.6-8 
We have used these principles to 
isolate an average of 123 000 high­
ly purified islets. Function was as­
sessed by prolonged follow-up after 
autoimplantation or alloimplanta- 
tion.
The purity of the preparations 
and the small graft mass (0.75 g) 
allowed us to embolize the tissue to
0 1  2 3 4 5 6 7 8 9  10
pancreatectomy & islet transplant Months
FIG. 1 — Fasting plasma glucose levels (mg/dl) after autoimplantation of purified 
islets in liver (triangles) or spleen (circles). Normoglycemia was maintained for 
more than 1 month in all dogs and hyperglycemic response to splenectomy (S) 
proves graft function. Delayed failures (F) of graft function were observed in three 
liver recipients after 6 weeks, 2 months and 8 months. One splenic graft failed at 
10 months. Squares =  Apancreatic control dogs. Numbers in brackets indicate no. 
of islets/kg.
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the liver. Although a transient rise 
in portal pressure occurred, portal 
hypertension was not a problem, in 
contrast with previous studies4 in 
which impure preparations were 
used. At the outset, fasting plasma 
glucose levels were normal in all 
autograft recipients and there was 
no significant difference between 
the two groups. On prolonged fol­
low-up, delayed autograft failures 
occurred, as previously observed for 
intraportal canine islet grafts.5 Al­
though similar quantities of islets 
were implanted into the liver and 
spleen, in our study three of the 
four failures were in recipients of 
liver implants. This may have been 
due to fatigue of an initial marginal­
ly adequate mass of islets, but this 
does not account for the observa­
tion that two of the intraportal 
failures occurred after greater than 
average numbers of islets were im­
planted. Alternative mechanisms for 
delayed failure may be reduced en- 
graftment in the intraportal location 
or chronic stimulation of the islets 
by hyperglycemia within the portal 
venous blood. Because of the small 
number of grafts in each of the two 
groups, statistical analysis cannot 
be used to validate the observation 
that they failed more frequently 
when implanted into the liver.
Serial glucose tolerance tests 
showed that the K value had de­
clined significantly (p < 0.05) from 
pretransplant levels in both auto­
graft groups, but levels in each 
were similar and the dogs remained 
nondiabetic (K > 1.0%/min). The
reduced level postoperatively was 
likely due to a smaller mass of 
functioning B cells, as reflected by 
the lower plasma insulin response 
after glucose challenge. A qualita­
tive difference in insulin release was 
seen between the group 2 dogs, 
showing a peak response within 1 
minute, and group 1 dogs whose 
peak response was delayed to 5 to 
10 minutes. This may result from 
reduced hepatic extraction of insu­
lin, which is released directly from 
intrahepatic islets into the post- 
sinusoidal hepatic veins.
Allografts of purified islets in­
duced fasting normoglycemia, evi­
dent throughout the 30-day follow­
up, when initial CsA trough blood 
levels were more than 300 ng/L . 
When one dog had initial levels
FIG. 2 — Response to intravenous glucose (0.5 g /kg) after (a) splenic or (b) liver autoimplantation showing plasma glucose 
(m g/dl) and corresponding plasma insulin (mU/L) levels. Rate of glucose decline is slower postoperatively and is accompanied 
by reduced insulin response. Peak insulin response occurred at 5 to 10 minutes in spleen recipients (a) and at 1 minute in liver 
recipients (b). n =  number of dogs, K =  decline of glucose level (%/min).
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below 300 ng/L , rejection occurred 
at 9 days, a finding similar to that 
of the nonimmunosuppressed con­
trols. Greater numbers of islets 
were available for allografts than 
autografts and provided a mass of 
endocrine tissue well in excess of 
the critical amount that we found 
necessary to induce normoglycemia. 
We believe this enabled us to distin­
guish graft failure due to rejection 
rather than fatigue of a marginally 
adequate islet mass, inadequate en- 
graftment or the toxic effects of 
CsA. Furthermore, islets were not 
allografted into the liver because of 
the frequency of delayed autograft 
failures at this site. The results 
showed that function of allografts 
of pure islets was assured when an 
adequate mass of tissue from one 
donor was implanted into a CsA- 
immunosuppressed recipient. This 
compares favourably with the re­
sults of Alejandro and associates12 
who frequently required purified is­
lets from multiple donor dogs to 
provide adequate graft function in 
one recipient and Kneteman and 
colleagues13 who used impure pan-
FIG. 3 — Results of alloimplantation 
of pure islets into spleen with CsA 
immunosuppression (squares). Com­
pared with three apancreatic controls 
(diamonds) normoglycemia occurred 
immediately and was maintained 
throughout study in six recipients of 
CsA at trough serum levels greater 
than 300 jtg/L. Fasting plasma glu­
cose (mg/dl) after splenic allograft 
implantation was higher than that 
after splenic autograft implantation 
(triangles).
creatic microfragments. The high 
levels of CsA required to prevent 
allograft rejection may, at least in 
part, have accounted for the higher 
plasma glucose levels seen in the 
allograft recipients, but did not 
cause graft failure within 30 days.
A critical question is, Do the 
results of our experiments in a 
large mammal suggest that islet 
transplantation can be made to 
work in man? Three key observa­
tions may assist us in achieving this 
difficult goal. First, earlier attempts 
at human islet transplantation did 
not account for an accurately quan­
tified mass of viable islets. Our data 
indicate that more than 5000 islets 
with an average size of 120 ^m 
must be provided per kilogram of 
body weight to induce long-term 
normoglycemia consistently in 
dogs.9 Since human islets are larger 
(150 /itm), a 70-kg adult recipient 
would require 2895 islets/kg or 
approximately 202 640 islets. We 
recently used the described isolation 
procedure to isolate pure viable 
human islets and found that yields 
of this order can be achieved.14 
Second, delayed failures of auto­
graft function can occur and the 
factors responsible for this require 
further study. Our data suggest 
that the intraportal site, if chosen 
for implantation, may play a role. 
Third, when allografts are implan­
ted, the adverse effects of im­
munosuppressive agents on islet 
function are of concern. Among 
these are the effects of steroids and 
azathioprine13 and potential adverse 
effects of CsA.15 Our data suggest 
that function of pure islets can be 
assured when CsA alone is used; 
however, the high serum trough 
levels of CsA would cause serious 
toxicity in humans. Therefore, some 
form of islet allograft immuno- 
modulation may be needed to re­
duce the requirements for immuno­
suppression.
In summary, our data show that
purified islets of Langerhans can 
maintain prolonged fasting normo­
glycemia in a large mammal. Some 
delayed failures of autograft func­
tion occur, which may be due to the 
intraportal site of implantation. Sin­
gle-donor purified islets induced 
normoglycemia after alloimplanta­
tion into pancreatectomized recipi­
ents on CsA immunosuppression 
who had adequate serum CsA lev­
els. This information will promote 
studies on immunomodulation of 
islet allografts in large mammals 
and encourage a realistic approach 
to clinical islet transplantation for 
juvenile onset diabetes.
We are grateful for expert technical 
assistance from D. Ellis, T. DeGroot, D. 
Untch, C. Erickson, K. Toth and V. 
Manikavel, and we thank C. Gardner for 
preparing the manuscript.
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SESAP V Critique
Items 253-255
Diagnostic techniques used in patients with soft tissue sarcomas define the location, nature, and extent of the 
disease. Conventional roentgenograms may demonstrate deformity of fascial planes and tumor calcification. 
Angiography can diagnose tumor vascularity, extent of disease, and relationship to major vessels, and may be 
used for infusion chemotherapy and tumor embolization. Ultrasonography differentiates cystic, solid, and 
complex masses. Computed tomography, the most useful radiographic procedure for axial soft tissue sarcomas, 
allows recognition of alterations in compartment anatomy. Because fewer than 5% of patients with soft tissue 
sarcoma have regional node involvement, lymphangiography is infrequently of value.
Although small superficial soft tissue tumors are suitable for excisional biopsy, incisional biopsy is preferred 
for adequate sampling of large lesions. The biopsy site must be included in the definitive surgical resection. 
Needle aspiration and “core” biopsies may be acceptable for metastatic disease, but for most tumors, the tissue 
obtained may be insufficient for a full pathologic evaluation. Wide local excision should not be performed until a 
tissue diagnosis has been established.
Wide anatomic, soft-part resection is indicated for liposarcoma of an extremity. The resection should include 
previous biopsy sites and a wide margin of uninvolved tissue. The role of additional treatment in the 
management of patients with soft tissue sarcomas is not currently well-defined. Radiation therapy may be used 
preoperatively to reduce the size and deep fixation of a tumor, and postoperatively to eradicate possible residual 
disease. Preliminary results with adjuvant postoperative chemotherapy suggest an improvement in disease-free 
and over-all survival. Although preoperative regional infusion chemotherapy has been used, no evidence 
currently favors preoperative systemic chemotherapy.
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Oophorovesicular-Colonic Fistula: a Rare 
Complication of Crohn’s Disease
S.D. Goldberg, MD, FRCSC;* R.R. Gray, MD, FRCPC;t K.I. Cadesky, MD, FRCSC;$
R.L. Mackenzie, MD, FRCSC*
Salpingitis and vesicular fistulas are rare complications of Crohn’s disease. In this 
report the authors describe a case of oophorovesicular-colonic fistula secondary to 
Crohn’s disease. The patient presented with bleeding from the bladder during 
menstruation, fecaluria and pneumaturia. A single-stage left salpingo- 
oophorectomy, sigmoid resection and repair of the fistula were carried out, with 
complete resolution of symptoms and preservation of fertility potential.
Les salpingites et les fistules vesiculaires sont deux complications rares de la 
maladie de Crohn. On decrit dans cet article un cas de fistule ovario-vesciulo-colique 
secondaire a une maladie de Crohn. La patiente montrait des signes de saignement 
par voie vesicale durant les menstruations, de fecalurie et de pneumaturie. Une 
intervention en un temps, comprenant une salpingo-ovariectomie gauche, une 
resection sigmoi'dienne et une reparation de la fistule, amena une resolution 
complete des symptomes, avec conservation possible de la fertilite.
C rohn’s disease is often compli­cated by fistula formation but 
salpingitis and vesicular fistulas are 
both rare. We report a case in 
which the patient had an oo­
phorovesicular-colonic fistula sec­
ondary to Crohn’s disease.
Case Report
A 31-year-old woman presented 
with complaints of crampy lower 
abdominal pain, generalized mal­
aise, weight loss and bloody diar­
rhea, diagnosed by barium enema 
examination and colonoscopy as 
Crohn’s disease. Her symptoms re­
solved with steroid treatment. She 
returned 16 months later with dif­
fuse lower abdominal pain and a left 
lower quadrant mass which was 
found at laparoscopy to involve the 
left adnexa, sigmoid colon and uter­
us. The patient was treated with 
broad-spectrum antibiotics. There 
was some shrinkage of the mass, 
but 3 weeks later she complained of 
hematuria, which subsequently be­
came cyclic and was accompanied
by urinary frequency, urgency, 
pneumaturia and fecaluria.
Culture of a urine sample grew 
Proteus mirabilis, Escherichia coli 
and Staphylococcus sp, all with 
more than 100 000 colonies/ml of 
urine.
An intravenous pyelogram re­
vealed a dilated left ureter with mild 
hydronephrosis. A Hypaque enema 
examination demonstrated a fistu­
lous connection between bowel and 
bladder, and contrast computed to-
FIG. 1 — Computed tomogram demon­
strating gas-containing left adnexal 
mass.
FIG. 2 — Computed tomogram of 
pelvis revealing air in bladder with 
intravenous contrast.
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mography of the abdomen (Fig. 1) 
and pelvis (Fig. 2) confirmed dilata­
tion of the left ureter and showed 
evidence of a poorly defined soft-tis­
sue mass involving uterus, bladder 
and colon. Contrast medium was 
evident in the uterus and left fallo­
pian tube.
Cystoscopy revealed bullous 
edema of the bladder wall and a 
small fistulous opening 1.5 cm pos­
terior to the ureteral orifices. Dif­
fuse mucosal inflammation with 
pseudopolyps at 25 to 30 cm was 
seen on flexible sigmoidoscopy and 
granulation tissue was seen pro­
truding from the cervical os on 
vaginal examination.
We performed a single-stage left 
oophorectomy, salpingectomy, ante­
rior sigmoid resection (with end-to- 
end anastomosis) and closed the 
vesicular fistula tract. The right 
fallopian tube and uterus appeared
FIG. 3 — Left adnexal mass connect­
ing left tube, ovary, bladder and colon.
unaffected and, to preserve fertility, 
were not removed. The operative 
specimen (Fig. 3) revealed active 
inflammatory changes in the sig­
moid colon consistent with Crohn’s 
disease. At follow-up 3 months later 
the patient was asymptomatic and 
having normal menstrual periods.
Discussion
Crohn’s disease is commonly 
complicated by the formation of 
fistulas between the involved bowel 
and adjacent organs. Genitourinary 
complications are reported in 4% to 
10% of patients.1 However, both 
salpingitis and enterovesical fistulas 
are extremely rare manifestations of 
active Crohn’s disease.2 Isolated fis­
tulas have been reported involving a 
fallopian tube, uterus, vagina and 
urethra.1 Crohn and Yarnis3 de­
scribed two cases of fistula forma­
tion between the ileum and right 
fallopian tube, and Wlodarski and 
Trainer2 reported isolated cases of 
Crohn’s disease associated with 
right oophoritis.
Patients who have bowel-bladder 
fistulas present with urinary fre­
quency, urgency, dysuria, pneuma- 
turia and fecaluria.4-7 In our case 
fistulous connection with the left 
ovary was unusual and ovulation 
into the tract provided the addition­
al symptom complex of cyclic hema­
turia.
The combined urologic and radi­
ologic investigations permitted ac­
curate preoperative diagnosis of the 
condition and successful multiteam 
surgery with preservation of fertility 
potential.
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Fine-Needle Aspiration Biopsy of an Islet 
Cell Tumour Simulating Pancreatic 
Carcinoma
Arthur H. Zalev, MD, FRCPC;* Harriette J. Kahn. MD, FRCPC;f Wedad Hanna, MD, FRCPCt
The importance of distinguishing between malignant islet cell tumour and 
pancreatic carcinoma is emphasized in this report of a 57-year-old woman who 
presented with an epigastric mass. Clinically and radiologically it was diagnosed as a 
pancreatic adenocarcinoma. A fine-needle aspiration biopsy specimen obtained under 
ultrasonic guidance showed tumour cells suggestive of an islet cell tumour. 
Immunostaining and electron microscopy were performed on the aspirate. The 
tumour cells stained positive with antibodies to keratin, glucagon and gastrin; 
ultrastructural examination revealed neurosecretory granules, confirming the 
diagnosis of an islet cell tumour. Angiography was performed to assess the 
possibility of debulking the mass. This case demonstrates the value of 
immunohistochemistry and electron microscopy on fine-needle aspiration biopsy 
specimens of the pancreas to differentiate islet cell tumours, which are potentially 
curable, from pancreatic adenocarcinomas, which carry a 5-year survival rate of less 
than 2%.
On souligne dans cet article l’importance de savoir distinguer une tumeur maligne 
des cellules insulaires d’un carcinome pancreatique. Le cas d’une femme de 57 ans 
presentant une masse epigastrique serf a illustrer le fait. Le tableau clinique et 
radiologique etait compatible avec un diagnostic d’adenocarcinome pancreatique. 
Une ponction-biopsie a l’aiguille fine obtenue sous echographie revela des cellules 
tumorales evocatrices d’un insulinome. L’echantillon de biopsie fut soumis a une 
immuno-coloration et a la microscopie electronique. Les cellules tumorales 
presentment une coloration positive avec des anticorps contre la keratine, le 
glucagon et la gastrine; l’examen ultrastructural revela des granules 
neurosecretoires confirmant le diagnostic d’un insulinome. Une angiographie fut 
pratiquee afin d’evaluer la possibility de reduire la masse tumorale. L’etude 
immunohistochimique et l’examen au microscope electronique des echantillons de 
ponction-biopsie sont utiles pour differencier les insulinomes qui sont curables, des 
adenocarcinomes pancreatiques, lesquels presentent une survie a 5 ans de moins de 
2%.
P ancreatic carcinoma has a poor prognosis, the 5-year survival 
rate being less than 2%> In spite of 
modern imaging techniques only
15% to 20% of tumours diagnosed 
are potentially resectable. Occasion­
ally, pancreatic masses with more 
favourable prognoses, such as islet
cell tumours, may mimic adenocar­
cinomas, and in such cases mul­
tidisciplinary investigations — radi­
ology, fine-needle aspiration cytolo­
gy with immunopathology and elec­
tron microscopy — can give a defin­
itive diagnosis without resort to 
more invasive techniques. We pres­
ent a case of non-functioning islet 
cell tumour in which the patient 
had clinical manifestations of a pan­
creatic adenocarcinoma. Our experi­
ence demonstrates the feasibility of 
using special techniques on material 
obtained by fine-needle aspiration to 
reach a conclusive diagnosis.
Case Report
A 57-year-old woman had a 
1-month history of increasing epi­
gastric pain radiating to the right 
side and back. During this time she 
lost 6.4 kg and became constipated. 
A hard, fixed epigastric mass, 10 
cm in diameter, was palpable. Ul­
trasonography and computed to­
mography (Figs. 1 and 2) suggested  
a pancreatic neoplasm. The comput­
ed tomogram showed superior mes­
enteric arterial and venous encase­
ment, indicating that the mass was 
unresectable (Fig. 2). At endoscopic 
retrograde cholangiopancreatogra­
phy (ERCP) only the common bile 
duct could be cannulated, and the 
ampullary segment was narrowed. 
Fine-needle aspiration was carried 
out under ultrasonic guidance. The 
resulting diagnosis of islet cell tu-
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mour led to angiography, which 
showed a mass involving the pan­
creatic head, neck and uncinate 
process, encasing the superior mes­
enteric vein (Fig. 3). Laparotomy 
was performed with the intention of 
debulking the tumour, but this was 
impossible because of its vasculari­
ty. The patient was subsequently 
discharged from hospital and che­
motherapy was started. Periodic so­
nograms showed gradual enlarge­
ment of the tumour and dilatation 
of the common bile duct. Hepatic 
metastases developed and the pa­
tient died 1 year after her initial 
presentation.
Diagnosis
Methods
A portion of the specimen ob­
tained by fine-needle aspiration was 
alcohol-fixed and stained by the 
Papanicolaou method. Small frag­
ments were also fixed in Bouin’s 
fixative for a cell block preparation. 
The biopsy tissue obtained from 
surgery was fixed in 10% buffered 
formalin. For light microscopy, sec­
tions were stained with hematoxylin 
and eosin.
The Bouin-fixed material and the 
formalin-fixed paraffin-embedded 
tissue sections were stained by the 
peroxidase antiperoxidase technique 
using antibodies to insulin, gluca­
gon, serotonin, gastrin and low- 
molecular-weight keratin, which 
recognizes keratins of 39, 43 and 
50 kilodaltons. The antibodies were 
obtained from Dako Corp., Santa 
Barbara, Calif., Immuno-Nuclear 
Corp., Stillwater, Minn, and Beck- 
ton Dickinson, Mountain View, Ca­
lif. Appropriate negative and posi­
tive controls were used.
A portion of the needle aspirate 
from the pancreas was placed in 
universal fixative. The specimen 
was centrifuged and the pellet pro­
cessed for routine electron micros­
copy. The sections were stained 
with uranyl acetate and lead citrate 
and examined by a Phillips 300 
electron microscope.
Results
The fine-needle aspirate from the 
pancreas showed clusters of uni­
form cells with little pleomorphism 
(Fig. 4) and an occasional mitotic 
figure — features suggestive of an 
islet cell tumour. Light microscopy 
of the subsequent surgical specimen 
confirmed the diagnosis of an islet 
cell tumour.
Immunohistochemical staining of 
the cell block of the needle aspirate 
and the biopsy specimen showed 
positive staining of the tumour cells 
for glucagon (Fig. 5a), serotonin 
and gastrin but not for insulin (Fig. 
5b). They also stained positively for 
low-molecular-weight keratin.
Ultrastructural examination of 
the aspirate revealed nests of tu­
mour cells joined by desmosomes 
and containing numerous neuro­
secretory granules (Fig. 6), thus 
confirming the diagnosis of islet cell 
tumour. The granules varied in size
from 130 to 230 nm, compatible in 
size and morphology with glycogen 
and gastrin granules. No insulin 
granules could be seen.
Discussion
it is important for therapy and 
prognosis to distinguish islet cell 
tumours from pancreatic adenocar­
cinomas. Prolonged survival has 
been reported after excision of the 
former, even those larger than 10 
cm,2 and isolated involvement of the 
portal vein does not preclude resec­
tion.2 Adjuvant chemotherapy may 
provide effective palliation in one- 
third of patients with malignant 
islet cell tumours.23 Fine-needle as­
piration biopsy is an effective meth­
od of obtaining material for diag­
nosing pancreatic carcinoma.4-6 The 
risks are minimal, the accuracy is 
about 86% and the technique obvi­
ates laparotomy.4 Islet cell tumours 
may be diagnosed from the cytology 
material but are sometimes difficult 
to differentiate from pancreatic car­
cinoma.
Radiology plays an important 
role in the diagnosis and manage-
FIG. 1 — Transverse ultasonogram at level of pancreatic head. Tumour is 
hypoechoic and encases superior mesenteric vein (arrow).
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ment of pancreatic lesions.7-9 Func­
tioning islet cell tumours usually 
present while still small. They are 
diagnosed biochemically, and radi­
ologic techniques are used for pre­
operative localization. 310 Nonfunc­
tioning islet cell tumours resemble 
adenocarcinomas in that they are 
usually large at the time of presen­
tation and may be assessed as “ma­
lignant” and unresectable. Clinical­
ly, both types of tumour can pres­
ent such symptoms as abdominal 
pain, nausea, vomiting, malaise, 
weight loss and jaundice. Although 
radiology is helpful in their evalua­
tion,3 they can both have the same
radiologic appearance. They are 
seen as irregular, solid masses 
encasing the adjacent vessels on 
ultrasonography and computed 
tomography . 1011 They produce 
abrupt, irregular strictures or occlu­
sions of the pancreatic and common 
bile ducts on ERCP; they also are 
seen displacing and invading the 
stomach and duodenum on barium 
contrast studies. 11 Computed to­
mography may suggest an islet cell 
tumour if contrast enhancement 
shows a homogeneous vascular or 
hypervascular lesion. 1012 In our pa­
tient the diagnosis was not suspect­
ed on computed tomography be­
cause the tumour had multiple 
areas of hemorrhage and necrosis 
resulting in a heterogeneous ap­
pearance. Adenocarcinoma and 
“malignant” islet cell tumours can 
be differentiated by selective arteri­
ography; both encase and displace 
the adjacent blood vessels. Howev­
er, the former are uniformly hypo- 
vascular and the latter show vascu­
lar or hypervascular areas (capillary 
blush). Hepatic metastases resemble 
their respective primary tumours. 
Arteriography is usually reserved 
for patients with potentially resect­
able lesions. 1113 In our patient, ul­
trasonography and computed to-
Fig. 2a Fig. 2b
FIG. 2 — Computed tomograms at level of pancreatic head. Tumour shows heterogeneous enhancement with intravenous 
contrast, (a) Superior mesenteric vein (long arrow) and artery (arrowhead) are encased, (b) Dilated right colic veins are seen 
(arrows).
FIG. 3 — Epinephrine-enhanced common hepatic arteriogram. 
Larger arteries are constricted. Vascular mass is seen in 
pancreatic head supplied by dorsal pancreatic artery (arrow­
head) and branches of gastroduodenal artery.
FIG. 4 — Fine-needle aspirate of pancreatic mass shows 
clusters of uniform cells with little plemorphism (Papanico­
laou’s stain, original magnification X 240).
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mography revealed encasement of 
the superior mesenteric vessels and 
therefore unresectability. Arteriog­
raphy was performed because of the
unexpected cytologic diagnosis and 
the possibility of surgical debulk- 
ing.
In addition to routine Papanico­
laou staining, the cytology material 
is also suitable for the application 
of immunohistochemical and ultras- 
tructural techniques.14^ 16 The pres-
Fig. 5a Fig. 5b
FIG. 5 — Immunoperoxidase staining of cell block shows (a) positive staining of tumour cells with antibody to glucagon and (b) 
no staining with antibody to insulin (original magnification X 384).
FIG. 6 — Electron photomicrograph of pancreatic aspirate shows cluster of tumour cells joined by desmosomes. Surface is 
covered by microvilli (MV). Apical portion of cytoplasm contains neurosecretory granules (arrowheads) (original magnification 
X 9200) which are shown at higher magnification in inset (original magnification X 35 000). N = nucleus.
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ence of low-molecular-weight kera­
tins in the tumour cells confirms 
the epithelial nature of the neo­
plasm, since keratins are the inter­
mediate filaments that have been 
detected in both adenocarcinomas 
and islet cell tumours.1718 However, 
they may not differentiate between 
these two types of neoplasms. Im- 
munohistochemically, the presence 
of pancreatic hormones confirms 
the diagnosis of islet cell tumours.19 
A single hormone or multiple hor­
mones have been detected im- 
munohistochemically in tissue sec­
tions of pancreatic endocrine tu­
mours.19
No clinical syndrome was evident 
in our case, indicating that the 
tumour cells were producing the 
hormones but not secreting them 
into the circulation. A block in the 
secretion of hormones has been 
described in a number of islet cell 
tumours.19 The type of hormone 
produced may also be of prognostic 
significance; tumours secreting in­
sulin tend to have a benign course 
whereas most gastrin-producing tu­
mours are malignant.20 In this case, 
the cells were positive for glucagon 
and gastrin, confirming that the 
mass was an islet cell tumour. With 
cells containing gastrin, one would 
expect the tumour to behave more 
aggressively than if the cells were 
producing other hormones. The 
fact that the tumour was located in 
the head of the pancreas, was al­
ready 10 cm in size at the time of 
presentation and had not caused 
biliary obstruction, suggests that it 
was slow growing and had been 
present for some time. Thus, the 
prognosis was considered better 
than a pancreatic adenocarcinoma
but worse than an islet cell tumour 
producing insulin.
Material obtained from fine-nee­
dle aspirates is adequate for ultras- 
tructural evaluation, providing it is 
representative of the tumour. Even 
if the tumour is necrotic and the 
material poorly fixed, neurosecreto­
ry granules can still be identified, 
thus helping to differentiate islet 
cell tumour from adenocarcinoma.
Fine-needle aspiration is an effec­
tive method for diagnosing pancre­
atic tumours.56 A conclusive diag­
nosis can be obtained by electron 
microscopy and immunohistochem- 
istry on the aspirate obtained under 
ultrasonic guidance. A prognosis 
may also be made, depending on the 
hormone produced by the tumour 
cells, even if it is not secreted into 
the bloodstream.
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Residual Hypothermia in Patients 
Recovering in the Intensive Care Unit 
From Cardiac Surgery
Daniel Marelli, MD; Ray C-J. Chiu, MD, PhD, FACS, FRCSC; David M. Fleiszer, MD, FRCSC; 
Rea A. Brown, MD, FRCSC
Because of inadequate rewarming or equilibration of body temperature, patients who 
undergo cardiac surgery with hypothermia often are still hypothermic after arrival 
in the intensive care unit. The incidence of residual hypothermia and its 
hemodynamic effects were assessed in this study.
Of 82 adults who underwent cardiac surgery, 41 were normothermic with core 
temperatures of 35.5°C or higher (mean 36.0 ± 0.1°C) and 41 were hypothermic 
with temperatures below 35.5°C (mean 34.9 ± 0.1 °C) on arrival at the intensive 
care unit (p < 0.005). Patients with hypothermia had significantly (1.9 ± 0.1 versus 
2.2 ± 0.1, p < 0.05) lower cardiac indices. Although not statistically significant, 
there was a trend toward higher systemic vascular resistance in the patients with 
hypothermia.
The authors conclude that mild residual hypothermia is still common after cardiac 
surgery and may contribute to the depressed hemodynamic status of these patients.
Que ce soit du a un rechauffement insuffisant ou a un probleme d’homeothermie, les 
patients qui subissent une chirurgie cardiaque sous hypothermie sont souvent 
encore hypothermiques a leur arrivee aux soins intensifs. La presente etude mesure 
l’incidence de l’hypothermie residuelle ainsi que ses effets hemodynamiques.
D’un groupe de 82 adultes soumis a une operation cardiaque, 41 etaient 
normothermiques avec une temperature de 35.5°C ou plus (moyenne 36.0 ± 0.1 °C) 
a leur arrivee aux soins intensifs, alors que 41 etaient hypothermiques avec une 
temperature inferieure a 35.5°C (moyenne 34.9 ± 0.1 °C, p < 0.005). Les patients 
souffrant d’hypothermie presentaient un index significativement plus faible (1.9 ± 
0.1 par rapport a 2.2 ± 0.1, p < 0.05); chez ces memes patients on constatait une 
tendance vers une resistance vasculaire generate plus elevee, quoi que la difference 
ne soit pas statistiquement significative.
Les auteurs concluent qu’il est frequent de recontrer une faible hypothermie 
residuelle apres une chirurgie cardiaque. Ceci pourrait contribuer a abaisser le 
statut hemodynamique de ces patients.
Systemic hypothermia is widely used during cardiac surgery, 
and patients are routinely rewarmed 
before they are taken off cardiopul­
monary bypass. Because of inade­
quate rewarming or equilibration of
uneven body temperature, they fre­
quently manifest a drop in body 
temperature in the early postopera­
tive period.12 Such' hypothermia 
may reduce myocardial contractility 
and increase myocardial irritability
and peripheral resistance, thus add­
ing to afterload in unanesthetized 
patients. We assessed the incidence 
of hypothermia after cardiac sur­
gery and determined its possible 
effects on cardiovascular function.
Patients and Methods
We reviewed the charts of pa­
tients who returned to the intensive 
care unit after cardiac surgery, for 
the 3 months from Oct. 1 to Dec. 
31, 1986. During this period 82 
patients underwent open-heart sur­
gery and were eligible for the study.
They were divided into two 
groups of 41, according to body 
core temperature on arrival at the 
intensive care unit: group 1 was 
normothermic (core temperature 
more than 35.5°C as measured with 
the Swan-Ganz catheter with 
thermistor tip) and group 2 hypo­
thermic (core temperature less than 
35.5°C). Central venous, pulmo­
nary artery and capillary wedge 
pressures were also measured with 
the Swan-Ganz catheter. Heart 
rates and blood pressures were 
monitored by radial artery cannula- 
tion. Cardiac output was deter­
mined by the thermodilution meth­
od. We used the Gould Cardiac 
Computer (Critical Care Division, 
Spectramed Inc., Oxnard, Calif.) to 
calculate cardiac index, systemic 
vascular resistance and stroke work 
index. Student’s t-test was used to 
evaluate differences in hemodyna­
mic status between the groups. The 
X2 frequency distribution was used
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to analyse the use of vasodilators 
and inotropic agents.
Findings
In group 1 (normothermic) pa­
tients the core temperature ranged 
from 35.5° to 37.7°C and in group 
2 (hypothermic) temperature ranged 
from 34.0° to 35.4°C. Aortocoro­
nary bypass was the most common 
operation and in both groups males 
predominated.
The mean cardiopulmonary by­
pass time and average aortic cross­
clamp time were comparable for 
both groups (Table I).
Comparison of hemodynamic sta­
tus between the two groups re­
vealed significantly (p < 0.05) lower 
cardiac indices in group 2 (Table II). 
Although not statistically signifi­
cant, there was also a trend toward 
higher systemic vascular resistance 
in these patients. Stroke work 
index was not significantly different 
in the hypothermic patients.
Approximately 25% of the pa­
tients in each group initially re­
quired inotropic agents after sur­
gery. Similarly, 20% required vaso­
dilator therapy. There was no statis­
tical difference between the two 
groups in this respect (Table III).
Discussion
Hypothermia and its physiologic 
effects have been studied extensive­
ly. As the core temperature falls, 
cell metabolic rate is reduced. This 
depresses various cell functions and 
accounts for most of the physiolog­
ic changes noted in hypothermia.3 
During cardiac surgery, periods of 
inadequate systemic circulation may 
occur, and experiments by Bigelow 
and colleagues4 have led to the 
widespread use of hypothermia in 
these circumstances. This enables 
vital tissues to survive periods of 
anoxia or ischemia.5
Early animal studies6 showed that 
cardiac output decreases with in­
duced hypothermia. This was also 
shown7 to occur in man in the 
operating-room setting. More re­
cently, Roberts and associates8 
found that 90% of patients who 
underwent coronary artery bypass 
grafting displayed a decrease in 
ejection fraction, left ventricular 
stroke work index and cardiac in­
dex, 2 hours postoperatively. Fur­
ther studies9 have shown that after 
myocardial revascularization there 
is transient temperature-dependent 
hemodynamic dysfunction during 
the rewarming period.
For the purpose of this study we 
defined hypothermia as a core tem­
perature of less than 35.5°C. Fifty 
percent of patients were found to be 
hypothermic on arrival at the inten­
sive care unit after cardiac surgery. 
Why this happened is uncertain, 
because all patients are rewarmed 
after cardiopulmonary bypass, but 
insufficient rewarming combined 
with a redistribution of heat to 
reduce the temperature gradient 
within body tissues is the likely 
explanation. Another possible ex­
planation may be the effect of anes­
thetic drugs on thermoregulation; 
these agents may impair responses 
to cooling such as vasoconstriction, 
shivering and increased metabolism. 
They also can alter feedback to and 
from the central nervous system.10
Hypothermia decreases myocardi­
al contractility and increases myo­
cardial irritability.5 Among the pa­
rameters of cardiovascular function 
studied, cardiac index was found to 
be significantly (p < 0.05) lower in 
patients with hypothermia. This 
may reflect reduced myocardial con­
tractility. Other findings suggest an 
increase in peripheral resistance and 
stroke work index, but the differ-
Table III -  U se  o f P h a rm a c o lo g ic  A g e n ts
Inotropic
Group agents, % Vasodilators, %
1 2 6 .8 22
2 2 6 .8 17
Table 1 - C lin ic a l D ata
Group 1 Group 2
(n =  41) (n =  41)
S ex (m a le : fe m a le ) 3 1 :1 0 2 9 :1 2
M ean age (range ), y r 62  (3 4  -  7 7 ) 62  (3 2  -  84)
M ean b yp a ss  t im e  (ra n g e ), m in 101 ( 4 1 - 1 5 6 ) 9 6  (4 3  -  143)
M ean a o rtic  c ro s s -c la m p  t im e  (ra n g e ), m in 60  ( 1 5 -  105) 5 7 ( 1 4  -  108)
T ype  o f s u rg e ry , no . o f  p a tie n ts
ACBP 33 35
M VR 5 2
AVR 1 2
M V R /A V R 1 1
A V R /A C B P 1 1
ACBP =  a o rto c o ro n a ry  b yp a ss , M V R  =  m itra l va lve  re p la c e m e n t, A V R  = a o r t ic  va lve  re p la ce m e n t.
Table II -  H e m o d y n a m ic  S ta tu s  (M ean  ±  S E M ) on  A rr iv a l a t th e  In te n s iv e  C are U n it
Group
Core
temperature,
°C
Stroke 
work index, 
g-m/m2 ■ beat'1
Cardiac 
index, 
L/min ■ n r2
Systemic 
vascular 
resistance, 
dyne/s ■cm5
1 3 6 .0  ±  0.1 2 5 .5  ±  1 .5 2 .2  ± 0 .1 1 4 8 4  ±  9 4 .6
(n  =  4 1 ) (n  =  29 ) (n  =  3 6 ) (n =  34)
2 3 4 .9  ±  0.1 2 5 .8  ±  2.1 1 .9  ±  0.1 1 6 0 8 .8  ± 9 8 .8
(n  -  4 1 ) (n  - 1 5 ) (n  =  2 7 ) (n  =  27)
p  < 0 .0 0 5 NS p < 0 .0 5 N S
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ences noted were relatively small 
and were not statistically signifi­
cant.
Our study revealed that mild re­
sidual hypothermia is still common 
after cardiac surgery. Although 
generally mild, it may partially ac­
count for the hemodynamic dys­
function observed in patients upon 
their arrival at the intensive care 
unit. Continued vigilance is needed 
to prevent residual hypothermia 
and, thus, cardiac depression dur­
ing this critical period.
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ANTIBIOTIC
ACTION
In vitro studies demonstrate that the bacteri­
cidal action of cefoxitin, a cephamycin derived 
fromcephamycin C, results from the inhibition 
of bacterial cell wall synthesis. Evidence 
suggests that the methoxy group in the 
la  position is responsible for the resistance of 
cefoxitin to degradation by bacterial beta- 
lactamases.
INDICATIONS AND CLINICAL USES
TREATMENT
The treatment of the following infections when 
due to susceptible organisms:
1 - In tra-abdom ina l in fections such as
peritonitis and intra-abdominal abscess
2 - G yneco log ica l in fe c tio n s  such as
endometritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and 
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies 
should be performed to determine the sus­
ceptibility of the causative organism(s) to 
MEFOXIN*. Therapy may be started while 
awaiting the results of these tests, however, 
modification of the treatment may be required 
once these results become available.
Organisms pa rticu la rly  appropria te for 
therapy with MEFOXIN' are:
Gram positive
Staphylococci, penicillinase producing and 
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing 
and non-producing strains)
E. coh
Klebsiella species (including K. pneumoniae) 
Proteus, indole positive and negative 
Haemophilus influenzae 
Providencia species 
Anaerobes 
Bacteroides fragilis
MEFOXIN* may also be appropriate for the 
treatment of infections involving susceptible 
strains of both aerobic and anaerobic bacteria.
MEFOXIN* is not active against Pseudomonas, 
most strains of enterococci, many strains of 
Enterobacter cloacae, and meth ici 11 in- 
res is tan t s ta p h y lo c o c c i and L is te ria  
monocytogenes.
Clinical experience has demonstrated that 
MEFOXIN* can be administered to patients 
who are a lso rece iv ing  c a rb e n ic illin , 
gentamicin, tobramycin, or amikacin (see 
PRECAUTIONS and ADMINISTRATION). 
Intravenous Administration 
The intravenous route is preferable for 
patients with bacteremia, bacterial septicemia, 
or other severe or life-threatening infections, 
or for patients who may be poor risks because 
of lowered resistance resulting from such 
deb ilita ting  cond itions as m alnutrition, 
trauma, surgery, diabetes, heart failure, or 
malignancy, particularly if shock is present or 
impending.
PROPHYLACTIC USE
MEFOXIN* may be administered periopera- 
tively (preoperatively, intraoperatively and 
postoperatively) to patients undergoing 
vaginal or abdominal hysterectomy and ab­
dominal surgery when there is a significant 
risk of postoperative infection or where the 
occurrence of postoperative infection is 
considered to be especially serious.
In patients undergoing cesarean section, intra­
operative (after clamping the umbilical cord)
and postoperative use of MEFOXIN* may 
reduce the incidence of surgery related post­
operative infections.
Effective prophylactic use depends on the 
time of administration. MEFOXIN* usually 
should be given one-half to one hour before 
the operation. Prophylactic administration 
should usually be stopped within 12 hours. It 
has been generally reported that continuing 
adm inistration of any antib io tic beyond 
24 hours following surgery increases the 
possibility of adverse reactions but, in the 
majority of surgical procedures, does not 
reduce the incidence of subsequent infection.
If signs of postsurgical infection should 
appear, specimens for culture should be 
obtained for identification of the causative 
organism(s) so that appropriate therapy may 
be instituted.
CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who 
have shown hypersensitivity to cefoxitin or to 
the cephalosporin group of antibiotics.
WARNINGS
Before therapy with MEFOXIN* is instituted, 
careful inquiry should be made to determine 
whether the patient has had previous hyper­
sensitivity reactions to MEFOXIN*, cephalo­
sporins, penicillins or other drugs. MEFOXIN* 
should be given with caution to penicillin- 
sensitive patients.
There is some clinical and laboratory evidence 
of pa rtia l c ross -a lle rg en ic ity  between 
cephamycins and the other beta-lactam anti­
b iotics, pen ic illins  and cephalosporins. 
Severe reactions (including anaphylaxis) have 
been reported  w ith most beta-lactam  
antibiotics.
Pseudomembranous colitis has been reported 
with virtually all antibiotics. This colitis can 
range from mild to life threatening in severity. 
Antibiotics should therefore be prescribed 
with caution in individuals with a history of 
gastrointestinal disease, particularly colitis. It 
is important to considers diagnosis of pseudo­
membranous colitis in patients who develop 
diarrhea in association with antibiotic use. 
While studies indicate that a toxin produced 
by Clostridium difficile is one primary cause of 
antibiotic-associated colitis, other causes 
should also be considered.
Any patient who has demonstrated some form 
of allergy, particularly to drugs, should receive 
antibiotics including MEFOXIN* with caution.
If an allergic reaction to MEFOXIN" occurs, 
administration of the drug should be discon­
tinued. Serious hypersensitivity reactions may 
require treatment with epinephrine and other 
emergency measures.
PRECAUTIONS
The total daily dosage should be reduced 
when MEFOXIN’ is administered to patients 
with transient or persistent reduction of 
urinary output due to renal insufficiency (see 
DOSAGE AND ADMINISTRATION) because 
high and prolonged serum antibiotic con­
centrations can occur from usual doses.
In patients treated with MEFOXIN* a false­
positive reaction to glucose in the urine may 
occur with Benedict’s or Fehling’s solutions 
but not with the use of specific glucose 
oxidase methods.
Using the Jaffe Method, falsely high creatinine 
values in serum may occur if serum concen­
trations of cefoxitin exceed 100 pg/mL. Serum 
samples from patients treated with MEFOXIN* 
should not be analyzed for creatinine if with­
drawn within two hours of drug administration. 
Increased nephrotoxicity has been reported 
fo llow ing concom itant administration of 
cephalosporins and aminoglycoside antibiotics. 
The safety of MEFOXIN* in the treatment of 
infections during pregnancy has not been 
e s tab lished . If the a d m in is tra tio n  of
MEFOXIN* to pregnant patients is considered 
necessary, its use requires that the anticipated 
benefits be weighed against possible hazards 
to the fetus. Reproductive and teratogenic 
studies have been performed in mice and rats 
and have revealed no evidence of impaired 
fertility or harm to the fetus due to MEFOXIN*. 
Cefoxitin has been observed in the milk of 
nursing mothers receiving the drug. 
Prolonged use of MEFOXIN* may result in the 
overgrowth of non-susceptible organisms. 
Repeated evaluation of the patient’s condition 
is essential and if superinfection occurs 
during therapy, appropriate measures should 
be taken. Should an organism become 
resistant during antibiotic therapy, another 
antibiotic should be substituted.
In children 3 months of age or older, higher 
doses of MEFOXIN* (100 m g/kg/day and 
above) have been associated w ith  an 
increased incidence of eosinophilia and 
elevated SGOT.
ADVERSE REACTIONS
MEFOXIN* is generally well tolerated. Adverse 
reactions rare ly required cessation of 
treatment and usually have been mild and 
transient.
Local Reactions
Thrombophlebitis has occurred with intra­
venous administration. Some degree of pain 
and tenderness is usually experienced after 
in tra m u scu la r in je c tio n s  using water. 
Induration has occasionally been reported.
Allergic
M aculopapular rash, urticaria, pruritus, 
eosinophilia, fever and other allergic reactions 
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can 
appear during or after antibiotic treatment. 
Nausea and vomiting have been reported 
rarely.
Blood
Transient eosinophilia, leukopenia, neutropenia, 
hemolytic anemia, and thrombocytopenia 
have been reported. Some individuals, particu­
larly those with azotemia, may develop 
positive direct Coombs tests during therapy 
with MEFOXIN*.
Liver Function
Transient elevations in SGOT, SGPT, serum 
LDH, and serum alkaline phosphatase have 
been reported.
Kidney
Elevations in serum creatinine and/or blood 
urea nitrogen levels have been observed. As 
with the cephalosporins, acute renal failure 
has been reported rarely. The role of 
MEFOXIN* in changes in renal function tests 
is d ifficu lt to assess, since factors pre­
disposing to prerenal azotemia or to impaired 
renal function have often been present.
TREATMENT OF OVERDOSE
Other than general supportive treatment, no 
specific antidote is known. MEFOXIN* can be 
eliminated by dialysis in patients with renal 
insufficiency.
DOSAGE AND ADMINISTRATION
MEFOXIN* may be administered intravenously 
or intram uscularly when required. (See 
complete monograph on ADMINISTRATION 
and RECONSTITUTION.)
TREATMENT DOSAGE 
Adults
The usual adult dosage is 1 g or 2 g of 
MEFOXIN* every 6 to 8 hours. Dosage and 
route of administration should be determined 
by severity of infection, susceptibility of the 
causative organisms, and condition of the 
patient. The usual adult dosages are shown in 
the Table below.
Usual Adult Dosage
Type of Daily Frequency
infection Dosage and Route
Uncomplicated 3-4 g 1 g every 6-8 h
forms* of in- I.V. or I.M.
fections such as
pneumonia,
urinary tract
infection, soft
tissue infection
Moderately 6-8 g 1 g every 4 h
severe or severe or
infections 2 g every6-8 h I.V.
Infections 12 g 2 g every 4 h
commonly or
needing anti- 3 g every 6 h I.V.
biotics in higher 
dosage (e.g. gas 
gangrene)
•Including patients in whom bacteremia is 
absent or unlikely
Therapy may be started while awaiting the 
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic 
streptococcal infectionsshould be maintained 
for at least 10days to guard against the risk of 
rheumatic fever or glomerulonephritis. In 
staphylococcal and other infections involving 
a collection of pus, surgical drainage should 
be carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN* may be used in patients with 
reduced renal function but a reduced dosage 
should be employed and it is advisable to 
monitor serum levels in patients with severe 
impairment.
In adults with renal insufficiency, an initial 
loading dose of 1 g to 2 g should be given. 
After a loading dose, the following recommen­
dations for maintenance dosage may be used 
as a guide:
RENAL CREATININE
FUNCTION CLEARANCE DOSE FREQUENCY
mL/min
Mild
impairment 50-30 1-2 g every 8-12 h
Moderate
impairment
Severe
29-10 1-2 g every 12-24 h
impairment 9-5 0.5-1 g every 12-24 h
Essentially 
no function <5 0.5-1 g every 24-48 h
In the patient undergoing hemodialysis, the 
loading dose of 1 - 2g should be given after 
each hemodialysis, and the maintenance dose 
should be given as indicated in the Table 
above.
Neonates (Including Premature Infants), 
Infants and Children (See WARNINGS for 
Neonates under ADMINISTRATION in the 
complete monograph.)
Premature Infants 
with Body Weights 
Above 1500 g 20-40 mg/kg every 12 h l*.V.
Neonates
0- 1 week of age
1- 4 weeks of age
20-40 mg/kg every 12 h I.V. 
20-40 mg/kg every 8 h I.V.
Infants
1 month to 2 years 
of age
20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
Children 20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
In severe infections, the total daily dosage in 
infants and children may be increased to 
200 mg/kg, but not to exceed 12 g per day. 
MEFOXIN* is not recommended fo r the
therapy of meningitis. If meningitis is sus­
pected, an appropriate antibiotic should be 
used.
At present there is in su ffic ie n t data to 
recommend a specific dosage for children 
with impaired renal function. However, if the 
administration of MEFOXIN* is deemed to be 
essential the dosage should be modified 
consistent with the recommendations for 
adults (see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of 
MEFOXIN* is recommended as follows: 
Vaginal or abdominal hysterectom y and 
abdominal surgery
2 g administered intramuscularly or intra­
venously just prior to surgery (approximately 
one-half to one hour before initial incision).
The second and third 2 g doses should be 
administered at 2-6 hour intervals after the 
initial dose.
Cesarean Section
The first dose of 2g should be administered 
intravenously as soon as the umbilical cord 
has been clamped. The second and third 
2 g doses should be given intravenously or 
intramuscularly four hours and eight hours 
after the first dose.
AVAILABILITY
MEFOXIN* is supplied as sterile powder in 
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
Storage
MEFOXIN* in the dry state should be stored 
below 30° C.
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Complications immediates de la resection 
transuretrale de la prostate: etude de 1000 1
cas consecutifs
Jean-Marie Paquin, MD, FRCSC; Jean-Paul Perreault, MD, FRCSC; Raymond Faucher, MD, FRCSC; 
Franqois Mauffette, MD, FRCSC; Luc Valiquette, MD, FRCSC; Steven Lapointe, MD, FRCSC
Les auteurs ont revise les dossiers de 1000 patients qui ont subi une resection 
transuretrale de la prostate. L'etude a porte sur les 30 jours postoperatoires. Des 
complications ont ete rencontrees chez 139 patients et il y eut 6 deces. Les 
problemes d’infection (urinaire dans 63 cas et septicemie dans 23 cas) sont les plus 
frequents, suivis de l’hemorragie et de la retention. Les deces etaient relies a des 
causes cardiaques.
pies chez 21 patients (tableau I). 
Six patients sont decedes en posto- 
peratoire.
Nous allons etudier de facon 
detaillee notre morbidite qui fut de 
14%.
The authors reviewed the charts of 1000 patients who underwent transurethral 
resection of the prostate. When the 30-day postoperative period was studied, it was 
found that 139 patients suffered complications and 6 died. Infectious complications 
(urinary tract in 63 cases and septicemia in 23 cases) were the commonest followed 
by hemorrhage and urinary retention. The deaths were related to cardiac problems.
L a resection transuretrale de la prostate est une intervention 
pratiquee de fagon quotidienne. Elle 
est consideree comme comportant 
peu de mortalite ou de morbidite.1 
Afin de preciser ces donnees nous 
avons etudie 1000 cas consecutifs 
de patients operes dans le service 
d’urologie de l’hopital Saint-Luc a 
Montreal.
Patients
De 1980 a 1986, 1000 patients 
furent admis pour traitement d’une 
pathologie prostatique. L’age des
Accepte pour publication le 12 janvier, 1988
malades variait de 45 a 97 ans 
(moyenne de 68.5 ans). Le sejour 
hospitalier moyen fut de 8.4 jours 
(de 3 a 61 jours). Au point de vue 
histologique, 864 patients etaient 
porteurs d’une pathologie benigne 
et 136 patients d’un cancer de la 
prostate.
Resultats
Nous avons releve les complica­
tions postoperatoires immediates 
sur les 1000 dossiers etudies. Cent- 
dix-huit ont eu une complication 
unique alors qu’elles furent multi-
Infection urinaire
L’infection urinaire, prouvee a la 
culture des urines, a ete retrouvee 
chez 63 patients. Ces cultures fu­
rent faites au moment ou la sonde 
uretrale fut retiree et lors de la 
visite de relance. Les germes les 
plus frequemment rencontres furent 
FEscherichia coli, l’enterocoque, le 
Klebsiella et le Staphylococcus epi- 
dermidis. Tous furent traites par 
antibiotherapie orale et les cultures 
de controle furent negativees.
Hemorragie postoperatoire
Trente-cinq patients ont presen­
te une hemorragie post-prostatec- 
tomie.2 Celle-ci a ete immediate 
dans 20 cas et retardee dans 15.
T a b le a u  1 -  C o m p lic a t io n s
C o m p lic a t io n N o .
In fe c t io n  u r in a ire 6 3
H e m o rra g ie 3 5
R e te n tio n  u r in a ire 2 7
S e p tic e m ie 2 3
C a rd io -v a s c u la ire 9
In c o n t in e n c e 9
F au x  t ra je ts 4
E p id id y m ite 2
H y p o n a tre m ie  de  d i lu t io n 2
P n e u m o n ie 1
Du departement de chirurgie, Universite de Montreal, service d ’urologie, hopital Saint-Luc, 
Montreal, PQ
Les demandes de tires a part doivent etre adressees au: Dr Jean-Marie Paquin, Departement de 
chirurgie, Hopital Saint-Luc, 1058. rue Saint-Denis, Montreal, PQ H2X 3J4
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COMPLICATIONS DE LA PROSTATECTOMIE TRANSURETRALE
Le cas le plus tardif a ete rencon­
tre au 21e jour postoperatoire. Le 
traitement approprie pour cette con­
dition fut varie; tous les malades 
ont bien repondu a la therapie 
(tableau II).
Retention urinaire
Vingt-sept patients ont presente 
une retention urinaire apres 
l’exerese de la sonde uretrale.
Chez 21 patients le traitement a 
consiste a l’emploi d’un parasympa- 
thicometique3 et de la mise en place 
d’une sonde uretrale pour des pe- 
riodes variant de 24 a 48 heures. 
Si le residu fait apres le retrait de 
la sonde etait inferieur a 100 ml 
le patient etait considere comme 
ayant repondu au traitement. Qua- 
tre patients ont quitte l’hopital 
avec une sonde a demeure; ils 
etaient connus comme souffrant 
d’une atonie en preoperatoire. 
Deux patients ont du subir une 
nouvelle resection transuretrale 
pour adenome residuel.
Septicemie
Chez les 1000 patients operes, 
23 ont presente une septicemie avec 
une hemoculture positive en periode 
postoperatoire.
Onze de ces patients avaient une 
urine sterile a l’admission et les 12
Tableau II -  Traitement
Periode immediate 
Electrocoagulation 
Ligature chirurgicale des arteres 
prostatiques 
Transfusion 
Periode eloignee 
Electrocoagulation 
Mise en place d'une sonde et 
irrigation avec ou sans 
transfusion
Tableau III -  Mortalite
Cause No.
Choc septique 1
Oedeme aigu du poumon 2
Infarctus aigu du myocarde 3
autres etaient porteurs d’une infec­
tion urinaire. Cette faible incidence 
de septicemie s’explique par la 
preparation preoperatoire des mala­
des porteurs ou presumes infectes 
en preoperatoire.4 En effet, ces der- 
niers ont requ de l’ampicilline et de 
la tobramycine intra-veineuse avant 
l’intervention et durant les jours 
postoperatoires.
Complications d ’ordre 
cardio-vasculaire
Neuf patients ont presente des 
complications cardiaques et vascu- 
laires. L’oedeme aigu rencontre 
chez quatre malades etait du a une 
surcharge vasculaire post resection 
transuretrale. Trois patients ont fait 
un infarctus du myocarde dans les 
24 premieres heures; ils n’avaient 
aucune histoire anterieure de mala- 
die cardiaque. Un patient a fait une 
thrombophlebite necessitant une 
anticoagulotherapie, tandis qu’un 
autre a fait une embolie pulmonaire 
non mortelle.
Incontinence urinaire
Neuf patients ont presente de 
l’incontinence urinaire en posto­
peratoire. Quatre manifestaient de 
l’incontinence d’effort qui a disparu 
avec le temps et chez cinq autres 
patients nous avons retrouve une 
vessie spastique pour expliquer 
leurs symptomes qui se sont amen- 
des avec un parasympathicolytique. 
Aucun patient n’a eu d’incontinence 
urinaire totale.
Faux trajets
Quatre patients ont eu durant les 
manipulations preoperatoires et pe- 
roperatoires des faux trajets ure- 
traux. Deux de ces patients etaient 
deja porteurs d’une cystostomie ins­
ta lls  en urgence. Un de ces pa­
tients a subi une perforation rectale 
au moment de l’introduction du
resectoscope. Une derivation par 
cystostomie fut faite et 2 mois plus 
tard il subissait une resection tran­
suretrale sans aucune sequelle.
Hyponatremie
Deux patients ont presente une 
hyponatremie de dilution sympto- 
matique. Dans les deux cas les 
symptomes se sont manifestos dans 
les 12 heures qui suivirent l’inter­
vention.
Epididymite
Seulement deux patients ont 
presente une epididymite dans la 
periode postoperatoire. Un patient 
porteur d’une sonde etait infecte 
avant l’intervention.
Mortalite
La mortalite postoperatoire fut 
minime (0.6%). La moyenne d’age 
des patients decedes etaient de 76 
ans. Le choc septique, l’oedeme 
aigu du poumon et l’infarctus fu- 
rent les principales causes de deces 
(tableau III).
Discussion
La mortalite et la morbidity ratta- 
ches a la resection transuretrale de 
la prostate sont faibles. En effet, 
seulement 14% des patients ont 
presente des complications. Pres de 
la moitie, c’est-a-dire 63 patients 
sur 139, etait secondaire a une 
infection urinaire.
L’hemorragie postoperatoire im­
mediate, bien que rare, peut etre 
corrigee en insistant davantage sur 
une meilleure hemostase5 tandis 
que l’hemorragie a long terme, bien 
que non previsible, pourrait etre 
evitee en donnant les conseils d’usa- 
ge, a savoir eviter les activites 
sexuelles et les activites physiques.
La septicemie peut etre reduite
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avec une plus grande rigueur d’a- 
sepsie et une identification des ma- 
lades susceptibies d’etre infectes ou 
porteurs d’infection avant (’inter­
vention de fagon a pouvoir leur 
donner une antibiotherapie preven­
tive au prealable.
La mortalite de 0.6% est basse et 
elle est comparable aux autres 
series connues. Afin de la diminuer 
il est tres important que tous les 
patients a risque aient une evalua­
tion preopera toire.
L’incontinence postoperatoire se- 
condaire a la technique s’est amelio- 
ree beaucoup a travers les annees. 
Nous pouvons constater que nous 
n’avons pas d’incontinence a long
terme mais seulement une inconti­
nence d’effort temporaire.
Les stenoses uretrales et les 
stenoses du col vesical sont des 
complications beaucoup plus tardi- 
ves qui surviennent encore malheu- 
reusement et pour lesquelles nous 
n’avons pas trouve de solution.
Conclusions
La resection transuretrale de la 
prostate est une intervention chirur- 
gicale a faible incidence de mortalite 
et de morbidite. II est toutefois tres 
important que le malade soit bien 
prepare et bien evalue.
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reports of each scientist in paper form 
allows for close scrutiny of the data.
The book is geared more to the 
research and research-oriented clinical 
laboratory in the field of growth factors 
and wound healing. The chapter dealing 
with platelet-derived wound healing fac­
tors in human clinical trials is especially 
relevant to surgical practice as is the 
chapter on clinical experience with 
crude preparation of growth factors and 
healing of chronic wounds in humans. 
The authors present state of the art 
information on alternatives to healing 
difficult ulcers or wounds for which 
conventional therapy is slow or ineffec­
tive.
The book is easy to read but would 
have benefited by more editorial com­
ment on how the various scientific 
presentations relate to clinical pratice. 
However, this does not deter from the 
overall aim of the book. It serves as an 
excellent reference for the research sci­
entist in the area of growth factors and 
other aspects of wound healing and is a 
very interesting and clinically relevant
reference source for the practising clini­
cal surgeon.
Nicolas V. Christou, MD, PhD, FRCSC, 
FACS
Associate Professor o f  Surgery,
McGill University,
Department o f  Surgery,
Royal Victoria Hospital,
687 Pine Ave. W,
Montreal, PQ 
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PRINCIPLES AND PRACTICE OF 
RESEARCH. Strategies for Surgical 
Investigators. Edited by Hans Troidl, 
Walter 0 . Spitzer, Bucknam McPeek, 
David S. Mulder and Martin F. 
McKneally. 385 pp. Illust. Springer- 
Verlag, New York. $58.00 (US). ISBN 
0-387-16340-9.
This book on surgical research is divid­
ed into six sections. The first section on 
the rationale of surgical research deals 
with the historical and philosophical
aspects and the role and training of the 
investigator. The second section con­
cerns itself with practical tools required 
by the investigator, including such top­
ics as literature review and appraisal, 
statistics, computers and preparation of 
grant proposals. The chapter on statis­
tics, entitled “Statistics demystified”, is 
excellent as a review or for the student 
who has had no exposure to research.
The various aspects of surgical re­
search are covered in the next section. 
They include animal experimentation, 
clinical research, multicentre trials and 
health service research. Three well-writ­
ten chapters in this section deal with 
particularly important subjects, not 
only for the surgical investigator but 
for every academic surgeon; they dis­
cuss the conduct and pitfalls of clinical 
trials, including multicentre clinical tri­
als, and the evaluation of the diagnostic 
process in medicine. Practical examples 
of how to calculate patient size in a 
clinical trial and how to evaluate diag-
continued on page 447
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Acute Pancoast’s Syndrome Caused by 
Fungal Infection
F.M. Shamji, MB, ChB, FRCSC;* J.R. Leduc, MD, FRCSC;* J. Bormanis, MD, FRCPC;t 
H.J. Sachs, MD, FACS, FACCP, FRCSC*
Nonmalignant causes of Pancoast’s syndrome are extremely rare. The authors 
report the case of a 32-year-old man, receiving treatment for acute lymphoblastic 
leukemia, who had a clinical picture resembling that of Pancoast’s syndrome. 
Invasive mucormycosis was diagnosed as the cause of the syndrome at emergency 
thoracotomy undertaken to control massive hemoptysis. In spite of adequate 
treatment, the patient died 5 weeks postoperatively of overwhelming sepsis. A 
review of the literature disclosed only two other similar cases. The authors conclude 
that the development of Pancoast’s syndrome in the immunosuppressed patient 
should raise suspicion of an invasive fungal infection. A precise early diagnosis may 
allow successful, specific antifungal therapy to be instituted.
Les causes non malignes du syndrome de Pancoast-Tobias sont rares. Les auteurs 
decrivent le cas d’un homme de 32 ans traite pour leucemie aigue lymphoblastique, 
qui presenta un tableau clinique evocateur d’un syndrome de Pancoast-Tobias. Lors 
d’une thoracotomie pratiquee en urgence pour venir a bout d’une hemoptysie 
massive, une mucormycose fut diagnostiquee comme cause de ce syndrome. En depit 
d’un traitement approprie, le patient deceda 5 semaines plus tard d’une septicemie 
irrepressible. Une revue de la litterature n’a revele que deux autres cas similaires. 
En conclusion, les auteurs indiquent qu’il faut soupfonner une infection fongique 
invasive quand un syndrome de Pancoast-Tobias apparait chez un patient dont les 
fonctions immunitaires sont deprimees. Un diagnostic precis et precoce pourrait 
permettre le succes d’un traitement antifongique specifique.
Pancoast’s syndrome, the associ­ation of pain in the shoulder 
and arm, sensorimotor symptoms in 
the involved upper limb and an 
ipsilateral Horner’s syndrome, is 
usually caused by a malignant api­
cal lung tumour invading the struc­
tures of the thoracic inlet.1 We 
present a case of rapidly evolving 
Pancoast’s syndrome that resulted 
from a fungal infection.
Accepted for publication Apr. 14, 1988
Case Report
A 32-year-old man presented with 
a 3-month history of fatigue, night 
sweats and anorexia. He had be­
come jaundiced 3 weeks earlier and 
his urine was dark. He had suffered 
from rheumatic fever as a child.
Physical examination revealed a 
jaundiced young man with petechi- 
ae scattered over most of his body.
He had enlarged cervical, axillary 
and femoral lymph nodes and hepa- 
tosplenomegaly. A chest film ap­
peared normal (Fig. 1). Blood smear 
and bone-marrow examination were 
diagnostic for acute lymphoblastic 
leukemia. Induction chemotherapy 
was with vincristine, prednisone and 
daunorubicin; the hepatospleno- 
megaly and lym phadenopathy 
quickly resolved. Remission as 
assessed by bone-marrow examina­
tion was achieved by 3 weeks.
During the neutropenic period, 
approximately 5 days after the initi­
ation of chemotherapy, severe cons­
tant pain developed in his left 
shoulder and over the left scapula. 
He remained afebrile with no cough 
or hemoptysis. Over the next 4 
days, the left shoulder pain in­
creased in severity and radiated 
down the medial aspect of the left 
arm; paresthesia developed in the 
fourth and fifth fingers.
The patient became febrile, so 
tobramycin, 100 mg intravenously 
every 8 hours, and cefazolin, 1.5 g 
every 6 hours, were started. All 
cultures were sterile but the patient 
remained febrile and a cough with 
mild hemoptysis developed. A chest 
film now revealed left upper lobe 
consolidation (Fig. 2). Ticarcillin, 3 
g intravenously every 4 hours, was 
substituted for cefazolin. Two days 
later, approximately 11 days after 
the initiation of chemotherapy, a 
left Horner’s syndrome developed 
and a supraclavicular mass that was 
fluctuant, tender and not erythema­
tous appeared on the left side.
From the *Division o f Thoracic Surgery and fDivision o f  Hematology, Ottawa Civic Hospital, 
University o f Ottawa, Ottawa, Ont.
Reprint requests to: Dr. F.M. Shamji, Division o f  Thoracic Surgery, Ottawa Civic Hospital, 1053 
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There was cavitation within the 
consolidation of the left upper lobe 
and subcutaneous emphysema in 
the left side of the neck (Fig. 3). A 
provisional diagnosis of lung ab­
scess or leukemic infiltration of the 
left upper lobe was considered.
Fiberoptic flexible bronchoscopy 
revealed erythema of the left upper 
lobe bronchus but no evidence of 
pus or active bleeding. Biopsy speci­
mens and cytologic brushings were 
obtained, and tissue was cultured. 
Apart from a light inflammatory 
exudate and nonspecific bronchitis, 
there was no evidence of malignant 
cells, bacteria or fungi. Approxi­
mately 8 hours after bronchoscopy, 
sudden massive hemoptysis devel­
oped and the patient suffered a 
cardiorespiratory arrest. He was re­
suscitated, but large quantities of 
arterial blood continued to drain 
through the endotracheal tube.
On fiberoptic flexible bronchos­
copy, the diseased left upper lobe 
was found to, be the source of 
bleeding. An emergency left thora­
cotomy, under one-lung ventilation 
using a Carlen’s tube, was then 
undertaken to remove the diseased 
lobe, which appeared to be consoli­
dated, necrotic and intimately in­
volved within the apex of the tho­
rax. Mobilization of the diseased 
necrotic lung from the thoracic 
inlet was difficult and when the 
lung was entered the necrotic proc­
ess was seen to involve the cervical 
sympathetic chain, the left subclavi­
an artery and the lower part of the 
brachial plexus. The dissection re­
sulted in extensive bleeding at the 
apex of the chest wall, apparently 
from the left subclavian artery; the 
bleeding was controlled with diffi­
culty using fine vascular sutures. A 
left upper lobectomy was then com­
pleted.
Amphotericin-B therapy was be­
gun; the initial dosage was 5 m g/d 
intravenously and he received a cu­
mulative dose of 1.57 g. Gram­
negative septicemia developed sec­
ondary to left lower lobe pneumonia 
and in spite of vigorous antibiotic 
and supportive therapy, aortic valve 
endocarditis and meningitis due to 
Serratia marcescens developed. He 
died of severe systemic sepsis 5 
weeks postoperatively.
Discussion
The pathological examination re­
vealed mucormycosis. The lung tis­
sue was necrotic and very friable 
with local thrombus formation in 
the blood vessels secondary to fun­
gal infection. Numerous fungi were
FIG. 1 — Normal chest film on admission.
FIG. 2 — Nine days after induction chemotherapy, film shows consolidation of 
upper lobe of left lung.
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seen in the lumen of the blood 
vessels. Examination of the bron­
chus showed evidence of chronic 
nonspecific bronchitis only. There 
was no leukemic infiltrate in the 
lung tissue or the hilar lymph 
nodes.
It was our impression that the 
necrotic disease process in the tho­
racic inlet of this patient resulted in 
a bronchovascular fistula between 
the subclavian artery and the ab­
scess cavity in the left upper lobe; 
in addition to massive hemoptysis, 
this fistula was also the source of
considerable bleeding that we en­
countered when we dissected the 
lung from the chest wall. Involve­
ment of the left brachial plexus and 
sympathetic chain was responsible 
for the left arm pain, paresthesia, 
and Horner’s syndrome.
A review of the medical literature 
revealed two reports2 3 of a rapidly 
evolving Pancoast’s syndrome oc­
curring in immunosuppressed pa­
tients and caused by invasive fungal 
infection. Our case resembled these 
in that all three patients were 
young adults, suffering from hema­
tologic malignant disease in whom 
an invasive fungal infection oc­
curred during or just after chemo­
therapy when neutropenia was pro­
found. The picture of well-estab­
lished Pancoast’s syndrome was ob­
vious in these cases within 4 weeks 
of receiving the induction chemo­
therapy. The cause of the infection 
in our case was mucormycosis; As­
pergillus sp and Allescheria boydii 
were seen in the other cases. Only 
one patient survived with antifungal 
therapy;2 the other3 died of over­
whelming sepsis, as did our patient.
FIG. 3 — Two days later there is cavitation in area of consolidation with 
subcutaneous air dissecting into left supraclavicular area (arrow).
Conclusions
The development of a rapidly 
evolving Pancoast’s syndrome in an 
immunosuppressed patient is sug­
gestive of an invasive fungal infec­
tion. A precise early diagnosis will 
allow specific antifungal therapy to 
be instituted, and treatment of the 
infection may be successful.
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Peritoneovenous Shunts — Devices of 
Last Resort
Karen E. Shepherd, MD;* Brian J. Miller, MD, FRCSCt
This study examines the usefulness of peritoneovenous shunts through a 
retrospective review of the charts of 16 patients who received this shunt at the 
University Hospital in Saskatoon up to May 1987. Fourteen shunts were placed for 
malignant ascites, 1 for alcoholic cirrhosis and 1 for nephrogenic ascites. All 
patients had symptoms related to abdominal pressure or dyspnea. Diuretics were 
most frequently used as initial management, and paracentesis was performed to 
relieve symptoms in all but one patient. However, a trial of sodium restriction was 
used in only eight patients, and only five of these trials lasted longer than 1 week. 
Thus, the adequacy of medical management was questionable. The death of one 
patient was directly attributable to the shunt, and the deaths of four others were 
suspected to be sequelae of surgery or shunting. Only five shunts were functioning 
at the time the patient died. In this study, the majority of the patients received little 
benefit from the peritoneovenous shunt.
Cette etude sur l’utilite des derivations peritoneo-veineuses fut faite par un examen 
retrospectif des dossiers de 16 patients qui regurent ce type de derivation jusqu’en 
mai 1987, a l’Hopital universitaire de Saskatoon. Quatorze derivations furent 
placees pour ascite maligne, 1 pour cirrhose alcoolique et 1 pour ascite nephrogeni- 
que. Tous les patients presentaient de symptomes relies a la pression abdominale ou 
a la dyspnee. Les diuretiques avaient le plus souvent ete utilises comme traitement 
initial, et une paracentese avait ete pratiquee pour soulager les symptomes chez 
tous les patients, sauf un. Toutefois, un apport hyposodique ne fut tente que chez 
huit patients seulement, et l’essai dura plus d’une semaine chez seulement cinq 
d’entre-eux. II est done possible que le traitement medical n’ait pas ete optimum. Le 
deces d’un des patients est directement attribuable a la derivation, et on soupconne 
que la mort de quatre autres soit une sequelle de la chirurgie ou de la derivation. 
Seulement cinq derivations etaient permeables au moment du deces des malades. 
Dans cette etude, la majorite des patients a peu profite d’une derivation peritoneo- 
veineuse.
S ince peritoneovenous shunts were introduced in 1974 for the 
management of ascites, opinions of 
their benefits and drawbacks have
been conflicting. Patient selection is 
an important factor in determining 
outcome. Postoperative manage­
ment may play an important role,
and variations in method may ac­
count for the variability in the re­
ported results. Even with identical 
data, different conclusions may be 
drawn because interpretation of 
data and perception of “benefit” 
vary between observers.
Thus, we wished to determine the 
value of peritoneovenous shunts in 
the context of our patient popula­
tion, selection criteria and perioper­
ative management regimens.
Methods
The charts of all 16 patients who 
received peritoneovenous shunts at 
University Hospital, Saskatoon, up 
to May 1987 were reviewed. Infor­
mation gleaned from the records 
included the patient’s age, disease, 
symptoms, management of the asci­
tes before surgery and the surgical 
procedure used (including type of 
shunt). The effectiveness of the 
shunt was determined by comparing 
preoperative and postoperative pa­
tient weights, abdominal girths and 
symptoms (on postoperative day 7, 
on discharge and as last reported in 
the chart or from the family physi­
cian’s, home or hospital record). 
Supplemental treatments, patency 
studies (e.g., Doppler flow) and au­
topsy findings were noted. Compli­
cations postoperatively and patient 
survival were also considered.
Findings
Patient age ranged from 21 to 79 
VOL. 31. NO. 6 NOVEMBER 1988/CJS
From the Department o f Surgery, University o f  Saskatchewan, Saskatoon, Sask.
*Resident in General Surgery, Department o f  Surgery, University o f  Saskatchewan 
tAssociate Professor, Department o f  Surgery, University o f  Saskatchewan 
Accepted for publication May 18, 1988
Reprint requests to: Dr. K.E. Shepherd, Apt. 207, 1200 Tower Rd„ Halifax, NS B3H 4K6 
444
PERITONEOVENOUS SHUNTS
years (mean 55 years) at the time 
the shunt was placed. In most pa­
tients, the disease giving rise to the 
ascites was malignant (Table I).
The symptoms present before 
shunt placement included abdomi­
nal pressure in 15 and dyspnea in 
13 patients. Pleural effusions, pres­
ent in 6 of the 13, likely contribut­
ed to the feeling of dyspnea; 1 of 
the 13 had congestive heart failure. 
Heartburn in two patients and back 
pain in one were less notable symp­
toms.
Initial medical management of 
the ascites varied widely. Diuretics 
were most frequently used (14 pa­
tients, Table II). Agents used were
Table 1 -  Diseases In Patients Who 
Received a Peritoneovenous Shunt
Disease No. of patients
Malignant
Adenocarcinoma of
breast 1
colon 3
endometrium 1
gallbladder/common
bile duct 2
ovary 2
pancreas (suspected) 2
stomach 1
Leiomyosarcoma
(anaplastic) 1
Lymphocytic lymphoma 1
Nonmalignant
Alcoholic cirrhosis 1
Renal failure/nephrotic
ascites 1
Table II -  Courses of Diuretics Given
Preoperatively
Length of course, wk No. of patients
0 -  1 2
1 -  2 0
2 -  4 4
4 -  8 2
8 - 1 6 2
> 16 4
Table III - Peritoneal Taps Preoperatively
No. of taps No. of patients
1 1
2 6
3 4
4 3
> 4 1
hydrochlorothiazide, furosemide 
and spironolactone. Paracentesis 
was also a popular therapeutic mea­
sure preoperatively. Of the 16 pa­
tients, 15 had at least one therapeu­
tic paracentesis (Table III). Only 
eight patients underwent a trial of 
sodium restriction to treat their 
ascites, and this lasted for less than 
1 week in three patients, less than 1 
month in two and less than 4 
months in two others. Fluid restric­
tion was tried in 3 of the 16 
patients; 2 were restricted for 5 
days and 1 for 29 days.
Until 1982, all shunts used were 
the LeVeen type (seven patients). 
Denver shunts were then intro­
Table IV -  Complications After Shunt 
Placement
Complication No. of patients (%)
Congestive heart
failure 2(12)
Coagulopathy (new)*
Asymptomatic 3(20)
Symptomatic 1(7)
Venous thrombosis 2(12)
Infection
Wound 1(6)
Sepsis 1(6)
Ascitic leak 1(6)
Pulmonary embolism 1(6)
Cerebrovascular
accident 1(6)
Renal failuref 1(6)
Shunt displacement 1(6)
*2 patients had coagulopathy preoperative­
ly that was unchanged postoperatively. 
Coagulation studies were not done on 1 
patient.
tPrerenal in nature, especially on days 3 to 
7, then resolved.
duced, and the other nine patients 
received this shunt.
Eleven patients (69%) had prob­
lems after shunting; in all, there 
were 15 complications (Table IV). 
In one of the four patients who 
received prophylactic antibiotics pe- 
rioperatively, an enterococcal 
wound infection developed; the 
same patient also suffered sepsis 
due to Peptostreptococcus.
Autopsy was performed on five 
patients; three had postoperative 
complications — congestive heart 
failure, massive pulmonary embo­
lism and cerebrovascular accident. 
The congestive heart failure oc­
curred 5 days postoperatively, the 
pulmonary embolism occurred 2 
hours postoperatively in a patient 
who had been heparinized at opera­
tion and the cerebrovascular acci­
dent occurred 5 days after opera­
tion (the autopsy reported “ tumour 
embolism” as a cause of the 
stroke). In each of these cases, the 
complication undoubtedly con­
tributed to the patient’s death. 
When autopsy was not done, it was 
impossible to prove that the compli­
cations were responsible for the 
patient’s death. We noted the time 
that elapsed between diagnosing 
the complication and death (Table 
V).
The length of patient survival 
with a functioning shunt was deter­
mined in patients surviving longer 
than 1 week (Table VI, Fig. 1). The
Table V -  Survival Related to Complications
Complication
Postop time of 
death, d
Time from diagnosis 
to death, d
Congestive heart failure 7 2
Congestive heart failure 10 mo 10 mo
Symptomatic coagulopathy 30 6
Wound infection +  sepsis 30 19
Thrombosis of superior vena cava 3 mo 83
Thrombosis of superior vena cava? 31 13
Ascitic leak 22 12
Renal failure 22 19
Cerebrovascular accident 5 wk 30
Pulmonary embolism 2 h -
Shunt displacement - *
"Alive 3 yr postoperatively.
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patient with alcoholic cirrhosis was 
still alive at the time of writing. The 
patient with nephrotic ascites, who 
died 10 months after shunt place­
ment, required repeated paracen­
teses, starting 5 months after oper­
ation. For at least 50% of his re­
maining life, he received no pallia­
tion from the shunt. Figure 2 
shows the results obtained with the 
shunt in patients who had malig­
nant ascites and survived longer 
than 1 week.
During the first week after shunt 
placement, most patients received a 
course of diuretics and, in some 
cases, sodium restriction. Nine of 
the 13 who survived longer than 1 
week required supplemental treat­
ment (Table VII).
Discussion
The results of reported studies to 
date have been comparable to ours. 
The complications we experienced 
have also been reported by other 
groups, although in varying propor­
tions. For example, coagulopathy 
has been reported in up to 39% of 
patients (all with nonmalignant asci­
T a b le  V I - R esu lts  A fte r  S h u n t P la ce m e n t
D ays N o. of No. w ith
a fte r  shunt p a tien ts functional
p la c e m e n t a liv e shunts
1 15 15
7 13 11
14 13 10
30 9 6
60 6 6
90 5 4
1 2 0 3 2
1 8 0 3 1
3 6 0 2 1
T a b le  V II -  S u p p le m e n ta l T re a tm e n ts
R e q u ire d  in P a tien ts  S u rv iv in g  M o re  Than  1
W eek A fte r S h u n t P la ce m e n t
T re a tm e n t No. of pa tien ts
D iu re tic s 8
S o d iu m  re s tr ic tio n 4
F lu id  re s tr ic tio n 1
R ep ea te d  paracen teses 2
tes)1 and in as few as 2% (mixed 
malignant and nonmalignant asci­
tes).2 The disproportion of malig­
nant cases (14) in our series may 
account for the relatively low coa­
gulopathy rate, because postopera­
tive coagulopathies have been 
found to develop less frequently in 
patients with malignant ascites than 
in those with cirrhosis.3 The infec­
tion rate in reported studies has 
ranged from 25%' to 2%,2 and ve­
nous thrombosis from 11%4 to 0%^ 
Similarly, reports of shunt failure 
have been inconsistent, but compar­
isons are difficult because of vary­
ing forms in which the data are 
presented (e.g., cumulative patency, 
patencies of selected subgroups at a 
given time, median patency dura­
tion). Grischkan and colleagues,5
FIG. 1 — Patient survival and shunt 
function after placement of perito- 
neovenous shunt. Solid line = patients 
alive, dotted line =  patients alive and 
shunt functioning.
for example, reported that 8 of 11 
patients studied required either a 
revision or replacement of the shunt 
due to malfunction, and Fry and 
associates6 found that 55% (33 of 
60 patients) had patent shunts at 3 
months. In the study of Lund and 
Moritz,2 only 10% (5 of 49) shunts 
failed “in long-term follow-up” 
(time unspecified).
High death rates have been re­
ported after shunt placement, par­
ticularly in patients with underlying 
malignant disease. One-year surviv­
al rates have ranged from 52%1 to 
19%.2 For malignant ascites, 1-year 
survival has been reported to vary 
from 0%3 to 11%2 compared with 
50%3 and 54%2 for patients with 
cirrhosis. In our study, only three 
patients (18%) were still alive at 1 
year, and this included one of the 
two patients with nonmalignant as­
cites.
Patient selection in our institu­
tion is based mainly on the referrals 
of our oncologists and gastroen­
terologists. The disproportion in 
the number of patients who had 
malignant ascites in our study com­
pared with those who had cirrhotic 
ascites reflects the biases of these 
specialists. We could not determine 
from chart review if, or how many, 
patients referred for shunt insertion 
were rejected by the surgeons.
120
FIG. 2 — Lifespan and shunt function in 10 patients with malignant ascites who 
survived longer than 1 week after peritoneovenous shunting. Black bars =  total 
days of life, lined bars =  days of shunt function.
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However, it was apparent that sev­
eral patients receiving shunts had 
not had optimal medical therapy 
first, and in many patients the in­
tractability of the ascites was ques­
tionable. Sodium restriction, the 
mainstay of ascites management, 
was not even tried in two patients 
and several had only brief courses. 
Diuretics were used, but again 
courses in many patients were brief. 
(Because fluid restriction can pre­
cipitate hepatorenal syndrome, it 
may have been considered undesir­
able.)
Morbidity and mortality were 
striking in this small series; 69% 
(11) of patients had complications. 
Surgery or the shunt itself likely 
contributed to the death of at least 
38% (six) of patients. Cause and 
effect could not be proved, even 
with autopsy, because of the myriad 
of variables. In all but two patients
BOOK REVIEWS
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nostic tests are provided. These chap­
ters are among the best in the book.
The fourth section deals with the 
reporting of research; abstracts, oral 
presentations and written presentations 
are considered. There is an excellent 
chapter on chairing panels, seminars 
and consensus conferences, areas that 
are not usually dealt with. All investiga­
tors no matter how senior can learn 
from this chapter.
The fifth section entitled “Interna­
tional perspectives on surgical re­
search” deals with contributions made 
from different countries. Particularly 
interesting in this section is a discus­
sion of the problems of developing 
clinical trials in Japan, given by Drs. 
Aoki and Hioki and Muto.
The final section of the book is 
concerned with opportunities and the 
future of surgical research with a chap­
ter written by Dr. F.D. Moore.
The book has a number of shortcom­
with complications, death occurred 
within 30 days of diagnosis.
Overall, patients did not live long 
after receiving their shunts. Only 
nine patients were alive 1 month 
postoperatively, three at 4 months 
and two at 1 year. Patients who 
survived longer than 1 week did not 
necessarily obtain palliation from 
their shunts for the rest of their 
lives (Fig. 2). In some cases, pallia­
tion was very brief. The majority of 
patients (69%) required some form 
of supplemental treatment, includ­
ing repeated paracentesis, in an 
attempt to control the ascites.
LeVeen and Denver shunts are 
not inexpensive. On the other hand, 
it is an ethical question whether 
palliation for a day or a month is 
worth the expense. We found that 
patients receiving a shunt had a 
high complication rate, adding to 
morbidity, and that, generally, they
ings. For example, a much more specif­
ic and practical discussion of the train­
ing of a surgical investigator would 
enhance the book; it should include 
such considerations as how to select a 
research supervisor, how to select an 
area of interest and whether or not a 
higher degree should be sought. The 
important subject of how to write a 
research paper lacks detail; only one 
paragraph is devoted to writing a dis­
cussion section. There is little or no 
instruction on the preparation of tables 
and figures. I also found the section on 
the role of the surgical investigator 
somewhat negative. The categorization 
of surgical investigators into “tightrope 
walkers, benchmen, or occasional sur­
geon-investigators” is not in my view 
likely to attract young people to this 
endeavour.
These criticisms do not diminish the 
considerable value of this book and I 
recommend it for the hospital library as
did not live long enough to benefit
substantially from the shunt.
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Professor o f  Surgery,
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TOTAL KNEE REVISION ARTHRO­
PLASTY. Edited by W. Norman Scott. 
223 pp. Illust. Grune & Stratton, Inc., 
Orlando, Fla.; Academic Press Canada, 
Don Mills, Ont., 1987. $88.25. ISBN 
0-8089-1864-8.
This is a timely book in the sense that 
knee revision procedures are becoming 
common. Unfortunately, its value is
continued on page 451
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Is Incidental Appendectomy a Safe 
Practice?
Andrus J. Voitk, MD, MSc, FRCSC; Josiah B. Lowry, MD
In an attempt to determine the safety of appendectomy performed as an incidental 
procedure, the authors reviewed 853 operations (458 hysterectomies and 395 
cholecystectomies) performed by five surgeons at one hospital between 1981 and 
1984 and compared the results in 35% of the patients who underwent incidental 
appendectomy with those in the remainder. Factors studied were operative time, 
postoperative stay, postoperative fever and leukocytosis, the need for intravenous 
fluids, parenteral analgesia and antibiotics, and infectious complications. Most of 
these variables differed between individual surgeons, but the addition of incidental 
appendectomy did not significantly alter any variable for an individual surgeon or 
for the group as a whole. Incidental appendectomy seems to be a safe practice and 
one that does not alter the outcome of hysterectomy or cholecystectomy but does 
protect against subsequent appendicitis.
Pour tenter d'etablir l’innocuite des appendicectomies effectuees accessoirement a 
une autre operation, les auteurs ont passe en revue 853 operations (458 
hysterectomies et 395 cholecystectomies) pratiquees par cinq chirurgiens d’un 
hopital, entre 1981 et 1984. Ils ont compare les resultats chez 35% de ces patients 
qui ont subi une appendicectomie accessoire, avec ceux observes chez les autres 
patients. Les facteurs etudies comprennent le temps operatoire, la duree du sejour 
postoperatoire, la pyrexie et la leucocytose postoperatoires, le besoin de solutes 
intraveineux, d’analgesiques et d’antibiotiques parenteraux, et les complications 
infectieuses. On a constate entre les chirurgiens des differences individuelles quant 
a la plupart de ces variables, mais l’appendicectomie accessoire n’a modifie aucune 
des variables pour aucun des chirurgiens ou pour l’ensemble de ceux-ci. L’appendi­
cectomie accessoire semble done etre une pratique sure qui ne modifie en rien les 
resultats de l’hysterectomie ou de la cholecystectomie, mais qui protege d’une 
appendicite subsequente.
The likelihood of appendicitis developing decreases with age, 
being approximately 20% for those 
under 20 years of age, then drop­
ping off abruptly to be only about 
1% for those 65 years of age and 
older.1 However, the death rate 
from appendicitis rises with age.2
The rate of perforation triples after 
60 years of age2 and the likelihood 
of death from a perforated appendix 
is three times that of an unperfora­
ted appendix.3 Thus, although the 
disease is less frequent in the elder­
ly, its effects are much more seri­
ous. In order to avoid the risks of
appendicitis associated with increas­
ing age, appendectomy performed 
incidentally at the time of another 
surgical procedure should be advo­
cated, particularly if it carries no 
increased risk to the patient.
To determine if incidental appen­
dectomy is associated with undesir­
able effects, we decided to review 
the results obtained in a small hos­
pital where incidental appendecto­
my is common. Cholecystectomy 
and hysterectomy were standard 
and frequently performed opera­
tions suitable for the study. In this 
setting, incidental appendectomy 
carries no monetary reward, as gov­
ernment health insurance allows no 
additional charge for appendectomy 
carried out in the course of other 
surgery.
Patients and Method
We reviewed the charts of 853 
patients who underwent hysterecto­
my (458 patients) or cholecystecto­
my (395 patients) at Orillia Soldiers’ 
Memorial Hospital between 1981 
and 1984 inclusive. All participat­
ing surgeons claimed to use the 
same three criteria for incidental 
appendectomy: an uncomplicated 
primary operation, a stable patient 
with no contraindication to addi­
tional surgery and an original inci­
sion providing access to the appen­
dix without need for enlargement. 
For hysterectomy (Table I), done by 
two gynecologists and one of the 
general surgeons, only elective op­
erations on nonpregnant patients
From the Department o f  Surgery, Orillia Soldiers’ Memorial Hospital, Orillia, Ont.
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were included; removal of ovaries, 
cysts and fallopian tubes were con­
sidered part of the procedure, if 
carried out. Patients who under­
went additional procedures, other 
than appendectomy, were rejected. 
For cholecystectomy (Table II), per­
formed by three general surgeons, 
no additional procedures were ac­
cepted, but both elective and emer­
gency (patients admitted through 
the emergency department who had 
their operation during the same 
admission) procedures were al­
lowed. The variables studied are 
listed in Tables III and IV. Because 
this is a retrospective study, wound 
infection is recorded only when it 
was listed as a complication in the 
discharge summary or progress 
notes, or when a procedure was 
noted to be draining pus from the 
wound. A deep abscess was diag­
nosed when it was necessary to 
drain pus from the abdominal cavi­
ty. The leukocyte count was not 
measured in all patients.
Differences between individual 
surgeons and variables were 
analysed by the x2 test with Yates’ 
correction; a p value of less than 
0.05 was considered significant.
Findings
The overall rate of incidental ap­
pendectomy was 35% (299 of 853),
30% (138 of 458) with hysterecto­
my and 41% (161 of 395) with 
cholecystectomy. For the five sur­
geons who performed the proce­
dures, the incidental appendectomy 
rate varied between 12% and 59% (p 
< 0.05). There was one death in the 
whole group; a nonogenarian man 
died of cardiac causes within 48 
hours of an emergency cholecystec­
tomy without appendectomy. Com­
parison of hysterectomy with chole­
cystectomy showed close similarity 
between the variables studied. With 
both operations, no significant dif­
ference between appendectomy and 
no appendectomy was seen with 
respect to any of the variables.
Of the 395 cholecystectomies 
112 (28%) were classified as emer­
gency. They were associated with a 
significantly lower appendectomy 
rate than elective cholecystectomies 
(22% versus 48%, p < 0.05) (Table 
II) and a significantly higher rate of 
leukocytosis (37% versus 6%, p < 
0.05), use of intravenous fluids 
(49% versus 19%, p < 0.05) and 
use of antibiotics (53% versus 15%, 
p < 0.05). But again, within each 
subgroup of emergency and elective 
cholecystectomies there was no dif­
ference between patients who did or 
did not have a concomitant appen­
dectomy.
Only infection rates and the inci­
dence of postoperative fever were 
similar for all surgeons (Table III);
all other variables differed signifi­
cantly from surgeon to surgeon, 
but no significant difference in any 
variable could be detected between 
patients who did and did not under­
go concomitant appendectomy.
There were no significant differ­
ences in the results of the 853 
operations. Specifically, the addi­
tion of appendectomy did not in­
crease the length of hospital stay, 
the incidence of fever or leukocyto­
sis or the need for intravenous 
therapy, antibiotics or parenteral 
analgesia. The 10-minute increase 
in average operative time was not 
significant. The superficial wound 
infection rate doubled with appen­
dectomy (6 of 291 versus 6 of 562, 
p > 0.05); deep abscesses occurred 
in three patients after appendecto­
my and none in those without. 
Total complications from infection 
tripled after appendectomy (2 of 
291 versus 6 of 562, p > 0.05).
Discussion
Ten series from this decade, re­
porting over 1500 patients, did not 
show a single death attributable to 
incidental appendectomy, nor did 
the authors report increased mor­
bidity except with respect to wound 
infection, where opinions differed. 
Cruse4 reported an increased rate of 
wound infection after cholecystecto­
my when appendectomy was done 
incidentally, but Strom and cowork­
ers5 were unable to confirm this in a 
prospective randomized study. De­
spite its apparent safety, incidental 
appendectomy does not enjoy uni­
versal blessing. Morris and col-
Table 1 -  Patients Who Underwent Hysterectomy
Surgeon With appendectomy Without appendectomy Total
1 102 201 303
2 15 106 121
3 21 13 34
Totals 138 320 458
Table II -  Patients Who Underwent Cholecystectomy
Surgeon
no.
With appendectomy Without appendectomy Totals
Elective Emergency Combined Elective Emergency Combined Elective Emergency Combined
3 96 17 113 59 21 80 155 38 193
4 32 3 35 45 14 59 77 17 94
5 8 5 13 43 52 95 51 57 108
Totals 136 25 161 147 87 234 283 112 395
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leagues6 found the observed in­
crease in wound infection rate fol­
lowing incidental appendectomy to 
be statistically insignificant, yet 
they advised against the practice. 
Nockerts and associates7 also ad­
vised against it, at least in the 
elderly, as did one-third of the 
American Surgical Program direc­
tors.8 Among its advocates are 
Tranmer and colleagues,9 Shennib 
and associates10 and Saade’s 
group.11
The variable appendectomy rate 
(12% to 59%) between individual 
surgeons in our study suggested 
that surgeons had used additional 
selection criteria to those listed or 
that their application had varied 
markedly. When we questioned the 
surgeons, drawing attention to this 
wide variation, one surgeon admit­
ted to an underlying wish to finish 
the operation quickly and another 
had concerns about litigation in the 
event of mishap. Not surprisingly, 
the incidental appendectomy rate 
for both these surgeons was lowest 
for the group at 12%. If their rates 
were eliminated, the difference lost 
its significance.
Clearly, application of the selec­
tion criteria favoured the better op­
erative candidates for appendecto­
my. Thus, the two groups are not 
necessarily comparable. The pa­
tients who had appendectomy 
would be expected to do well, so it 
is not surprising that they fared as 
well as the others.
This study demonstrates that in­
cidental appendectomy, as practised 
in the clinical setting using the 
selection criteria outlined, seems 
safe. To obtain a “true” picture of 
the contribution of appendectomy, a 
prospective randomized study 
would be required with full disclo­
sure to the patient. Such a study 
would have to eliminate individual 
variations of practice by having the 
operation totally standardized; post­
operative care would also need to be
standardized and provided by some­
one other than the operating sur­
geon. Our study suggests that the 
negative contribution of appendec­
tomy is so small when measured 
against the concomitant primary 
operation, that such a complicated 
study is not warranted.
Most investigators have failed to 
show any significant difference in 
patient outcome by the addition of 
incidental appendectomy, with the 
possible exception of complications 
due to infection. In our study, both 
superficial and deep infection was 
more frequent after incidental ap­
pendectomy. Although this differ­
ence was not significant, a study 
with greater numbers might show 
this to be a “true” observation. The 
potential risk of infection must be 
weighed against the potential gain 
when deciding to carry out appen­
dectomy at the time of another 
procedure.
The most objective variable stud­
ied was postoperative fever. Body 
temperature was recorded every day 
for all patients by a reliable and 
disinterested observer (the nurse). 
There was no significant difference 
in the occurrence of fever between 
any of the patients. Despite marked 
individual variation in other areas, 
fever rates did not vary significantly 
between individual surgeons. Leu­
kocytosis was a variable that might 
be expected to be objective. Howev­
er, since it was not measured on all 
patients, the difference probably re­
flects the degree to which individual 
surgeons requested this measure­
ment. A difference in operative time 
would be expected, and postopera­
tive stay also seemed to vary with 
the individual surgeon’s routine.
Table III - Maximal Surgeon Variation
Variable
All
surgeons
Average values
Lowest
individual
Highest
individual p value*
Incidental appendectomy, % 34 12 59 <0.05
Average operative time, min 74 62 101 <0.05
Average postoperative stay, d 6.3 4.7 8.1 < 0.05
Fever, % 42 25 53 > 0.05
Leukocytosis, % 12 0 25 < 0.05
Intravenous fluids > 24 h postop, % 15 7 47 < 0.05
Parenteral analgesia > 48 h postop, % 23 5 29 < 0.05
Antibiotics > 24 h postop, % 18 5 27 <0.05
Total infection rate (wound and deep 2 0 5 > 0.05
abscess), %
‘ Difference between highest and lowest.
Table IV -  Comparison of Average Values for All Patients
Average values
All With Without
patients, appendectomy, appendectomy,
Variable n =  853 n =  291 n =  562 p value
Incidental appendectomy, % 34 100 0 -
Average operative time, min 74 81 71 > 0.05
Average postoperative stay, d 6.3 6.3 6.3 > 0.05
Fever, % 42 37 45 > 0.05
Leukocytosis, % 12 9 13 > 0.05
Intravenous fluids > 24 h postop, % 15 15 15 > 0.05
Parenteral analgesia > 48 h postop, % 23 22 23 > 0.05
Antibiotics > 24 h postop, % 18 15 19 > 0.05
Wound infection rate, % 1 2 1 > 0.05
Deep abscess incidence, % 0.4 1 0 > 0.05
Total infection rate (wound and 2 3 1 > 0.05
abscess), %
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Similarly, use of intravenous fluids, 
antibiotics and parenteral analgesia 
seemed more a function of individu­
al practice than operative procedure 
or patient need.
Awareness of individual practice 
is important in clinical studies. For 
example, although the appendecto­
my rate for each surgeon perform­
ing cholecystectomies was less in 
the emergency situation, the differ­
ences were not significant. Yet, 
when all emergency cholecystecto­
mies were compared with all elec­
tive ones, the lower appendectomy 
rate in the emergency situation was 
significant. This can be explained 
by the fact that the surgeon with 
the lowest appendectomy rate con­
tributed over half the emergency 
cholecystectomies, whereas the sur­
geon with the highest appendecto­
my rate contributed over half of the 
elective cholecystectomies.
Regardless of significant differ­
BOOK REVIEWS
continued from page 447
limited, having been written by the 
“cement is best, now and forever” 
school of knee replacement.
The quality of the chapters varies. 
Some, such as Dohr’s on the mecha­
nisms of failure of prostheses, are quite 
good. Some contain information that, 
while technically correct, is downright 
dangerous. Craig, a plastic surgeon, has 
written a good chapter on skin grafting 
around the knee, but states that “a 
lateral or medial parapatellar incision, 
even when very long, can safely co-exist 
with the midline approach to the knee”. 
Early in my experience I tried this and 
in two patients lost the skin off the 
front of the knees. I believe that the 
majority of surgeons doing this proce­
dure would advise using the old inci­
sion, even if the placement is subopti- 
mal.
Another curious chapter deals with 
massive defects in the femur on remov­
ing ingrowth-type prosthetic compo­
nents. The authors’ technique seems to
ences observed between individual 
surgeons, the addition of appendec­
tomy to hysterectomy or cholecys­
tectomy in our study made no sig­
nificant difference to any measured 
variable for any surgeon and thus 
had no significant effect on patient 
outcome. It appears to be an effec­
tive and safe prophylaxis against 
appendicitis, its application seeming 
to depend on individual judgement 
and training. The only caveat is a 
potential increase in infection. De­
spite its apparent safety, increasing 
litigation in this country may make 
this practice less appealing in the 
future.
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be to lock on a large slap hammer and 
batter out the component. If the femo­
ral component is well fixed, it is not 
surprising that they pull out a lot of 
bone, indeed it is surprising that they 
don’t pull off the whole distal femur. 
Fortunately, in a later chapter, other 
authors indicate the appropriate way to 
remove these implants.
There is no mention in the book of 
stress shielding or stress relief os­
teoporosis which is an important factor 
in knee revisions. Takedown of a knee 
fusion is mentioned briefly, and it is 
stated that a constrained prosthesis is 
always required. This is definitely not 
the case.
Hinges and fixed axis prostheses are 
condemned, the preferred alternatives 
being a total condylar III or a custom 
prosthesis. Custom implants cost at 
least $5000. so they really have no 
market outside the United States. The 
only noncustom prosthesis with huge 
stems is the Guepar II hinge. If the
ligaments do not help to stabilize the 
knee, then stability comes from the 
prosthetic components. The interface 
between bone and implant therefore 
sees roughly the same loads whether or 
not the implant is a true hinge or an 
unlinked hinge such as the total condy­
lar III. This would seem reasonably easy 
to understand, but the authors seem to 
have a conceptual block on this subject. 
In spite of this book, I recommend that 
any surgeon doing a knee revision have 
a Guepar II hinge on the back table, 
just in case it is needed.
The target audience for this book is 
not obvious, except perhaps the ortho­
pedic residents in New York and Bos­
ton.
Hugh U. Cameron, MB, ChB, FRCSC 
Ste. 318,
43 Wellesley St. E,
Toronto, Ont.
M4Y1H1
VOL. 31, NO. 6 NOVEMBER 1988/CJS 451
HISTORY OF SURGERY
Doctor or Mister (the Correct Appellation 
of British Surgeons)
Philip Eibel, MD, FRCSC
The form of address for British surgeons — “Mister” instead of “Doctor” — has 
mystified other members of the medical profession for years. The author attempts to 
show that the designation “Mister” is neither an affectation nor a denigration but a 
natural consequence of the history of British barbery, barber-surgery and ultimately 
surgery, resulting from the advice and tutelage of King Henry VIII and Parliament.
Le titre do® e aux chirurgiens 1 itanniques, “Monsieur” plutot que “Docteur”, 
continue, depuis des annees, ? aisser perplexes les autres membres de la profession 
medicale. L’auteur tente de d.montrer que la designation “Mister” n’est pas utilisee 
par affectation et qu’elle n’a pas de connotation pejorative, mais qu’elle decoule 
plutot de l’Histoire des barbiers, barbiers-chirurgiens et, ultimement, chirurgiens 
britanniques, consequence de l’avis et de la tutelle du roi Henri VIII et du 
Parlement.
S urgeons from the United States and Canada visiting hospitals in 
Great Britain find it difficult to 
understand why their British col­
leagues are referred to as “Mister” 
and not “Doctor”. After many ardu­
ous years of study to acquire the 
much-coveted fellowship in surgery 
it can be disconcerting to address 
similarly qualified British colleagues 
by the seemingly lowly title of “Mis­
ter” . Actually, “Mister” is not a 
denigration, and British surgeons 
may even be offended if addressed 
as “Doctor”. But why the differ­
ence from almost universal prac­
tice?
Despite personal communication 
with the Royal College of Physi­
cians and Surgeons of England 
(January 1987) and with the Well­
come Institute for the History of
Medicine (March 1987), I could not 
find documentation of the origin of 
this British custom. This appella­
tion may have arisen from events 
that began when surgery and barb­
ery were first recognized as arts and 
vocations in Britain.
After the dissolution of the 
Roman Empire, the little surgery 
that continued to be carried out in 
Europe was to be found only in 
monasteries,1 where monks and 
their assistants, the barbers, carried 
on the almost forgotten art of sur­
gery bequeathed to them by the 
Greeks and Romans. In addition to 
clipping hair and shaving, barbers 
helped the monks with more com­
plicated tasks such as blood-letting, 
believed to be the origin of the 
colours on the barber’s pole — red 
stripes representing blood and
white, the bandages used for 
stanching.
In 1123 AD, Pope Calistas II 
decreed that monks must not shed 
blood. This ruling gave an extraor­
dinary boost to the barbers who 
now performed, in addition to their 
regular chores, more complicated 
procedures such as tooth-pulling, 
blood-letting and treatment of frac­
tures. Because of this, barbers now 
became known as barber-surgeons 
and, in keeping with the Pope’s 
orders, monks ministered only to 
the souls of patients; their guiding 
principle was Ecclesia abhorret a 
sanguine (the Church abhors the 
shedding of blood).2 Even so, they 
continued for a long time, as ob­
servers and advisers, to impart their 
superior knowledge of surgery.
Originating at about the same 
time as the barber-surgeons was a 
more exalted but less numerous 
group, the “pure” surgeons. They 
were more skilled than the barbers 
but were likewise unlettered, manu­
al workers. They were apprenticed, 
not university trained and, unlike 
physicians, could not speak Latin. 
Because they had no university de­
gree, they could not style them­
selves as “Doctors” .
In 1423, an attempt was made to 
improve the practice of medicine by 
forming a conjoint college of the 
university trained physicians and 
apprentice-trained surgeons;3 the 
barber-surgeons were excluded. The 
association survived only 1 year, 
probably because of the opposition 
of barber-surgeons who were afraid
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of losing their control of the field of 
surgery, or perhaps because of the 
tendency of physicians to look 
down upon the surgeons.3
In 1493, the surgeons decided to 
enter into a working agreement 
with the barber-surgeons regarding 
their respective spheres of influence 
in the practice of surgery and barb­
ery.4 However, encroachment on 
each other’s territory led to bicker­
ing. Surgeons were not above hair­
clipping and barbers would occa­
sionally dabble in surgery.
In 1540, Henry VIII, by act of 
Parliament, completed and extended 
the particulars, uniting the two 
groups under the name of the 
“Masters, Governors, of the Mys­
tery and Commonalty of Barbers 
and Surgery of London” .5 Hence­
forth, by royal edict, the barbers 
could engage only in barbery and 
the drawing of teeth; surgeons had 
to abstain from cutting hair and 
shaving. This association was main­
tained for over two centuries, until 
1745.
The advantages of union were 
mutual. The surgeons, who were a 
more select body though fewer in 
number, helped to raise the prestige 
of the barber-surgeons. The latter 
group, more numerous and more 
affluent, had their own hall (the 
Barbers’ Hall), where lectures were 
given in anatomy and surgery,46 
thus perfecting and advancing the 
art of surgery.
King Henry VIII gave each mem­
ber of the newly formed group the 
right to be addressed as “Master.”
In time, according to the New En­
glish Dictionary on Historical Prin­
ciples, “Master” was pronounced 
“Mister” .7 Skeat, in his Etymologi­
cal Dictionary o f the English Lan­
guage8 adds that “Mister” is a back 
formation from “Mistress” , the 
feminine for “Master” . It seems, 
therefore, that when a British sur­
geon is addressed as “Mister” he is 
actually being honoured — in reali­
ty he is being called “Master” .
The union of barbers and sur­
geons lasted until 1745 when the 
latter petitioned Parliament to effect 
a separation.
From this date, although they 
had been instrumental in reviving 
and spreading the knowledge of 
anatomy and surgery, the place of 
barber-surgeons was gradually 
taken over by surgeons. The bar­
bers and barber-surgeons became 
an honourable, benevolent organi­
zation to which leading surgeons of 
England are now proud to belong. 
They hold bimonthly Court dinners 
and maintain the traditions of the 
old barber-surgeons. Only one-third 
of them are members of the medical 
profession. They are now a charita­
ble foundation, dispensing bursaries 
for deserving boys and girls and 
pensions to retired barbers and to 
nurses in need. They provide study 
grants for the history of surgery. 
The Cutting Edge,9 a detailed histo­
ry of the early surgeons, was writ­
ten in 1974 by a non-medical mem­
ber, Theodore R. Beck, who is an 
architect and antiquarian.
The original beautiful Barbers’
Hall was destroyed by incendiary 
bombs in 1940. It contained many 
treasures, including the painting by 
Holbein of King Henry VIII and the 
barber-surgeons. It was rebuilt and 
was reopened in 1969 by Her Maj­
esty the Queen Mother who grace­
fully accepted honorary member­
ship in the Worshipful Company of 
Barbers.10
With these romantic traditions 
stemming from a time when surgery 
in Britain was in its infancy, it is 
easy to see why British surgeons 
adhere tenaciously to the salutation 
of “Mister”.
References
1. Paterson Ross J: From trade guild to 
Royal College. St. Barth Hosp J 1957; 
61: 369-373
2. Mencken HL (ed): A New Dictionary o f 
Quotations on Historical Principles from 
Ancient and Modern Sources, Knopf, 
New York, 1942: 111
3. Dobson J, W alker RM: Barbers and 
Barber-Surgeons o f London, Blackwell 
Sci, Oxford, 1979: 25, 26
4. MacNalty AS: The sovereign and the 
surgeon. The Practitioner 1953; 170: 
488-498
5. Dobson J, Walker RM: Barbers and 
Barber-Surgeons o f London, Blackwell 
Sci, Oxford, 1979: 31-35
6. Russell KF: Anatomy and barber-sur­
geons. Med J Aust 1973; 1: 1109-1115
7. New English Dictionary on Historical 
Principles, Oxford, 1908: 214
8. Skeat WW: An Etymological Dictionary 
of the English Language, Oxford U Pr, 
1879-1882: 365, 380
9. Beck RT: The Cutting Edge, Lund 
Humphries, London, 1974
10. Dobson J, W alker RM: Barbers and 
Barber-Surgeons o f London, Blackwell 
Sci, Oxford, 1979: 75, 76
VOL. 31, NO. 6 NOVEMBER 1988/CJS 453
BOOKS RECEIVED
continued from page 403
Progess in Clinical and Biological Re­
search, Volume 277. Advances in Uro- 
logic Oncology. Edited by Nasser Ja- 
vadpour and Gerald P. Murphy. 150 pp. 
Illust. Alan R. Liss, Inc., New York, 
1988. $48.00 (US). ISBN 0-8451- 
5127-4.
Reconstruction Surgery and Trauma­
tology, Volume 20. Gentamicin- 
PMMA-Chains in Bone and Soft-Tissue 
Infections. Edited by H. Eberle. 122 pp. 
Illust. S. Karger AG, Basel, 1988. 
$73.50 (US). ISBN 3-8055-4603-3.
Revascularization for the Ischemic 
Brain. Edited by Donald L. Erickson. 
294 pp. Illust. Futura Publishing Co., 
Inc., Mount Kisco, New York, 1988. 
$45.00 (US). ISBN 0-87993-320-8.
Vascular and Multi-Infarct Dementia.
Edited by John Stirling Meyer, Helmut 
Lechner, John Marshall and James F. 
Toole. 276 pp. Illust. Futura Publishing 
Co., Inc., Mount Kisco, New York, 
1988. $39.00 (US). ISBN 0-87993- 
323-2.
ADVERTISERS’ INDEX
Davis & Geek
Outside Back Cover
Merck Sharp & Dohme Canada
Mefoxin 416, 417, 436, 437 
Primaxin 406 A,B,C,D,E,F,G,H
Parke-Davis Canada Inc.
Anusol-HC 428
Upjohn Company of Canada, The 
Dalacin C 380, Inside Front Cover
Week
Hemoclip X20 Inside Back Cover
S2L
CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable 
classified advertisements. The deadline is 1 month before issue date. Regular classified rates 
(for each insertion): $42.00 for the first 40 words or less, additional words 55d each 
(additional $16.00 for frame). Special Display under 75 words, 2 lA  in. X 2 in., $105.00. $6.00 
charge (first insertion only) for CJS box numbers. Display rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario 
K1G 0G8.
SURGICAL DIRECTOR OF LIVER TRANS­
PLANTATION: BC — the Department of Sur­
gery at the University of British Columbia and 
the British Columbia Transplant Society are 
seeking a surgical director of liver transplanta­
tion for a newly established provincial multi­
organ transplant program. This is a geographic 
full-time tenure track position with salary com­
mensurate with faculty rank. This individual 
must be fully trained in liver transplantation with 
at least one year of post-fellowship experience 
in an established program, have a proven re­
cord of independent research and possess the 
technical, organizational and academic skills 
which would enable him/her to develop and 
lead an integrated clinical/academic program. 
An opportunity exists to oversee the develop­
ment of additional programs in intestinal and 
multi-visceral transplantation. The British Co­
lumbia transplant program is fully funded for 
clinical operation and equipped with the neces­
sary surgical and laboratory research space. In 
accordance with Canadian immigration require­
ments, this advertisement is directed to Canadi­
an citizens and permanent residents. Starting 
date is January 1, 1989. Closing date is De­
cember 1st, 1988, or until a suitable applicant 
is chosen. Apply, enclosing curriculum vitae to: 
Dr. Paul Keown, director, BC Transplant 
Society, Room 8, Heather Pavilion, 855 
West 12th Ave., Vancouver, BC V5Z 1M9.
-S88-43
GENERAL SURGEON: ON -  An opportunity 
exists for a general surgeon to join the staff of 
the Oakville-Trafalgar Memorial Hospital. At 
present there are 4 general surgeons in this fully 
accredited 330-bed hospital. Please reply to: 
Dr. G. Lloyd, Department of Surgery. Oak­
ville-Trafalgar Memorial Hospital, 327 Reyn­
olds St., Oakville, ON L6J 3L7. -S88-38
HEAD, DIVISION OF UROLOGY: BC -  The
Department of Surgery at the University of 
British Columbia is seeking an academic head 
for the Division of Urology, University of British 
Columbia and Vancouver General Hospital. This 
is a geographic full-time tenure track position 
with salary commensurate with qualifications 
and experience, the successful candidate must 
hold FRCSC qualifications with specialty training 
in urology and sufficient academic experience 
with a background in research. In accordance 
with Canadian immigration requirements, priori­
ty is given to Canadian citizens and permanent 
residents. Other candidates will be considered 
if no suitable candidate is found. Starting date is 
January, 1989. Closing date is December 1st, 
1988, or until a suitable applicant is chosen. 
This position is subjected to final budgetary 
approval. Apply, enclosing curriculum vitae to: 
Dr. A. D. Courtemanche, acting head. De­
partment of Surgery, 910 W  10th Ave., 3rd 
Floor, Vancouver, BC V5Z 4E3. -S88-42
BIOGRAPHY: -  Material for biography of the 
late Professor J. C. Grant required. Personal 
memoirs, anecdotes, photographs, welcome.
Information treated with discretion and material 
returned promptly. Reply to: Dr. Clayton Rob­
inson. 808 - 750 W  Broadway, Vancouver, 
BC V5Z 1 H7. -S88-39
HAND SURGERY FELLOWSHIP: ON -
Available, starting July 1, 1989. For infor­
mation contact: The office of Dr. J. H. 
Roth, (FRCSC), 345 Westminster Ave., 
London, ON N6C 4V3 Tel: (519)
439-0701. -S88-40
GENERAL SURGEON: NT -  The board is 
seeking a general surgeon to join a medical staff 
of seven physicians, to function as a team 
member in an isolated location. The Baffin 
Regional Hospital is located in Iqaluit (Frobisher 
Bay) on Baffin Island. The hospital acts as a 
referral centre for 12 outlying health centres in 
the eastern arctic and serves a total population 
of 10 000. The candidate is required to under­
take cesarian sections, general surgery, emer­
gency trauma and some general practitioner 
clinical sessions. Surgical specialists - ENT, 
GYNE, ORTHO visit on a regular basis from 
McGill University affiliated hospitals. Candidates 
for this position will preferably be FRCSC and 
be eligible for licensure in the Northwest Terri­
tories. Competitive salary, generous incentive 
bonus. Benefits: housing allowance, vacation 
travel assistance, paid educational leave, re­
location expenses, dental, pension and insur­
ance plan. Furnished accommodation. Closing 
date to remain open until suitable candidate is 
recruited. Please send resume to: Chief Execu­
tive Officer, Head office, Baffin Regional 
Health Board, Bag 200, Iqaluit, NT XOA 
OHO. -S88-41
RATE CHANGE
effective with the 
January 1, 1989 issue
REGULAR CLASSIFIED RATES
(for each insertion)
$ 45.00 40 words or less
$ .60 each additional word
$ 6.00 CMA box numbers
$ 17.00 box frame (1 pt. rule)
$ 110.00 special display
(21/4x2)
under 100 words
Copy should be mailed to: 
THE CANADIAN JOURNAL 
OF SURGERY 
P.O. Box 8650 
Ottawa, ON K1G 0G8
454 VOL. 31, NO. 6 NOVEM BER 1988/CJS
FINALLYu
The Ligating Clip you’ve 
trusted for 25 years is now 
available in a one-handed, 
fully-automatic, disposable 
unit. Featuring continuous 
feed Titanium Hemoclips®.
Hemoclip® X20 
Applier
One of the Weckstat™ Family 
of Closure Products.
s.
W ICK
hemoaip 
/ ® W ECK
MEDIUM
WECK/DIVISION OF SQUIBB CANADA INC.
221 Amber Street, Markham, Ontario, L3R 3J7 •  Tel. (416) 477-6790  
Ontario/Quebec 1-800-387-9607 •  Elsewhere in Canada 1-800-387-9632
Meet some members
of our family
...now comes the 
Even Greater Stapler
• Soft, supple, flexible
• Resists kinking
• Yields secure Knots 
•Strong
the manageable monofilament.
Pre-Cyde's broad antibacterial 
spectrum makes it an excellent 
bactericidal and fungicidal 
antiseptic!*
Pre-Cyde Is safe, virtually 
non-irritating,1 and has a 
pleasant emollient...for a  
difference you can feeL
Now a monofilament suture 
that is easy to handle and tie:
Ultra Light Compact 
disposable skin stapler 
Automatically released staples 
Improved staple visibility 
Proven reliability 
Allows for excellent accuracy 
Quality stapler supplied inexpensively
DEXON* PLUS
Excellent knot security plus superior handling 
and smoother tissue passage.
FO RA D IFFi 
YO U  CAN] 
N E W P R E
iRENCE
FEEL.
C Y D E *
(Oikxheodine Gluconate)
V Tew  Pre-Cyde is the only 
1 N  germicidal antiseptic hand 
wash that combines all the 
effectiveness of chlorhexidine 
with a  gentle emollient to 
sooth the skin
■ i  / 1
quality professional products from VAy
DAVIS+GECK
Cyanamid Canada Inc.
A  T R A D I T I O N  O F  IN N O V A T IO N
I A  HELPING HAND FROM 
JOHNSON &  JOHNSON
I Using sterile scissors, cutting gauze sponges and removing loose threads the
sponge may have left in the wound... not the most convenient use of your time! 
Convenience, safety and patient comfort were precisely our main objectives in 
designing and developing special pre-cut drain sponges.
Pre-cut drain sponges 
for your convenience
Pre-cut hole and slits 
^allow the sponge to fit 
around drains, tubes 
and catheters
Two sponges per enve­
lope to help stabilize 
drains and provide 
better absorbency
Saves time — no need 
for sterile scissors
►  Sterilized and specially 
designed for your 
patients’ safety and 
comfort
►  NU GAUZE* sponges are preferred over ordinary 
gauze sponges because they:
Sterile packaging en­
sures aseptic delivery
Virtually lint-free and 
non-fraying NU GAUZE* 
fabric eliminates 
risk of loose threads 
adhering to the wound
• Are more absorbent
• Are virtually lint-free 
and non-fraying
• Adhere less to wounds
• Are softer
• And because NU GAUZE 
sponges are more 
economical in use 
than other gauze 
sponges
rs
-
Specially designed NU GAUZE* 
tracheostomy and drain sponges, 
an integral part of the NU GAUZE* 
family, developed and manufactured 
in Canada.
PELER VERS LE BAS 
PEEt^RlOWN
PELER VERS LE BAS
PEE^^JOWN
PELER VERS LE BAS
P E E ^ O W ,
j^ o m p r e s s e s
NU GAUZEr
|  c o m p re s s e s  p o u r  d ra in s
NU GAUZE
■  d r a in  g n n n n w s —
I
NU GAUZE
1 tracheostomy sponge
iL._
' . 1 ■ ! , . U ,  1 : L"
‘ T r a d e m a r k  o f
J O H N S O N  &  J O H N S O N
polyglyconate monofilament absorbable suture
The multi-faceted 
absorbable suture 
appearing in 
Plastic and 
General surgery 
theatres
everywhere. For a 
personal 
presentation call 
your D + G 
Representative
